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Mechanisms of Post-hemorrhagic Hydrocephalus after Germinal Matrix Hemorrhage 
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Damon William Klebe 
Doctor of Philosophy, Graduate Program in Physiology 
Loma Linda University, June 2016 
Dr. John H. Zhang, Chairperson 
 
The inherently fragile vasculature of the germinal matrix is susceptible to rupture, 
possibly as a result of hemodynamic and cardiorespiratory instability associated with 
prematurity. Germinal matrix hemorrhage is a leading cause of morbidity and mortality 
in preterm and/or very low birthweight infants, and post-hemorrhagic hydrocephalus is 
major consequence of severe grade hemorrhages. Chronic post-hemorrhagic 
hydrocephalus treatment involves surgical insertion of shunts, which are costly and prone 
to complications. Thus, a safe non-invasive therapeutic approach towards post-
hemorrhagic hydrocephalus clinical management would significantly improve the quality 
of life for this patient population. Thrombin, cerebroventricular blood clots, and iron have 
been identified as causative factors of hydrocephalus formation. Thrombin stimulates 
proteinase-activated receptors, leading to subsequent mTOR activation and extracellular 
matrix protein proliferation, which possibly obstruct the cerebroventricular system. Blood 
clots may directly impair cerebrospinal fluid circulation and absorption. PPARγ 
stimulation enhances micgroglial/macrophage phagocytosis of erythrocytes via CD36 
scavenger receptor, augmenting clot resolution and improving outcomes after adult 
cerebral hemorrhage. Additionally, lysed erythrocytes and metabolized hemoglobin 
release iron, which is associated with brain injury after adult cerebral hemorrhage and 
 xv 
contribute to post-hemorrhagic hydrocephalus development. The central aim of this 
proposal is to determine the role of activated thrombin/PAR-1/mTOR pathway as well as 
the role of hematoma resolution by PPARγ/CD36 and iron chelation by Deferoxamine in 
hydrocephalus development after germinal matrix hemorrhage. Direct thrombin 
inhibition reduced short-term mTOR activation and ameliorated long-term post-
hemorrhagic hydrocephalus development, neurocogntive deficits, and extracellular 
matrix protein proliferation, although PAR-1 inhibition alone did not achieve the same 
therapeutic benefits. PPARγ stimulation improved short-term hematoma resolution, 
which was reversed by PPARγ antagonism and CD36 knockdown. PPARγ stimulation 
attenuated long-term neurocognitive deficits and post-hemorrhagic hydrocephalus, which 
was reversed by PPARγ antagonism. Acute and delayed iron chelation also reduced long-
term post-hemorrhagic hydrocephalus development, neurocognitive deficits, and 
extracellular matrix protein proliferation. Thus, thrombin/PAR/mTOR pathway 
inhibition, enhanced PPARγ/CD36 mediated hematoma resolution, and iron chelation 
significantly ameliorated short and long-term brain sequelae after germinal matrix 
hemorrhage and are clinically viable therapeutic targets warranting further investigation. 
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Abstract 
In addition to being the leading cause of morbidity and mortality in premature 
infants, germinal matrix hemorrhage (GMH) is also the leading cause of acquired 
infantile hydrocephalus. The pathophysiology of post-hemorrhagic hydrocephalus 
development after GMH is complex and vaguely understood, although evidence suggests 
fibrosis and gliosis in the periventricular and subarachnoid spaces disrupts normal 
cerebrospinal fluid dynamics. Theories explaining general hydrocephalus etiology have 
substantially evolved from the original bulk flow theory developed by Dr. Dandy over a 
century ago. Current clinical and experimental evidence supports a new hydrodynamic 
theory for hydrocephalus development involving redistribution of vascular pulsations and 
disruption of starling forces in the brain microcirculation. In this review, we discuss 
cerebrospinal fluid flow dynamics, history and development of theoretical hydrocephalus 
pathophysiology, and GMH epidemiology and etiology as it relates to post-hemorrhagic 
hydrocephalus development. We highlight known mechanisms and propose new avenues 
that will further elucidate GMH pathophysiology, specifically related to hydrocephalus. 
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Introduction 
Germinal matrix hemorrhage (GMH) occurs in approximately 3 live births per 
1,000, has a 20-30% mortality rate, and accounts for 1.7% of all neonatal deaths in the 
United States (Ballabh 2014; Osterman, Kochanek et al. 2015). Premature infants have a 
much higher rate of occurrence; for infants born before 32 weeks of gestation up to 20%, 
(about 12,000 infants) develop GMH each year in the US (Kochanek, Kirmeyer et al. 
2012). Fortunately, the premature birthrate and percentage of low birthweight (<2500g) 
infants have steadily declined between 2006 and 2013, although remaining higher than in 
the 1980s and 1990s.  In 2013, the preterm birthrate was 11.39% and the percentage of 
low birthweight infants was 8.02%. The percentage of very low birthweight (<1500g) 
was 1.41% in 2013 (Osterman, Kochanek et al. 2015). A study investigating premature 
infants dating back to 1914 determined median postnatal survival increased from 2 to 26 
days, and median gestational age decreased from 33 to 27 weeks. Interestingly, GMH 
incidence was 4.7% before 1960, but it increased to 50.0% between 1975 and 1980, and 
then decreased to 12.5% after 2005 (Hefti, Trachtenberg et al. 2015). The introduction of 
positive pressure ventilation in preterm clinical management after the 1960s increased 
survival while simultaneously increasing GMH incidence, which may be attributed to 
cardiorespiratory and hemodynamic instability associated with mechanical ventilation, 
and the decline in GMH incidence after the 1980s may be attributed to improvements in 
mechanical ventilation methodology as well as the use of antenatal steroids and 
surfactant. Despite improving trends in premature birth incidences and outcomes, GMH 
remains the leading cause of morbidity and mortality in premature and/or very low 
birthweight infants, and its incidence has remained steady in the past decade.   
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Premature and very low birthweight infants are prone to hemodynamic and 
cardiorespiratory instability, leading to abrupt fluctuations in cerebral blood flow 
(Ballabh 2014). The fetal brain is hypothesized to lack vascular autoregulatory 
mechanisms to adequately respond to cerebral blood flow fluctuations, although clinical 
research involving cerebral blood flow monitoring in preterm infants has produced 
ambiguous results (Tsuji, Saul et al. 2000; Soul, Hammer et al. 2007; du Plessis 2008; 
Wong, Leung et al. 2008; Caicedo, De Smet et al. 2011; Alderliesten, Lemmers et al. 
2013). The germinal matrix layer, which is present in the fetus and matures by term, 
contains many neuronal and glial precursor cells and is a site of rapid angiogenesis 
relative to other parts of the brain (Ballabh, Braun et al. 2004; Ballabh, Xu et al. 2007). 
The germinal neurovascular unit, consisting of neurons, astrocytes, pericytes, vascular 
smooth muscle cells, and vascular endothelial cells, is deficient in fibronectin at the 
endothelial basal lamina, glial fibrillary acidic protein at astrocyte end-feed, and pericyte 
coverage (Ballabh 2010; Ballabh 2014). Thus, the germinal matrix vasculature is 
inherently weak and vulnerable to hemorrhage under abnormal conditions, regardless if 
the premature infant brain has autoregulatory mechanisms to adequately respond to 
cerebral blood flow fluctuations. 
GMH severity is graded on an I-IV scale based on the extent and localization of 
bleeding. Incidence of higher GMH grades (III-IV) increases as gestational age and/or 
birthweight decreases (Robinson 2012). Between 50-75% of GMH survivors develop 
long-term neurocognitive sequelae, including cerebral palsy, learning disabilities, 
psychiatric disorders, and post-hemorrhagic hydrocephalus (PHH), and higher-grade 
GMH survivors are most vulnerable to worse long-term outcomes (Ballabh 2010; Ballabh 
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2014). The mortality rate for severe grade (III-IV) GMH is approximately 44%, with 
60% of survivors developing PHH and 25% requiring surgical installation of shunts 
(Vassilyadi, Tataryn et al. 2009). Another study estimates 10% of GMH patients (any 
grade) and 20% of severe GMH patients (III-IV) will require surgical insertion of 
permanent shunts (Robinson 2012). Shunt dependency is not desirable, given the large, 
costly, detrimental complications that occur due to shunt infection, occlusion, and 
displacement. Additional approaches to manage or prevent PHH include serial lumbar 
punctures, ventricular taps, external ventricular drainage, ventricular access device, 
ventricular-subgaleal shunt, endoscopic third ventriculostomy, and endoscopic 
coagulation of the choroid plexus (Tully and Dobyns 2014). A non-invasive, therapeutic 
approach towards ameliorating PHH would significantly improve long-term quality of 
life for GMH patients.  
PHH pathophysiology after GMH remains vague and complex, and minimal 
advancements have been made in its clinical management. In this review, we discuss CSF 
flow dynamics, particularly focusing on its importance in GMH. We highlight 
advancements made in hydrocephalus research after Dr. Dandy first proposed the bulk 
flow theory over a century ago. We discuss the current hydrodynamic theory for 
hydrocephalus pathophysiology and how it applies to PHH development after GMH. 
Special attention is given to the neurovascular unit in both the choroidal and glymphatic 
microcirculation, where CSF is produced and reabsorbed, respectively. We identify gaps 
in current research and propose avenues for further exploration.   
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Cerebrospinal Fluid Flow Dynamics 
Cerebrospinal fluid (CSF) is an isotonic solution that primarily acts as a 
mechanical cushion for the brain, although it serves many other physiologically vital 
functions as well (Chakravarthi 2012).  CSF has a lower specific gravity than brain tissue, 
creating a buoyant force that reduces the effective mass of the brain. CSF [H+] 
concentration is detected by central chemoreceptors located at the ventrolateral medullary 
surface, which help regulate pulmonary ventilation and cerebral blood flow to ensure the 
brain receives ample oxygen and nutrients. CSF also maintains a stable external 
environment for growth and development of neurons and glia (Chakravarthi 2012).  
Importantly, CSF serves as a cerebral lymphatic conduit utilized for removing metabolic 
waste and transporting neuropeptides, glucose, and lipids (Iliff, Wang et al. 2012; Xie, 
Kang et al. 2013). 
 
Production 
Between 400-600 mL of CSF is produced per day and the brain renews its CSF 
between 3-4 times within a 24 hour period (Pierce, Lambertsen et al. 1962; Cutler, Page 
et al. 1968; Sahar 1972; Sato, Bering et al. 1975). CSF is primarily produced by the 
ependymal lining of the ventricles, which compose the blood-CSF barrier. Ependymal 
cells of the blood-CSF barrier are interconnected by tight junctions that are variably 
distributed and leakier than ependymal cells of the blood-brain barrier. Over two thirds of 
produced CSF originates from the choroid plexus (Pollay 1975; Segal and Pollay 1977). 
The choroid plexus lines the lateral ventricles from the inferior horns to the 
interventricular foramen, where it becomes continuous into the third ventricle and 
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continues into the fourth ventricle. The choroid epithelium protrudes into the ventricles 
through invaginations of the pia matter containing choroidal capillaries, called tela 
choroidea, which significantly increase the surface area of the choroidal epithelium 
(Davson and Segal 1970; Keep and Jones 1990; Speake and Brown 2004; Johanson, 
Stopa et al. 2011). Non-choroidal ependymal cells, brain interstitial fluid, and capillaries 
may be other CSF sources as well, which is secreted by transependymal seepage into the 
brain ventricles or transpinal seepage into the subarachnoid space (Pollay and Curl 1967; 
Davis and Milhorat 1975; Milhorat, Davis et al. 1975; Saunders, Habgood et al. 1999).    
The posterior choroidal, anterior choroidal, inferior cerebellar and superior 
cerebellar arteries supply the choroid plexus of the lateral ventricles, third ventricle, 
fourth ventricle, and temporal horns, respectively (Milhorat 1978; Sakka, Coll et al. 2011; 
Chakravarthi 2012). Blood flow to the choroidal epithelium is estimated at 4 - 6 mL / 
minute / gram tissue, which is significantly greater than blood flow to other brain tissue 
estimated at 0.9 - 1.8 mL / minute / gram tissue (Maktabi, Heistad et al. 1991). The 
choroidal interstitial compartment is the region between choroidal capillaries and 
choroidal ependymal cells. Choroidal capillaries lack tight junction proteins in their 
endothelial cells, making them more permeable, and blood plasma filtrate passively 
crosses into the choroidal interstitial compartment from the choroidal capillaries 
primarily by Starling forces (Wright 1972; Welch 1975). Thus the main source for 
produced CSF is technically choroidal capillaries, not the choroid plexus itself 
(Oreskovic and Klarica 2010; Bulat and Klarica 2011; Oreskovic and Klarica 2011). 
[Na+] and [Cl-] from choroidal interstitium are actively exchanged for [H+] and [HCO3
-], 
generated by cytosolic carbonic anhydrase on choroidal ependymal cells, using carrier 
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proteins in the choroidal ependymal basolateral membrane. Pumps on the choroidal 
ependymal apical membrane then expel [Na+], [Cl-], [K+], and [HCO3
-] into the ventricle 
lumen, which generates an osmotic pressure (Pollay 1975; Spector and Johanson 1989; 
Keep and Jones 1990). Water flows down the created osmotic gradient with the help of 
aquaporin 1 on the choroidal ependymal apical membrane (Reiber 2003). The CSF 
contains higher concentrations of [Na+], [Mg2+], and [Cl-] than blood plasma but less 
[Ca2+], [K+], [HCO3
-], [PO4
+], protein (contains 0.3% plasma proteins), amino acids, and 
glucose (Felgenhauer 1974).  
The choroidal epithelium can alter CSF secretion in response to multiple factors 
and mechanisms. Most regulatory mechanisms target membrane transporters, carbonic 
anhydrase, and aquaporins (Faraci, Mayhan et al. 1990; Sakka, Coll et al. 2011). The 
NaK2Cl cotransporter, located on the choroidal ependymal apical membrane, helps 
regulate CSF composition and secretion by its bi-directional transport ability. Arginine 
vasopressin, atrial natriuretic peptide, serotonin, melatonin, and dopamine receptors are 
located on choroidal epithelium. Arginine vasopressin and atrial natriuretic peptide 
decrease CSF secretion.  CSF secretion can also be increased by sympathetic innervation 
and decreased by cholinergic innervation (Chakravarthi 2012). Pharmaceutical drugs that 
inhibit carbonic anhydrase or sodium transporters, such as diuretics, reduce CSF 
production, while drugs that augment cerebral blood flow tend to increase CSF 
production. Increased intracranial pressure also tends to decrease CSF production, 
although evidence suggests CSF production tends to remain constant despite large 
increases in hydrostatic pressure (Sakka, Coll et al. 2011). 
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Circulation 
CSF flows from the sites of secretion at the choroidal epithelium to the sites of 
absorption in the subarachnoid space. The mean CSF volume within the brain is 150 mL, 
with 25 mL in the ventricles and 125 mL in the subarachnoid space (Sakka, Coll et al. 
2011). Generally, CSF flows from the lateral ventricles, passes through the 
interventricular foramen of Monro into the third ventricle, and finally passes into the 
cerebral aqueduct of Sylvius into the fourth ventricle. From the fourth ventricle, CSF 
enters through three openings, the lateral apertures of Lushka and median aperture of 
Magendie, into the subarachnoid space where it is absorbed. A portion of the CSF exits 
the cranium through arachnoid villi and cranial nerves while the remainder enters along 
the spinal cord and exit through spinal nerve roots (Dichiro 1964; Milhorat 1976; 
Chakravarthi 2012). 
CSF circulates through the brain’s ventricular system and spinal cord in a 
pulsatile manner. Cerebral arterial pulse waves are the primary drivers of CSF 
circulation, although jugular venous pressure, respiratory waves, and even physical 
activity play minor roles as well (Post, Allen et al. 1974; Williams 1976). CSF flow, 
however, is very slow and sometimes occurs bi-directionally through ventricle 
compartments with each cardiac and/or respiratory cycle, but net CSF flow occurs from 
the lateral ventricles to the subarachnoid space. Additionally, ventricular ependymal cells 
have cilia that generate current and propel CSF through the brain ventricles.  CSF 
pressure gradients, which are generated by continuous CSF secretion and arterial 
pulsations, are also important for maintaining CSF flow. This pressure gradient is 
particularly important in driving CSF flow through the subarachnoid spaces and venous 
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sinuses.  Indeed, CSF flow across the subarachnoid epithelium is driven by a 6 cm H2O 
pressure difference between subarachnoid CSF pressure (approximately 15 cm H2O) and 
superior sagittal sinus pressure (approximately 9 cm H2O), and the pressure continues to 
drop into the jugular vein and systemic venous system (Shulman, Yarnell et al. 1964; 
Bradley 1970; Sahar, Hochwald et al. 1970; Milhorat 1975).   
 
Reabsorption 
Conventionally CSF is reabsorbed in the subarachnoid space and enters through 
the dural venous sinuses, where it returns to the internal jugular system (Chakravarthi 
2012). Subarachnoid villi, called pacchonian bodies, were originally thought to be the 
main reabsorption sites (Brierley and Field 1948; Welch and Friedman 1960; Welch 
1975), but evidence suggests CSF is mainly reabsorbed by capillaries and cerebral 
lymphatic channels (Bradbury, Cserr et al. 1981; Zakharov, Papaiconomou et al. 2003; 
Oreskovic and Klarica 2010; Bulat and Klarica 2011; Oreskovic and Klarica 2011). The 
vast majority of CSF is reabsorbed at the superior sagittal sinus with the remainder 
reabsorbed at dural sinusoids in dorsal root nerves. Reabsorption is driven by pressure 
gradients between the subarachnoid space and venous sinuses as well as Starling forces at 
the capillaries (Cutler, Page et al. 1968; Zlokovic, Segal et al. 1990; Saunders, Habgood 
et al. 1999; Pollay 2010). Increased intracranial pressure tends to increase CSF 
reabsorption, but very high intracranial pressure that persists for a long period of time 
tends to actually decrease CSF reabsorption, mostly because venous pressure tends to 
increase with intracranial pressure while the overall pressure gradient diminishes. Some 
evidence suggests CSF flows along cranial nerves and spinal nerve roots and is 
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reabsorbed in lymphatic channels (Bradbury, Cserr et al. 1981; Zakharov, Papaiconomou 
et al. 2003).  Indeed, CSF reabsorption in the nasal submucosal lymphatic channels 
through the cribriform plate, which feed into the cervical lymph nodes, is relatively 
important (Courtice and Simmonds 1951; Erlich, McComb et al. 1986; Cserr, DePasquale 
et al. 1992; Kida, Pantazis et al. 1993; Silver, Li et al. 1999; Mollanji, Bozanovic-Sosic et 
al. 2002). Lymphatic vessels have also been recently characterized surrounding the dural 
sinuses, which are also connected to cervical lymph nodes, further suggesting the 
lymphatic system plays an important role in CSF reabsorption (Bradbury, Cserr et al. 
1981; Zervas, Liszczak et al. 1982; Zakharov, Papaiconomou et al. 2003). Lymphatic-
mediated CSF reabsorption is thought to play a greater role in neonates, since 
subarachnoid granulations are more sparsely distributed. 
While the central nervous system lacks a conventional lymphatic system, 
evidence suggests the presence of a functional waste clearance pathway involving 
exchange between CSF and interstitial fluid, occurring mostly within perivascular 
Virchow-Robin spaces in the brain parenchyma (Iliff, Wang et al. 2012; Iliff and 
Nedergaard 2013; Jessen, Munk et al. 2015). This exchange system is called the 
glymphatic system for its lymphatic-like function and dependence upon glial cells 
(Figure 1.1). Cerebral arteries at the cortical surface extend into pial arteries running 
through the subarachnoid space and subpial space, which turn into arterioles surrounded 
by astrocyte end-feet as they run deeper into the brain parenchyma. The Virchow-Robin 
space is the CSF containing perivascular space between the astrocyte end-feet and 
arteriole, with both walls lined by a leptomeningeal cell layer (Zhang, Inman et al. 1990; 
Kulik, Kusano et al. 2008; Zlokovic 2011; Prince and Ahn 2013). Virchow-Robin spaces 
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along veins lack this leptomeningeal cell layer. Arteriole Virchow-Robin spaces become 
continuous with the basal lamina, which has minimal resistance to CSF flow due to its 
loosely structured extracellular matrix (ECM). CSF flows along arteriole Virchow-Robin 
space, through basal lamina surrounding capillaries, and exits through the venous 
Virchow-Robin space. Arterial pulsation is the main force driving perivascular fluid bulk 
movement from the subarachnoid space into the Virchow-Robin spaces; although 
respiration, slow vasomotion, and CSF pressure gradients play minor roles too (Iliff, 
Wang et al. 2012; Iliff and Nedergaard 2013; Jessen, Munk et al. 2015). Astrocyte end-
feet have high expression of aquaporin 4 and are important for CSF exchange with 
interstitial fluid, since astrocyte end-feet surround perivascular spaces and drive 
convective interstitial fluid fluxes from periarterial to perivenous spaces. Interstitial fluid 
then drains into cervical lymph channels from perivenous spaces (Johnston, Zakharov et 
al. 2004; Murtha, Yang et al. 2014).  
The glymphatic system is particularly important for distributing nutrients, such as 
glucose and lipids, as well as for removing soluble proteins and metabolites from the 
brain (Rangroo Thrane, Thrane et al. 2013). Glymphatic-mediated exchange is greatest 
during sleep, which is thought to be important for removing metabolic waste during the 
resting state (Xie, Kang et al. 2013). In rodent models of Alzheimer’s disease, 
glymphatic-mediated exchange was reduced by 65% in aquaporin 4 knockout mice, 
resulting in increased accumulation of β-amyloid plaques (Iliff, Wang et al. 2012). In a 
mouse repeated traumatic brain injury model, glymphatic exchange was reduced at 24 
hours after the last injury and persisted for up to 4 weeks, which was attributed to gliosis 
(Plog, Dashnaw et al. 2015). Furthermore, the glymphatic system was significantly 
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impaired after subarachnoid hemorrhage, due to blood clots occluding perivascular 
spaces, and during ischemic stroke, due to reduced arterial pulsations (Gaberel, Gakuba 
et al. 2014). More research is further elucidating the pathophysiological role the 
glymphatic system plays in multiple neurodegenerative diseases and injuries, and this 
system may be particularly important in neonatal GMH and consequent PHH 
pathophysiology due to the role it plays in CSF dynamics. 
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Figure 1.1: Overview of the glymphatic system. Cerebrospinal fluid enters within para-
arterial Virchow-Robin spaces in the brain parenchyma and an astroglia-mediated 
mechanism exchanges cerebrospinal fluid with interstitial fluid and flushes wastes out 
within para-venous Virchow-Robin spaces (A). Astrogliosis (B) from brain injury 
possibly disrupts this astroglia-dependent mechanism. 
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Hydrocephalus 
The International Hydrocephalus Imaging Working Group defines hydrocephalus 
as “an active distension of the ventricular system resulting from inadequate passage of 
cerebrospinal fluid from its point of production within the cerebral ventricles to its point 
of absorption into the systemic circulation” (Rekate 2008). Clinical consequences can 
include increased intracranial pressure, seizures, mental deterioration, and tunnel vision. 
Most treatments involve surgical implantation of shunts that divert CSF from the brain or 
surgery, if possible, to repair any malformations that contribute towards hydrocephalus 
development (Kahle, Kulkarni et al. 2015). Dr. Dandy and Dr. Blackfan classified 
hydrocephalus into communicating and non-communicating hydrocephalus in 1914 after 
inducing hydrocephalus in dogs by obstructing the foramen of Monro (Dandy 1914). 
They proposed the bulk flow theory, which states that CSF flows in bulk from the sites of 
production in the ventricles to the sites of reabsorption in the subarachnoid space. 
Hydrocephalus, according to bulk flow theory, had to result from an imbalance in CSF 
production and absorption. Using the same conceptual framework, Dr. Russell proposed a 
more specific classification of hydrocephalus in 1949 into non-obstructive and 
obstructive hydrocephalus, which corresponds to communicating and non-
communicating hydrocephalus, respectively (Russell 1949). The original terms proposed 
by Dr. Dandy, however, remain the most pervasively utilized. Advancements involving 
CSF tracers and imaging technology, however, has produced evidence challenging the 
bulk flow theory (Symss and Oi 2013). New hydrocephalus classifications have been 
proposed based on more recent experimental and clinical evidence, which will be 
discussed. 
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Non-communicating Hydrocephalus 
Hydrocephalus resulting from an obstruction of CSF flow through ventricular and 
subarachnoid spaces is called non-communicating hydrocephalus, also known as 
obstructive hydrocephalus (McAllister 2012; Kahle, Kulkarni et al. 2015). Non-
communicating hydrocephalus is typically caused by congenital cerebral malformations. 
Arnold-Chiari malformation, which is the displacement of the cerebellar tonsils through 
the foramen magnum, often obstructs the fourth ventricle, leading to dilation of the lateral 
ventricles and cerebral aqueduct (Gardner 1965). Dandy-Walker malformations, 
characterized by the absence of the cerebellar vermis, often obstruct the foramina of 
Luschka and foramen of Magendie, resulting in prominent dilation of the fourth ventricle 
(Hirsch, Pierre-Kahn et al. 1984). Colloid cysts may obstruct the Foramen of Monro, 
resulting in lateral ventricular dilation (Camacho, Abernathey et al. 1989). Other lesions 
may cause abhorrent narrowing of the aqueduct of Sylvius, called aqueductal stenosis, 
resulting in third and lateral ventricular dilation. 
 
Communicating Hydrocephalus 
Communicating hydrocephalus is impaired CSF reabsorption in the absence of 
any obstruction to CSF flow through the ventricles and subarachnoid spaces (McAllister 
2012; Kahle, Kulkarni et al. 2015). Communicating hydrocephalus was believed to 
primarily result from impaired arachnoid granulations, resulting in reduced reabsorption 
of CSF. Indeed, cerebral malformations resulting in the absence of arachnoid villi has 
resulted in hydrocephalus development (Gutierrez, Friede et al. 1975). Subarachnoid 
hemorrhage and intraventricular hemorrhage, which induce inflammation and glial 
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scarring in the subarachnoid space, can cause communicating hydrocephalus as well 
(Korobkin 1975; Vassilouthis and Richardson 1979). Accumulating evidence, however, 
challenges the presumption that CSF is mostly absorbed by subarachnoid villi (Greitz 
2004; Oreskovic and Klarica 2011). Normal pressure hydrocephalus is a form of 
communicating hydrocephalus that results in ventriculomegaly without increased CSF 
pressure. CSF pressure readings are within normal range because ventricular dilation 
compensates for accumulated CSF in the ventricles, thus increased CSF pressure is 
compensated by increased ventricular volume in this pressure-volume compensatory 
relationship (Black and Ingraham 2008). In general, the elderly population is most 
vulnerable to normal pressure hydrocephalus, and causes are either idiopathic or related 
to other central nervous system diseases and injuries, particularly subarachnoid 
hemorrhaging. Hydrocephalus ex vacuo is different from normal pressure hydrocephalus 
because ventricular dilation results from brain tissue atrophy, usually due to a 
neurodegenerative disorder, and not as a compensatory mechanism for increased CSF 
pressure (Rekate 2009). Normal pressure hydrocephalus, however, contradicts bulk flow 
theory, because the ventricles should not dilate without increased mean CSF pressure. 
 
Current Hydrodynamic Theory 
Although bulk flow theory is congruent with non-communicating hydrocephalus 
development, when a ventricular obstruction creates back pressure that dilates the 
ventricles preceding the obstruction, it is incongruent with communicating 
hydrocephalus, because the apparent obstruction is within the subarachnoid space, which 
does not dilate or increase in volume (Greitz 2004; Oreskovic and Klarica 2011). In 1914, 
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Dr. Weed injected Prussian blue into the ventricles of dog and cat brains and found the 
dye accumulated near pacchonian bodies (Weed 1914). Prussian blue, however, was also 
found in other brain parenchymal areas, and further research concluded Prussian blue 
cannot cross pacchonian bodies under normal conditions (Symss and Oi 2013). Even Dr. 
Dandy recognized reduced bulk flow across pacchonian bodies should result in 
subarachnoid CSF pressure being greater than ventricular CSF pressure and the 
subarachnoid space should expand before the ventricles, neither of which is observed. Dr. 
Dandy concluded CSF is primarily reabsorbed in the subarachnoid space and quickly 
enters the circulatory system, based on intrathecal dye injections that rapidly entered the 
blood and urine (Dandy 1929). The idea that CSF is mostly reabsorbed at pacchonian 
bodies, however, remained pervasive. In 1960, Dr. Welch reported pacchionian bodies 
could act as mechanical valves, although future anatomical studies found no mechanical 
valve presence (Welch and Friedman 1960). Dr. Di Chiro started experimenting with 
radionuclide cisternography and, in 1966, suggested CSF was reabsorbed at pacchionian 
bodies because radionuclide accumulated there after 24 hours (Di Chiro 1966). Future 
studies, however, challenged this conclusion since other radionuclides enter the 
circulatory system within minutes and most are reabsorbed in the spinal canal (Greitz 
1993; Greitz and Hannerz 1996; Greitz, Greitz et al. 1997). Furthermore, sites where 
radionuclides accumulate after a long period of time may indicate sites where CSF 
reabsorption is actually very limited. A radionuclide cisternography study in patients with 
venous vasculitis and high intracranial pressure, performed by Dr. Greitz and Dr. 
Hannerz in 1996, found no tracer in vessel outlets near capillary beds of pacchonnian 
bodies, providing evidence for an alternative site of CSF reabsorption (Greitz and 
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Hannerz 1996). Another major issue is pacchonian bodies are absent in infants and young 
children, suggesting CSF must be reabsorbed by a different mechanism (Papaiconomou, 
Bozanovic-Sosic et al. 2002).  
Some scientists investigated if abnormal vascular and CSF pulsations may be the 
root cause for communicating hydrocephalus. In 1943, after observing normal pressure 
hydrocephalus patients and noting inconsistencies with the bulk flow theory, Dr. 
O’Connell proposed communicating hydrocephalus may result from increased ventricular 
pulse pressure (O’Connell 1943). Dr. Bering provided experimental evidence in 1962 that 
choroid plexus pulsations deliver the means for ventricular enlargement instead of 
increased mean CSF pressure (Bering 1962). Dr. Bering used a kaolin-induced 
hydrocephalic dog model and excised the choroid plexus from one lateral ventricle, 
which resulted in asymmetric ventricular dilation. Increased mean CSF pressure, 
therefore, could not account for asymmetric ventricular dilation. Dr. Di Rocci provided 
additional experimental evidence in 1978 in which extreme ventricular pulsation, caused 
by inflating and deflating a microballon inserted into the lateral ventricles, can produce 
hydrocephalic ventricular dilation in sheep (Di Rocco, Pettorossi et al. 1978). 
Concurrently, Dr. Guinane in 1977 produced olfactory ventricular dilation, which lacks a 
choroid plexus, in rabbits by obstructing surrounding subarachnoid spaces with silicone 
rubber (Guinane 1977). The silicone rubber obstruction decreased subarachnoid arterial 
and venous compliance as well as increased capillary pulsations. Increased capillary 
pulsations, therefore, had to generate the force necessary for the observed ventricular 
dilation. Using magnetic resonance imaging and radionuclide cisternography, Dr. Greitz 
reported in the early to mid-1990s arterial pulsation and expansion provides the force 
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necessary for CSF pulsatile circulation in both the brain and spinal cord, and arterial 
compliance is important for keeping capillary and venous pulsation low (Greitz 1993; 
Greitz and Hannerz 1996; Greitz, Greitz et al. 1997; Greitz 2004).  
According to bulk flow theory in which CSF malabsorption is a causative factor 
for communicating hydrocephalus, the subarachnoid CSF-venous pressure gradient 
would increase, the subarachnoid space would expand, and the ventricles would dilate 
after subarachnoid space compliance is at maximum. In actuality, the subarachnoid space 
is smaller, and the subarachnoid CSF-venous pressure gradient is diminished, although 
both the subarachnoid CSF pressure and venous pressure increase. In 2002, Dr. Egnor 
developed a mathematical model of communicating hydrocephalus caused by a 
redistribution of CSF pulsations in the brain (Egnor, Zheng et al. 2002). Decreased 
intracranial compliance causes abnormal distribution of vascular pulsations, such that 
arterial pulsations are weaker while capillary and venous pulsations are stronger, and 
stronger pulsations reach the ventricles while weaker pulsations reach the subarachnoid 
space. Thus, this vascular pulsation redistribution causes the ventricles to expand at the 
expense of the subarachnoid space and decreases the subarachnoid CSF-venous pressure 
gradient. Dr. Edgor’s model, based on alternating current electric circuitry, accounted for 
experimentally and clinically observed CSF malabsorption, increased resistive index, 
ventricular dilation, intracranial pressure waves, reduced cerebral blood flow, and 
diminished CSF-venous pressure gradient. Dr. Greitz elaborated on this concept in 2004 
in his discussion of hydrodynamic theory of chronic hydrocephalus development. 
Reduced intracranial compliance causes decreased arterial pulsations and increased 
compensatory capillary pulsations, generating transmantle pulsatile stress responsible for 
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hydrocephalus. CSF malabsorption, therefore, is not a causative factor of communicating 
hydrocephalus but an effect from vascular pulsatile redistribution (Greitz 2004). Dr. 
Oreskovic further suggests that disruption of Starling forces in the brain parenchymal 
microvasculature lead to an imbalance in interstitial fluid and CSF exchange, contributing 
to hydrocephalus development (Oreskovic and Klarica 2011). 
In light of our increased understanding of hydrocephalus pathophysiology, Dr. Oi 
and Dr. Di Rocco proposed a new classification based on the involved pathway: major 
pathway hydrocephalus and minor pathway hydrocephalus (Oi and Di Rocco 2006). 
Major pathway hydrocephalus accounts for CSF circulation disruption from the ventricles 
to the subarachnoid spaces. Major pathway hydrocephalus encompasses most obstructive 
/ non-communicating hydrocephalus cases. Minor pathway hydrocephalus accounts for 
disruptions in CSF circulation within the subarachnoid space and brain parenchyma. 
Evidence suggests this pathway is very important for CSF reabsorption in the embryo, 
fetus, and infants, making it critical for infantile hydrocephalus development 
(Papaiconomou, Bozanovic-Sosic et al. 2002). Minor pathway hydrocephalus is 
disruption of CSF flow and reabsorption in newly elucidated channels in the brain 
parenchyma, which involve deep vascular structures and lymphatic channels (Figure 1.2). 
Dr. Nedergaard further characterized this pathway in rodents using in vivo two photon 
imaging and coined the term “glymphatic system”, since this functional waste clearance 
pathway involves astroglia and lymphatic-like paravascular channels (Iliff, Wang et al. 
2012). CSF enters from the subarachnoid space into paravascular artery channels and 
exchanges with interstitial fluid, which is cleared through paravascular veins. Additional 
lymphatic channels lining the dural sinuses and meningeal arteries were characterized by 
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Dr. Louveaue and Dr. Aspelund (Aspelund, Antila et al. 2015; Louveau, Smirnov et al. 
2015). These lymphatic vessels connect the meningeal compartment with the glymphatic 
system. As the cerebral glymphatic / lymphatic systems are further characterized, more 
research is warranted on their potential pathophysiological roles played in hydrocephalus 
development.  
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Figure 1.2: Paravascular Virchow-Robin spaces depicted on MRI. Axial non-
contrasted brain MRI demonstrating perivascular spaces (arrows) that appear hypointense 
to brain tissue and isointense to CSF in T1-weighted (A) and T2-weighted (B) sequences. 
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Post-hemorrhagic Hydrocephalus Pathophysiology and Potential Mechanisms 
PHH is a common debilitating consequence of severe grade GMH, and the 
mechanisms contributing to PHH development remain to be elucidated.  
Cerebroventricular expansion leads to mechanical compression of surrounding brain 
tissue, causing injury and consequent neurological deficits in patients surviving the initial 
bleed (Robinson 2012). PHH was commonly theorized to be caused by blood clots 
obstructing the cerebral aqueduct or formanina of Luschka and Magendie or by 
microthrombi obstructing small CSF outflow passages in the subarachnoid space. Much 
evidence suggests a variety of inter-related pathophysiological mechanisms that 
potentially alter normal CSF dynamics play significant roles in PHH development as well 
(Strahle, Garton et al. 2012; Whitelaw and Aquilina 2012; Tang, Tao et al. 2016). 
Applying concepts in current hydrocephalus theory towards PHH development after 
GMH may better illuminate potential mechanisms for therapeutic intervention (Figure 
1.3). 
 
Blood Clots, Hemoglobin, and Iron 
 Non-communicating / obstructive PHH may result from cerebroventricular blood 
clots and microthrombi directly impairing CSF circulation and absorption by obstructing 
the cerebral aqueduct, formanina of Luschka and Magendia, and subarachnoid CSF 
outflow passages. Subsequently, it was hypothesized intraventricular fibrinolytic therapy 
would remove cerebroventricular blood clots and reduce PHH incidence (Whitelaw and 
Aquilina 2012). In an adult intraventricular hemorrhage dog model, in which 
intraventricular blood injection resulted in 80% of dogs developing PHH, intraventricular 
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urokinase injection reduced PHH incidence to 10% (Pang, Sclabassi et al. 1986). Clinical 
investigations of intraventricular streptokinase, urokinase, or tissue plasminogen activator 
injections after GMH, however, concluded fibrinolytic therapy did not improve long-term 
dependence on ventriculo-peritoneal shunts (Whitelaw 1993). Thus, cerebroventricular 
obstruction from thrombi may play only a minor role in long-term PHH development. 
 Although intraventricular fibrinolytic therapy failed to improve clinical PHH 
outcomes, evidence suggests hemoglobin and iron may play an important role in PHH 
development (Strahle, Garton et al. 2014). Erythrocyte lysis after hemorrhage, typically 
from complement activation and consequent membrane attack complex formation, 
releases hemoglobin and iron into surrounding brain tissue. Experimental adult cerebral 
hemorrhage models conclude hemoglobin metabolites and iron contributes towards brain 
edema (Chen, Gao et al. 2011). Hemoglobin metabolites were also found in the CSF of 
rabbit pups with intraventricular hemorrhage, and iron was elevated in the CSF of 
preterm infants with PHH (Savman, Nilsson et al. 2001; Lee, Keep et al. 2010). 
Intraventricular injection of hemoglobin or iron into neonatal rat pups also resulted in 
significant acute ventricular dilation (Strahle, Garton et al. 2014). Additionally, acute and 
delayed iron chelation by Deferoxamine reduced long-term PHH development in 
neonatal rats after GMH (Klebe, Krafft et al. 2014). Iron, thus, is a quintessential player 
in PHH formation, although the exact mechanisms remain unclear. 
 Gene deletion studies determined iron transport and iron-dependent metabolic 
proteins are highly expressed in the ependymal lining compared to other brain tissue 
(Keep and Smith 2011). Thus, the ependymal lining may be adversely affected from iron 
overload due to GMH. Indeed, ependymal cells are theorized to prevent iron diffusion 
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into the brain parenchyma by up-taking it from the CSF (Moos 2002). Additionally, iron 
overload has been associated with increased expression of aquaporin 4 in adult rats with 
cerebral hemorrhage, and Deferoxamine treatment reduced aquaporin 4 expression (Qing, 
Dong et al. 2009). Iron, thus, may regulate expression of ependymal ion and water 
channels, such as aquaporin 4, and contribute towards PHH by altering CSF production 
dynamics at the ependymal layer. It should be noted, however, that diuretic treatments 
targeting ependymal channels were evaluated in clinical trials of preterm GMH patients 
and determined to have no clinical benefit. More research is needed to further elucidate 
iron’s pathophysiological role in development of hydrocephalus. 
 
Inflammation, Fibrosis, and Gliosis 
Inflammation has been associated with subependymal gliosis, fibrosing 
arachnoiditis, and meningeal fibrosis after GMH (Cherian, Whitelaw et al. 2004; Oi and 
Di Rocco 2006). GMH patients also have increased expression levels of inflammatory 
markers in their CSF, including TNF-α (Savman, Blennow et al. 2002). Vessel rupture 
results in blood and serum components entering the brain parenchyma. Resident immune 
cells, namely microglia, are activated by stimulating toll-like receptors and nod-like 
receptors with damage-associated molecular patterns, molecules that induce a non-
infectious inflammatory response (Klebe, McBride et al. 2015). Activated microglia 
secrete pro-inflammatory cytokines, extracellular proteases, and oxidative species, which 
damage surrounding tissue and recruit leukocytes that exacerbate inflammation (Chen, 
Yang et al. 2015; Yang, Salayandia et al. 2015). In neonatal rat pups with GMH, 
microglia proliferation was observed in the perihematoma region, microglia activation 
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was associated with phosphorylated ERK, and modulating microglia activation with 
minocycline or cannabinoid receptor 2 agonist ameliorate inflammation and improved 
outcomes (Tang, Chen et al. 2015; Tang, Tao et al. 2015). Interestingly, microglia may 
play an important role in hematoma resolution, since stimulating PPARγ improved short-
term hematoma resolution, which was dependent upon CD36 scavenger receptor and was 
associated with inducing the alternatively activated M2 microglia/macrophage phenotype 
(Flores, Klebe et al. 2016). 
Fibrosis is the forming of excess connective tissue as a consequence of a 
reparative process after inflammation (Birbrair, Zhang et al. 2014). Excess fibrous tissue 
formation may disrupt the normal functioning of surrounding tissue. Multiple factors 
trigger fibrosis after GMH. Thrombin, which is significantly active up to 10 days after 
GMH in neonatal rats, cleaves fibrinogen into fibrin to form fibrin clots, activates the 
complement pathway to augment inflammation, and stimulates protease-activated 
receptors (PARs), a family of G protein-coupled receptors (Luo, Wang et al. 2007; Babu, 
Bagley et al. 2012; Lekic, Klebe et al. 2015). PAR stimulation has been associated with 
fibrosis in several tissues, including liver, renal, pulmonary, and cardiac tissues. PAR 
stimulation upregulates mammalian target of rapamycin (mTOR), which is associated 
with ECM protein proliferation. Additionally, PAR stimulation exacerbates inflammation 
by upregulating cyclo-oxygenase 1 and 2 activity (Kataoka, Hamilton et al. 2003; 
Steinhoff, Buddenkotte et al. 2005; Luo, Wang et al. 2007). Phosphorylated mTOR and 
cyclo-oxygenase 2 levels were increased by 72 hours after GMH in rats, which were both 
reduced by combinatorial PAR-1,4 inhibitor administration (Lekic, Klebe et al. 2015). 
ECM proteins are theorized to deposit within the cerebroventricular system, similar to 
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blood clots and microthrombi (Strahle, Garton et al. 2012; Bowen, Jenkins et al. 2013; 
Tang, Tao et al. 2016). ECM protein overproduction, therefore, may obstruct normal CSF 
flow pathways. Indeed, fibronectin and vitronectin expression levels are significantly 
increased in GMH rats with long-term PHH (Klebe, Krafft et al. 2014; Manaenko, Lekic 
et al. 2014). Inhibiting mTOR with rapamycin and inhibiting cyclo-oxygenase 2 activity 
ameliorated long-term PHH and neurocognitive deficits in GMH rats, although 
expression levels of ECM proteins was not determined in this study (Lekic, Klebe et al. 
2015).  
TGF-β stimulates mesenchymal stem cells and fibroblasts, which produce ECM 
matrix proteins and deposit connective tissue (Bowen, Jenkins et al. 2013). TGF-β can be 
secreted from activated microglia, and TGF-β secretion can be induced by thrombin 
(Schuliga 2015). ECM production induced by TGF-β stimulation may deposit in the 
cerebroventricular system, disrupting CSF dynamics (Tada, Kanaji et al. 1994). A rabbit 
pup GMH model indicated TGF-β, fibronectin, and laminin expression levels were 
significantly increased in the ependymal and subependyma tissue after GMH (Cherian, 
Thoresen et al. 2004). Mice with transgenic TGF-β overexpression developed 
hydrocephalus with higher expression of ECM proteins in the brain than wild-types 
(Wyss-Coray, Feng et al. 1995). In a clinical study, increased TGF-β1 and ECM protein 
expression in the CSF were associated with PHH development in preterm infants 
(Aquilina, Chakkarapani et al. 2012; Douglas-Escobar and Weiss 2012). The TGF-β1 
isoform is most associated with PHH after IVH in neonates and adults (Gomes, Sousa 
Vde et al. 2005). Intrathecal TGF-β1 injection in mice resulted in hydrocephalus 
development, and TGF-β1 expression was significantly increased in brains of neonatal 
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rats with PHVD after intraventricular blood injection (Tada, Kanaji et al. 1994; Cherian, 
Thoresen et al. 2004). Indeed, TGF-β1 was elevated in both animal models and premature 
infants with PHH, although some studies dispute this (Heep, Stoffel-Wagner et al. 2004). 
In a rat GMH model, TGF-β1 was elevated within hours after GMH, but normalized by 
24 hours post-ictus (Tang, Chen et al. 2015). Additionally, inhibiting TGF-β1 
ameliorated long-term PHH and neurocognitive deficits as well as reduced vitronectin 
and GFAP expression in rats (Manaenko, Lekic et al. 2014). Although the mechanism of 
TGF-β signaling after GMH and its association with PHH development has been 
established, studies are lacking that discern the changes to CSF dynamics as a 
consequence of TGF-β signaling and fibrosis.  
Gliosis results from damage to the central nervous system and is characterized by 
the nonspecific reactive proliferation of astrocytes, microglia, and oligodendrocytes 
(Sofroniew 2009). Hydrocephalus development is also associated with 
neuroinflammation and reactive gliosis (Del Bigio, Wilson et al. 2003; Deren, Forsyth et 
al. 2009). Gliosis was observed in cerebral cortical biopsies from hydrocephalic children 
with shunts (Glees and Hasan 1990). Increased expression of Iba-1 and GFAP, markers 
for microglia and astrocytes respectively, were also observed in the brains of neonatal 
rats with hydrocephalus (Deren, Packer et al. 2010). Reactive gliosis in the subarachnoid 
space was associated with hydrocephalus development after subarachnoid hemorrhage in 
rats. In an IVH rat model, long-term GFAP expression is markedly increased, and 
injection of umbilical cord blood-derived mesenchymal stem cells reduced GFAP 
expression as well as long-term PHH development (Ahn, Chang et al. 2013). Aquaporin 4 
knockout mice more rapidly developed hydrocephalus after kaolin injection, although 
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increased aquaporin 4 expression is observed in hydrocephalus too (Bloch, Auguste et al. 
2006; Mao, Enno et al. 2006). Aquaporin 1 is expressed on the choroid plexus apical 
membrane and aquaporin 1 knockout mice had decreased CSF production (Oshio, 
Watanabe et al. 2005). Given the important role astrocytes play in the blood-brain and 
blood-CSF barrier functions as well as in glymphatic mediated CSF-interstitial fluid 
exchange, gliosis may have a profound effect on CSF dynamics and PHH development, 
which warrants further investigation. 
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Figure 1.3: Summary of GMH Pathophysiological Pathways. Know pathways and 
potential mechanisms disrupting cerebrospinal fluid dynamics and contributing to post-
hemorrhagic hydrocephalus development after germinal matrix hemorrhage.  
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Conclusions 
Our understanding of hydrocephalus has changed significantly since Dr. Dandy’s 
first experiments in the early 20th century and the bulk flow theory was proposal. The 
source for CSF production is choroidal and ependymal capillaries, and the source for CSF 
reabsorption are subarachnoid and parenchymal capillaries as well as perivascular 
channels following glymphatic mediated CSF-interstitial fluid exchange. The current 
hydrodynamic theory suggests hydrocephalus develops from disruptions in hydrostatic 
and osmotic pressures in the brain microvasculature as well as disruptions in vascular 
pulsatile distribution due to alterations in overall brain compliance. Our purpose is to 
reconcile our knowledge of GMH and PHH development with the current hydrodynamic 
theory of hydrocephalus. Indeed, many GMH/IVH studies suggest PHH is a consequence 
of obstructions within the cerebroventricular system and subarachnoid drainage pathways 
due to thrombi, gliosis, and fibrosis. In line with current hydrocephalus school of thought, 
we suggest thrombi, gliosis, and fibrosis after GMH are not merely obstructing CSF 
passages but are altering barrier dynamics in the microvasculature and ependymal lining, 
altering CSF dynamics and CSF-interstitial fluid exchange to cause PHH development. 
Future research should elucidate these potential mechanisms. 
 
Specific Aims 
 Post-hemorrhagic hydrocephalus is a debilitating consequence of germinal matrix 
hemorrhage (Ballabh 2010; Heron, Sutton et al. 2010). Thrombin as well as 
intracerebroventricular blood clots have been identified as causative factors of 
hydrocephalus formation. Thrombin initiates inflammatory responses, gliosis, and 
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overproduction of ECM proteins that may permanently obstruct the cerebroventricular 
system (Xue, Balasubramaniam et al. 2003; Cherian, Whitelaw et al. 2004; Volpe 2009). 
Thrombin mediates brain injury by activating PARs (Kataoka, Hamilton et al. 2003; 
Steinhoff, Buddenkotte et al. 2005). PAR stimulation leads to phosphorylation and 
subsequent activation of mTOR, which is linked to overproduction of ECM proteins that 
cause impaired CSF circulation and absorption (Paul, Leef et al. 2000; Crews, Wyss-
Coray et al. 2004; Del Bigio 2004; Xue and Del Bigio 2005; Ballabh, Xu et al. 2007; 
Dummula, Vinukonda et al. 2010). Blood clots directly impair CSF circulation and 
absorption. Previous studies of adult hemorrhagic stroke suggest activation of PPARγ 
enhances microglial phagocytosis of red blood cells via CD36 scavenger receptor, which 
results in enhanced clot resolution and improved neurobehavioral outcomes (Zhao, Zhang 
et al. 2006; Zhao, Sun et al. 2007). Additionally, lysed red blood cells and metabolized 
hemoglobin releases non-protein bound iron, which mediates brain injury and is 
associated with PHH development. The objective of this proposal is to characterize the 
extent of GMH-induced brain injury and evaluate the implications of thrombin, PARs, 
PPARγ, CD36, and iron in GMH pathophysiology. The long-term goals are to provide 
non-invasive, therapeutic approaches for GMH patients. The central hypothesis is the 
inhibition of thrombin or thrombin’s downstream effectors PAR-1 and mTOR as well as 
enhancement of clot and iron clearance via PPARγ and iron chelation respectively 
reduces GMH-induced hydrocephalus and improves long-term neurological function in 
rats. The hypothesis will be tested in two specific aims. 
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Aim 1 
 Determine the role of PPARγ in clot clearance as well as iron chelation by 
Deferoxamine after GMH. PPARγ activation will enhance CD36-mediated microglial 
phagocytosis of red blood cells and, thus, reduce blood clots and subsequent 
hydrocephalus after GMH. Iron chelation will also improve long-term neurological and 
brain morphological outcomes after GMH. Aim 1A will investigate the time-course of 
PPARγ and CD36 expression as well as the time course of hematoma resolution after 
PPARγ stimulation or inhibition after GMH. Long-term brain morphological and 
neurological outcomes following PPARγ stimulation or inhibition will also be evaluated. 
Short-term hematoma resolution from PPARγ stimulation will be reversed by CD36 
knockdown. Aim 1B will investigate if acute or delayed iron chelation treatment will 
improve long-term neurological and brain morphological outcomes as well as reduce 
ECM protein proliferation after GMH. 
 
Aim 2 
Determine the role of activated thrombin/PAR-1/mTOR pathway in GMH 
induced hydrocephalus. Thrombin activation and stimulation of its downstream receptor, 
PAR-1, will lead to mTOR activation and consequent ECM overproduction after GMH, 
resulting in long-term post-hemorrhagic hydrocephalus development and neurological 
deficits. Aim 2A will investigate the time course of thrombin activation and if 
combinatorial PAR-1 and PAR-4 inhibition will reduce short-term COX-2 and mTOR 
activation as well as if COX-2 and mTOR inhibition will improve long-term 
neurobehavioral and brain morphological outcomes. Aim 2B will investigate if direct 
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thrombin or PAR-1 inhibition will reduce short-term mTOR activation, improve 
neurobehavioral and brain morphological outcomes, and reduce long-term ECM protein 
proliferation. PAR-1 stimulation will attempt to reverse effects from PAR-1 inhibition.  
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Figure 1.4: Schematic representation of the overall central hypothesis and research 
aims. Our central hypothesis is thrombin/PAR-1/mTOR pathway inhibition, enhanced 
PPARγ/CD36 mediated phagocytosis of blood clots, and iron chelation after germinal 
matrix hemorrhage will ameliorate long-term post-hemorrhagic hydrocephalus and 
consequent neurofunctional deficits. Aim 1 will investigate PPARγ/CD36 mediated 
hematoma resolution by microglia/macrophage phagocytosis as well as iron chelation by 
Deferoxamine. Aim 2 will investigate the thrombin/PAR-1/mTOR pathway and 
extracellular matrix protein proliferation. 
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Abstract 
Germinal matrix hemorrhage remains the leading cause of morbidity and 
mortality in preterm infants in the United States with little progress made in its clinical 
management.  Survivors are often afflicted with long-term neurological sequelae, 
including cerebral palsy, mental retardation, hydrocephalus, and psychiatric disorders.  
Blood clots disrupting normal cerebrospinal fluid circulation and absorption after 
germinal matrix hemorrhage are thought to be important contributors towards post-
hemorrhagic hydrocephalus development.  We evaluated if upregulating CD36 scavenger 
receptor expression in microglia and macrophages through PPAR stimulation, which 
was effective in experimental adult cerebral hemorrhage models and is being evaluated 
clinically, will enhance hematoma resolution and ameliorate long-term brain sequelae 
using a neonatal rat germinal matrix hemorrhage model.  PPAR stimulation (15d-PGJ2) 
increased short-term PPAR and CD36 expression levels as well as enhanced hematoma 
resolution, which was reversed by a PPAR antagonist (GW9662) and CD36 siRNA.  
PPAR stimulation (15d-PGJ2) also reduced long-term white matter loss and post-
hemorrhagic ventricular dilation as well as improved neurofunctional outcomes, which 
were reversed by a PPAR antagonist (GW9662).  PPAR-induced upregulation of CD36 
in macrophages and microglia is, therefore, critical for enhancing hematoma resolution 
and ameliorating long-term brain sequelae. 
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Introduction 
The ganglionic eminence consists of neuronal and glial precursor cells located at 
the head of the caudate nucleus below the lateral ventricles of the developing fetus, and 
the highly vascularized region within the subependymal tissue is the germinal matrix.  
Cerebral blood flow fluctuation associated with hemodynamic and respiratory instability 
in preterm infants in conjunction with the inherent fragility of the germinal matrix often 
leads to germinal matrix hemorrhage, a very common and major neurological 
complication of prematurity. Germinal Matrix Hemorrhage (GMH) occurs when 
immature blood vessels rupture within the subependymal (or periventricular) germinal 
region of the ganglionic eminence in the immature brain (Ballabh 2010). In the United 
States alone, GMH occurs in approximately 12,000 lives births per year, and the number 
of moderate-to-severe GMH cases has remained steady over the past two decades 
(Fanaroff, Stoll et al. 2007; Jain, Kruse et al. 2009; Osterman, Kochanek et al. 2015). 
Clinical studies indicate GMH afflicted infants often suffer from long-term neurological 
deficits, cerebral palsy, mental retardation, hydrocephalus, and psychiatric disorders 
(Kadri, Mawla et al. 2006; Ballabh 2014). Prenatal glucocorticoid treatment remains the 
best treatment for preventing GMH, yet minimal advancements have been made in GMH 
clinical management post-ictus (Shankaran, Bauer et al. 1995; Roberts and Dalziel 2006).   
Hemodynamic and respiratory instability in preterm infants results in fluctuations 
of cerebral blood flow in the inherently frail germinal matrix vasculature, often resulting 
in spontaneous bleeding (Ballabh 2014). The consequent hematoma applies mechanical 
pressure to glia and neurons, resulting in cytotoxicity and necrosis, as well as evokes an 
inflammatory response, leading to secretion of destructive proteases and oxidative 
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species (Lekic, Klebe et al. 2015). In adult cerebral hemorrhage, clinical studies indicate 
hematoma volume is the best prognostic indicator; larger hematoma volumes have 
worsened outcomes (Keep, Xi et al. 2005; Xi, Keep et al. 2006). Experimental adult 
cerebral hemorrhage studies proved more rapid hematoma resolution is necessary for 
quickly ameliorating inflammation and improving neurological recovery (Zhao, Sun et al. 
2007; Zhao, Grotta et al. 2009).  Additionally, blood clots directly impair cerebrospinal 
fluid circulation and absorption after GMH, significantly contributing towards post-
hemorrhagic hydrocephalus development (Cherian, Whitelaw et al. 2004; Aquilina, 
Chakkarapani et al. 2011). Therefore, we hypothesize enhancing hematoma resolution 
will improve GMH outcomes. 
Microglia are resident macrophages of the central nervous system and are critical 
drivers of the neuro-inflammatory response after GMH and other hemorrhagic brain 
injuries (Aronowski and Zhao 2011; Tang, Chen et al. 2015). Activated microglia recruit 
hematogenous phagocytes to the injured site, which engulf the hematoma as well as 
damaged or dead tissue (Cox, Crossley et al. 1995; Aronowski and Hall 2005). The role 
microglia play in hemorrhagic brain injury pathogenesis is different in neonates than 
adults (Woo, Wang et al. 2012).  Unlike the adult brain where microglia cells and 
macrophages contribute to brain injury after stroke through the production of 
inflammatory cytokines (Vexler and Yenari 2009), neonatal brains demonstrate the 
opposite as the depletion of these cells enhances injury by removing endogenous 
protective mechanisms (Faustino, Wang et al. 2011).    
Scavenger receptor CD36, a trans-membrane glycoprotein, is involved in several 
biological functions, such as foam cell formation, immune cell chemotaxis, and 
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phagocytosis of apoptotic cells (Woo, Wang et al. 2012). CD36 receptor is reportedly 
located on the cell surface of several cell types, including monocytes, endothelial cells, 
and microglia. CD36 plays an important role in phagocytosis, and upregulating its 
expression beneficially enhances hematoma resolution (Zhao, Sun et al. 2007). 
Transfection of non-phagocytic cells with a CD36-expressing gene converted those cells 
into phagocytes (Ren, Silverstein et al. 1995). CD36 genetic deletion worsened injury 
after acute focal stroke in neonatal mice, partially by decreasing removal of apoptotic 
cells (Woo, Wang et al. 2012).  
Peroxisome proliferator-activated receptor gamma (PPAR), a member of the 
nuclear hormone receptor superfamily, plays a major role in the upregulating CD36 
expression (Zhao, Sun et al. 2007; Zhao, Grotta et al. 2009).  PPAR stimulation exerts 
anti-inflammatory effects in several central nervous system injuries and disorders 
(Pereira, Hurtado et al. 2005; Landreth, Jiang et al. 2008). Many studies demonstrated 
PPAR is neuroprotective in various experimental stroke models (Pereira, Hurtado et al. 
2005; Zhao, Sun et al. 2007; Woo, Wang et al. 2012; Shao and Liu 2015). In adult 
intracerebral hemorrhage (ICH) experimental models, PPAR activation was directly 
associated with upregulation of CD36 expression, leading to enhanced phagocytosis-
mediated clearance of the hematoma as well as dead or damaged cells by microglia and 
macrophages. PPAR stimulation reduced expression of pro-inflammatory mediators, 
ameliorated secondary brain injury, and improved functional recovery after ICH (Zhao, 
Sun et al. 2007). Currently, PPAR stimulation for enhancing hematoma resolution and 
ameliorating secondary brain injury is being clinically tested in ICH patients (Gonzales, 
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Shah et al. 2013). Yet, no clinical trials are evaluating PPAR stimulation in GMH 
patients.   
In this study, we assess if PPAR stimulation enhances CD36-mediated 
hematoma resolution in a neonatal rat germinal matrix hemorrhage model. We 
hypothesize PPARγ stimulation, using 15d-PGJ2, will augment microglia/macrophage 
phagocytosis of blood clots, reducing post-hemorrhagic hydrocephalus, inflammation, 
behavioral dysfunction, and neuronal loss, which will be reversed by CD36 knockdown 
or PPAR antagonist administration.  
 
Materials and methods 
Animals and Surgeries 
All experimental procedures were conducted in accordance with the National 
Institutes of Health guidelines for the treatment of animals, and were approved by the 
Institutional Animal Care and Use Committee of Loma Linda University. Two hundred 
and sixty P7 Sprague-Dawley neonatal pups (Harlan, Indianapolis, IN) weighing 12-15 g 
(brain development is comparable to 30-32 week gestation humans) were used in this 
study. Germinal matrix hemorrhage was achieved by stereotactic-guided injection of 
bacterial collagenase, as previously described (Lekic, Manaenko et al. 2012). Pups were 
anesthetized with 3% isoflurane (delivered through medical grade oxygen and mixed air) 
while being stabilized onto a stereotaxic frame. Isopropyl alcohol followed by betadine 
was applied to the incision site. Incision was made on the longitudinal plane to expose the 
skull and reveal bregma. The stereotactic coordinates from bregma were as follows: 1.6 
mm (rostral), 1.6 mm (right lateral), and 2.8 mm (depth) from the dura. A burr hole (1 
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mm) was drilled, into which a 27 gauge needle was inserted at a rate of 1 mm/min. 0.3 
units of clostridial collagenase VII-S (Sigma Aldrich, MO) in 1 µL was infused over a 
period of 3 minutes with a Hamilton syringe guided by a microinfusion pump (Harvard 
Apparatus, Holliston, MA). After completing infusion, the needle is left into position for 
an additional 10 minutes after injection to prevent “back-leakage” and then removed at a 
rate of 1 mm/min. Once the Hamilton is removed, the burr hole is sealed with bone wax 
and the incision site sutured. Animals are then given buprenorphine and allowed to 
recover on a 37°C heated blanket. When fully recovered, pups are then placed back with 
the mother. Surgery time per animal is approximately 30 minutes. Sham animals were 
subject to needle insertion without collagenase infusion.  The same procedures were 
performed for intraventricular injection of siRNA, except the stereotactic coordinates 
from bregma were as follows: 1.0 mm (rostral), 1.0 mm (left lateral), and 1.8 mm (depth) 
of the dura. 
 
Animal Treatments and Experimental Groups 
P7 rat pups were randomly divided into the following groups: sham-operated 
(n=38), Vehicle (n=38), GMH + 15d-PGJ2 (n=38), GMH + 15d-PGJ2 + GW9662 (n=38), 
GMH + CD36 siRNA (n=12), GMH + 15d-PGJ2 + CD36 (n=12), GMH + scrambled 
siRNA (n=12). The PPARγ agonist (15d-PGJ2, 0.1mg/kg; Sigma Aldrich), antagonist 
(GW9662, 4mg/kg; Sigma Aldrich) + agonist, and saline (for sham and vehicle groups) 
were administered intraperitoneally to experimental animals at 1 hour post-GMH and 
then once daily for 7 days. CD36 siRNA (1.2 ng, Cell Signaling & Santa Cruz), and 
scrambled siRNA (1.2 ng, Santa Cruz) were administered via intraventricular injection to 
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experimental animals 24 hours prior to GMH induction. Buprenorphine (0.01 mg/kg) was 
administered subcutaneously to all groups after completing surgery. 
 
Animal Perfusion and Tissue Extraction 
Animals were euthanized using isoflurane (≥5%) followed by trans-cardiac 
perfusion with ice-cold phosphate buffered saline (PBS) for hemoglobin assay and 
Western blot samples or with ice-cold PBS followed by 10% formalin for histology 
samples. Forebrains for hemoglobin assay and Western blot were snap-frozen with 
liquid-nitrogen, then stored in -80°C freezer before protein extractions or 
spectrophotometric quantification.  Histological brain samples were post-fixed in 10% 
Fomaldehyde for at least 3 days and then 30% sucrose for at least 3 days, all stored in 
4°C fridge.  Forebrains were next embedded in Optimal Cutting Temperature compound 
and stored in -20°C freezer. 
 
Hemoglobin Assay 
Spectrophotometric measurements were used to assess hemorrhagic volume using 
well-established protocols (Choudhri, Hoh et al. 1997; Tang, Liu et al. 2004; Lekic, 
Manaenko et al. 2011). Frozen extracted forebrains were placed into individual glass 
tubes containing 3 mL of PBS. The tissue was homogenized for 60 seconds (Tissue Miser 
Homogenizer; Fisher Scientific, Pittsburgh, PA) followed by ultrasonication for 1 minute 
to lyse erythrocyte membranes.  The products were then centrifuged for 30 minutes and 
the supernatant was separated from the pellets. A 4:1 ratio of Drabkin’s reagent (Sigma-
Aldrich) and supernatant were combined, which were left to react for 15 minutes. 
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Absorbance, using a spectrophotometer (540 nm; Genesis 10uv; Thermo Fisher 
Scientific, Waltham, MA), was calculated into a hemorrhagic volume (μL) on the basis of 
a standard curve as routinely performed (Lekic, Manaenko et al. 2011).  
 
Intracranial Pressure (ICP) Measurements 
At 28 days post-ictus, animals were anesthetized and mounted onto a stereotaxic 
frame, where the head was inclined downward at a 30 degree angle. A midline skin 
incision was made to expose the atlanto-occipital membrane. The cisterna magna was 
punctured with a 26G Hamilton needle, which was connected to a pressure transducer of 
a Digi-Med LPA 400-low pressure Anayzer  (Micro-Med-Louisville, Kentucky, USA) as 
described (Lackner, Vahmjanin et al. 2013) 
 
Western Blotting 
Protein concentrations for immunoblot (Lekic, Manaenko et al. 2011) were 
determined by DC protein assay (Bio-Rad, Hercules, CA). 30 µg protein per sample were 
loaded into wells of 4-20% gels, ran for 30 minutes at 50V then 90 minutes at 125V, then 
transferred onto nitrocellulose membranes at 0.3A for 120 minutes (Bio-Rad). 
Membranes were incubated for 2 hours in 5% non-fat milk in Tris-buffered saline 
containing 0.1% Tween20. Then the following primary antibodies were incubated 
overnight: anti-PPARy (1:1000; Santa Cruz, Dallas, Texas), CD36 (1:500, Santa Cruz, 
Dallas, Texas), and mannose receptor (CD206) (1:500, ABcam, Cambridge, 
Massachusetts). Secondary antibodies (1:2000; Santa Cruz Biotechnology, Santa Cruz, 
CA) were then applied to the membranes and incubated for 2 hours and then processed 
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with the ECL plus Kit (GE Healthcare and Life Science, Piscataway, NJ). β-actin was 
used as an internal control against the anti-body (1:1000; Santa Cruz Biotechnology, 
Santa Cruz, CA). ImageJ software (4.0, Media Cybernetics, Silver Spring, MD) was used 
to analyze the relative density of the resultant protein immunoblot images as described 
(Tang, Liu et al. 2004). 
 
Histological Volumetric Analysis 
10 μm thick coronal brain sections were cut every 600 μm using a cryostat (Leica 
Microsystems LM3050S) and were placed onto poly-L-lysine-coated slides. Brain slices 
were Nissl stained morphometrically analyzed using computer-assisted (ImageJ 4.0, 
Media Cybernetics, Silver Spring, MD) hand delineation of the ventricle system (lateral, 
third, cerebral aqueduct, and fourth), hemisphere (cortex, subcortex), caudate, thalamus, 
hippocampus, and corpus callosum (white matter) (Lekic, Manaenko et al. 2011). These 
structures were delineated using optical dissector principles from prior stereological 
studies (Reisert, Wildemann et al. 1984; Oorschot 1996; Tang, Lopez et al. 2001; 
Bermejo, Jimenez et al. 2003; Avendano, Machin et al. 2005; Ekinci, Acer et al. 2008; 
Klebe, Krafft et al. 2014). Volumes were calculated using the following equation: 
[(Average [(Area of coronal section) × Interval × Number of sections) (MacLellan, Silasi 
et al. 2008).  
 
Immunohistochemistry 
10 μm thick slices were first stained with OX-42 (1:1000, ABcam) and mannose 
receptor (1:1000, ABcam) overnight at 4 °C, followed by incubation with appropriate 
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fluorescence conjugated secondary antibodies (Jackson Immunoresearch, West Grove, 
PA). The peri-hemorrhagic area was imaged by a Fluorescent Olympus-BX51 
microscope and analyzed using MagnaFire SP 2.1B software (Olympus, Melville, NY). 
At least six sections per animal group over a microscopic field of 20 × (for microglia) 
were averaged and expressed as cells/field, as described (Wang and Dore 2007). 
 
Neurobehavioral Analysis 
Neurobehavioral function was evaluated in a blinded manner using a battery of 
tests, described below, to detect sensorimotor and cognitive deficits 28 days after GMH 
as previously described (Hartman, Lekic et al. 2009; Klebe, Krafft et al. 2014): Foot Fault 
Test: Rats were placed on a wire grid (20x40 cm) kept above the floor level and allowed 
to walk on the grid for 2 minutes. Number of foot faults will be recorded when a 
complete paw falls through the openings in the grid. Rotarod Test: Rats were placed on a 
rotarod (Columbus Instruments, Columbus, OH), which consists of a rotating horizontal 
cylinder (7 cm diameter) divided into 9.5-cm-wide lanes. Rats walked forward when the 
cylinder is rotating to avoid falling down. Rats were tested at a starting 5 RPM or 10 
RPM with acceleration at 2 RPM per 5 seconds. A photobeam circuit detected the latency 
to fall off the cylinder. Water Maze Test: Rats were released in a metal pool (110 cm 
diameter) filled with water and containing spatial cues on the walls, and they were 
allowed to swim to find a submerged platform (11 cm diameter). Each animal performed 
10 trials per day for 4 days, 5 blocks of 2 consecutive trials, with a 10-min interval 
between successive blocks. Over the next 3 days, the platform was submerged 1 cm 
below the water and surface and the rats had to find and remember the platform location. 
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Additionally, at the end of each day, the platform was removed and animals were allowed 
to swim to find the platform quadrant. An overhead camera with a computerized tracking 
system (Noldus Ethovision; Noldus, Tacoma, WA) recorded the swim path and measured 
the swim distance, swim speed, and time spent in probe quadrant. 
 
Statistical Analysis 
A power analysis using a type I error rate of 0.05 and a power of 0.8 on a 2-sided 
test was used to estimate sample size. Data are expressed in Mean ± Standard Deviation. 
One-way ANOVA on ranks using the Student-Newman-Keuls post-hoc test was used to 
analyze behavioral, histological, western blots, and immunohistochemistry. A P-value 
<0.05 was considered statistically significant. 
 
Results 
PPAR Stimulation Ameliorated Long-term Neurological Deficits 
The vehicle group performed significantly worse compared to sham in the Morris 
Water Maze evaluation, yet PPARγ stimulation improved spatial learning and memory 
compared to vehicle and was not significantly different from sham.  Treatment effect was 
reversed by the PPAR antagonist (*P<0.05 versus Sham; #P<0.05 versus Vehicle; 
†P<0.05 versus GW9662 + 15d-PGJ2; Figure 2.1.A-B). Treatment also significantly 
improved sensorimotor function in the foot fault test compared to other GMH groups 
(*P<0.05 versus Sham; #P<0.05 versus Vehicle; †P<0.05 versus GW9662 + 15d-PGJ2; 
Figure 2.1.C). Yet no significant difference was achieved in the treated group compared 
to vehicle and antagonist groups in the rotarod sensorimotor evaluation (*P<0.05 versus 
Sham; #P<0.05 versus Vehicle; †P<0.05 versus GW9662 + 15d-PGJ2; Figure 2.1.D). 
 63 
 
 
 
 
 
Figure 2.1: Long-term neurocognitive and sensorimotor outcomes after 15d-PGJ2 
treatment and PPARγ inhibition with 15d-PGJ2 treatment at 3-4 weeks after GMH. 
Neurofunctional assessment of (A and B) Morris water maze, (C) foot fault, and (D) 
rotarod at 21 to 28 days after germinal matrix hemorrhage. Values are expressed as 
mean±SD. *P<0.05 compared with sham, #P<0.05 compared with vehicle, and †P<0.05 
compared with inhibitor and agonist. N=8 per group; and RPM, rounds per minute. 
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PPAR  Stimulation Improved Long-term Brain Morphology 
Since increased intracranial pressure is associated with hydrocephalus, ICP was 
measured in rats at 4 weeks post-ictus. ICP was significantly decreased in treated groups 
when compared to vehicle and PPAR antagonist groups (*P<0.05 versus Sham; #P<0.05 
versus Vehicle; †P<0.05 versus GW9662 + 15d-PGJ2; Figure 2.2.B). Calculated cortical 
thickness is presented as a ratio to the mean of sham and was significantly deceased in 
the vehicle and PPAR antagonist group, but the PPAR stimulated group had 
significantly less cortical loss (*P<0.05 versus Sham; #P<0.05 versus Vehicle; †P<0.05 
versus GW9662 + 15d-PGJ2; Figure 2.3.A). Ventricular volume was significantly 
increased in vehicle and PPAR antagonist groups, but 15d-PGJ2 treatment reduced post-
hemorrhagic ventricular dilation (*P<0.05 versus Sham; #P<0.05 versus Vehicle; 
†P<0.05 versus GW9662 + 15d-PGJ2; Figure 2.3.B). White matter loss is presented as a 
percentage of white matter present to mean of sham. White matter loss was reduced by 
PPAR stimulation, but vehicle and PPAR antagonist groups had significant white 
matter loss (*P<0.05 versus Sham; #P<0.05 versus Vehicle; †P<0.05 versus GW9662 + 
15d-PGJ2; Figure 2.3.C). Basal ganglia loss is presented as a percentage of basal ganglia 
present to mean of sham. The 15d-PGJ2 treated group had significantly decreased basal 
ganglia loss compared to the vehicle group. Surprisingly, basal ganglia loss in the 
GW9662 group was not significantly different from PPAR agonist or vehicle groups 
(*P<0.05 versus Sham; #P<0.05 versus Vehicle; †P<0.05 versus GW9662 + 15d-PGJ2; 
Figure 2.3.D).  
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Figure 2.2: Effects of 15d-PGJ2 treatment and PPARγ inhibition with 15d-PGJ2 
treatment on brain morphology and intracranial pressure 4 weeks after GMH. 28 
days after germinal matrix hemorrhage. Representative microphotographs of (A) Nissl-
stained brain sections were taken and (B) Intracranial pressure (ICP) in mm Hg. Note: 
measurement on the right side of the representative pictures indicates the location of the 
brain section from bregma. Values are expressed as mean±SD. *P<0.05 compared with 
sham, #P<0.05 compared with vehicle, and †P<0.05 compared with inhibitor and agonist. 
N=6 per group; and mmHG, millimeters of Mercury. 
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Figure 2.3: Quantification of brain morphological outcomes from 15d-PGJ2 
treatment and PPARγ inhibition with 15d-PGJ2 treatment at 4 weeks post-GMH. 
Quantification of (A) cortical thickness, (B) ventricular volume, (C) white matter loss, 
and (D) basal ganglia loss at 28 days after germinal matrix hemorrhage. Values are 
expressed as mean±SD. *P<0.05 compared with sham, #P<0.05 compared with vehicle, 
and †P<0.05 compared with inhibitor and agonist. N=6 per group.  
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PPAR  Stimulation Enhanced Hematoma Resolution, Increased Activated 
Microglia, and Induced M2 Polarization 
A hemoglobin assay time-course was conducted at 24 hours, 72 hours, and 7 days 
to determine PPAR’s role in hematoma resolution. At 24 hours, all groups had 
significantly greater hemoglobin content in the brain compared to sham (*P<0.05 versus 
Sham; Figure 2.4.A). At 72 hours, all groups had significantly greater hemoglobin 
content in the brain compared to sham, but 15d-PGJ2 treatment had significantly less 
hemoglobin content compared to vehicle, which was reversed by GW9662 treatment 
(*P<0.05 versus Sham; #P<0.05 versus Vehicle; †P<0.05 versus GW9662 + 15d-PGJ2; 
Figure 2.4.B).  At 7 days, only the vehicle and PPAR antagonist groups had significantly 
greater hemoglobin content compared to sham, but the PPAR agonist group had 
significantly less hemoglobin content compared to vehicle and PPAR antagonist groups 
(*P<0.05 versus Sham; #P<0.05 versus Vehicle; †P<0.05 versus GW9662 + 15d-PGJ2; 
Figure 2.4.C). Since significantly greater hematoma resolution was observed in the 
PPAR stimulated group at 72 hours, representative photographs of immuno-stained  
activated microglia/macrophages (OX-42) in the peri-hematoma region are presented at 
this time point (Figure 2.5.A). The 15d-PGJ2 treated group had relatively increased 
number of microglia/macrophage compared to sham, vehicle, and PPARγ antagonist 
group ((*P<0.05 versus Sham; #P<0.05 versus Vehicle; †P<0.05 versus GW9662 + 15d-
PGJ2; Figure 2.5.B).  Additionally representative photographs of the co-localization of 
activated microglia/macrophages (OX-42) and mannose receptor (CD206) in the peri-
hematoma region are presented at 72 hours, showing an increase in OX-42/mannose 
receptor expression in 15d-PGJ2 treated group in comparison to all other groups (Figure 
2.5.A). 
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Figure 2.4: Short-term hematoma resolution after GMH from 15d-PGJ2 treatment, 
PPARγ inhibition with 15d-PGJ2 treatment, CD36 knockdown, and CD36 
knockdown with 15d-PGJ2 treatment. Hemoglobin assay at (A) 24 hours, (B) 72 hours, 
and (C) 7 days. At 72 hours (D) Hemoglobin assay was conducted on siRNA groups. 
Values are expressed as mean±SD. *P<0.05 compared with sham, #P<0.05 compared 
with vehicle, and †P<0.05 compared with inhibitor and agonist, %P<0.05 compared CD 
36 siRNA, and @P<0.05 compared to scrambled siRNA. N=6 per group. 
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Figure 2.5: Microglia / Macrophage activation and differentiation into M2 subtypes 
at 3 days post-GMH following 15d-PGJ2 treatment, CD36 knockdown, and CD36 
knockdown with 15d-PGJ2 treatment.  Immunohistochemistry representative pictures 
were taken showing the co-localization of (A) activated microglia (OX-42; scale bar: 
20 µm) with Mannose Receptor and DAPI staining and (B) quantification of activated 
microglia was conducted at 72 hours. Western blots were conducted at 72 hours for (C) 
CD206 Expression. Note: peri-hematoma region is below the yellow broken line (A) and 
the representative GMH brain indicates where IHC images were taken. Values are 
expressed as mean±SD. *P<0.05 compared with sham, #P<0.05 compared with vehicle, 
†P<0.05 compared with inhibitor and agonist, %P<0.05 compared CD36 siRNA, and 
@P<0.05 compared to scrambled siRNA. N=6 per group; and ICH, 
Immunohistochemistry. N=6 per group. 
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PPARγ Stimulation Increased CD36 and PPARγ Expression at 72 Hours 
  A time-course study was conducted to determine endogenous PPARγ and CD36 
expression levels in GMH at 0, 3, 6, 12 hours and 1, 3, 5, and 7 days after GMH. 
Endogenous PPARγ expression was significantly increased at 3, 6, 12 hours and 1 day 
compared to 0 hour (*P<0.05 versus 0 hours; Figure 2.6.A). Correspondingly, 
endogenous CD36 expression was significantly increased at 3, 6, 12 hours, and 1 day 
compared to 0 hour (*P<0.05 versus 0 hours; Figure 2.6.B), and tended to remain 
elevated by 7 days. PPARγ and CD36 expression levels were determined at 72 hours for 
all experimental groups. PPARγ expression was significantly increased in the 15d-PGJ2 
group compared to all other groups (*P<0.05 versus Sham; #P<0.05 versus Vehicle; 
†P<0.05 versus GW9662 + 15d-PGJ2; Figure 2.6.C). Much like PPARγ, CD36 expression 
was significantly increased in the 15d-PGJ2 group compared to all other groups (*P<0.05 
versus Sham; #P<0.05 versus Vehicle; †P<0.05 versus GW9662 + 15d-PGJ2; Figure 
2.6.D). 
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Figure 2.6: Short-term time course of CD36 and PPARγ expression after GMH and 
the effects of 15d-PGJ2 treatment, PPARγ inhibition with 15d-PGJ2 treatment, 
CD36 knockdown, and CD36 knockdown with 15d-PGJ2 treatment on CD36 and 
PPARγ expression levels. Western blot was conducted for time-course studies of (A) 
PPARγ and (B) CD36 at 0, 3, 6 , 12 hours, 1, 3, 5, 7 days after GMH. Western blot was 
then conducted at 72 hours for (C) PPAR-Υ and (D) CD36. Values are expressed as 
mean±SD. *P<0.05 compared with sham, #P<0.05 compared with vehicle, and †P<0.05 
compared with inhibitor and agonist. N=6 per group; and h and d, hour(s) and day(s).  
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CD36 Knockdown Reversed PPAR Agonist-enhanced Hematoma Resolution 
and M2 Expression at 72 Hours 
At 72 hours, CD36 knockdown reversed PPARγ agonist-enhanced hematoma 
resolution, which was not reversed in the scrambled siRNA group (*P<0.05 versus Sham, 
#P<0.05 versus Vehicle, %P<0.05 versus CD-36 siRNA + 15d-PGJ2, @P<0.05 versus 
scrambled siRNA+15d-PGJ2, Figure 2.4.D). Additionally, CD36 knockdown reversed 
PPARγ mannose receptor expression, which was not reversed in the scrambled siRNA 
group (*P<0.05 versus Sham, #P<0.05 versus Vehicle, %P<0.05 versus CD-36 siRNA + 
15d-PGJ2, @P<0.05 versus scrambled siRNA+15d-PGJ2, Figure 2.5.C). 
 
Discussion 
Neonatal brain hemorrhage is a common affliction of premature infants. The 
resultant hematoma is thought to play a major role in causing post-hemorrhagic 
hydrocephalus development because blood clots disrupt cerebrospinal fluid circulation 
and absorption in the ventricles (Crews, Wyss-Coray et al. 2004). Rapid hematoma 
resolution was neuroprotective in adult hemorrhagic stroke models (Zhao, Sun et al. 
2007; Zhao, Sun et al. 2015). In particular, PPARγ stimulation upregulates CD36 
expression in microglia/macrophages, leading to increased phagocytosis of blood 
products and more rapid hematoma resolution after adult intracerebral hemorrhage (Zhao, 
Sun et al. 2007). In this study, we examined the effects of stimulating PPARγ with 15d-
PGJ2 on hematoma resolution as well as long-term brain morphological and 
neurofunctional outcomes after collagenase-induced GMH in neonatal rats. In addition, 
we determined if PPARγ and CD36 inhibition reversed observed therapeutic effects from 
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PPARγ stimulation by 15d-PDJ2. This study is the first to assess this treatment approach 
in neonates for enhancing hematoma resolution as well as the first to evaluate its 
therapeutic potential for ameliorating long-term white matter loss, post-hemorrhagic 
hydrocephalus development, and neurological deficits.   
We evaluated the efficacy of 15d-PGJ2 treatment, a PPARγ agonist, administered 
1 hour post-ictus as a potential therapeutic modality for GMH-induced brain injury. 
Although treatment did not significantly increase hematoma resolution at 24 hours, it did 
significantly enhance hematoma resolution at 72 hours and 7 days after GMH (Figure 
2.4.A-C). PPARγ stimulation demonstrated more rapid hematoma clearance after GMH 
in neonates, starting at 72 hours, than after ICH in adults, which took 7 days (Zhao, Sun 
et al. 2007). 15d-PGJ2 co-admiration with GW9662, a PPARγ antagonist, reversed 15d-
PGJ2 treatment effects on enhanced hematoma resolution at 72 hours and 7 days after 
GMH. To determine if endogenous expression of PPARγ and CD36 changes after GMH, 
we performed a Western blot time course using 0, 3, 6, 12 hour, 1, 3, 5, and 7 day 
endpoints following GMH induction. Endogenous PPARγ expression increased at 3, 6, 
12 hour, and 1 day after GMH induction, then returned to baseline by 3 days (Figure 
2.6.A). Endogenous CD36 expression significantly increased at 3, 6, 12 hours, and 1 day 
after GMH induction, and tended to remain elevated through 7 days (Figure 2.6.B). 
Because endogenous PPARγ and CD36 expression returned near baseline at 72 hours and 
because 15d-PGJ2 treatment enhanced hematoma resolution at 72 hours, we determined 
treatment effects on PPARγ and CD36 expression levels by Western blot at 72 hours.  As 
expected, 15d-PGJ2 treatment significantly increased PPARγ expression compared to 
sham and vehicle, and 15d-PGJ2 co-administration with GW9662 reversed this effect 
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(Figure 2.6.C). Similarly, 15d-PGJ2 treatment significantly increased CD36 expression 
compared to sham and vehicle, and 15d-PGJ2 co-administration with GW9662 reversed 
this effect (Figure 2.6.D). 
CD36 receptor is an important scavenger receptor located on several cell types, 
including monocytes, endothelial cells, and microglia/macrophages. CD36 plays an 
important role in microglia/macrophage phagocytosis, and upregulating its expression 
beneficially enhances hematoma resolution (Zhao, Sun et al. 2007). More activated 
microglia were observed in the peri-hematoma region of treated GMH animals than all 
other groups, providing evidence of PPARγ’s treatment effects are dependent upon these 
critical immune cells (Figure 2.5.A-B). All GMH groups seemed to have increased DAPI 
stained cells post-ictus compared to sham. The germinal matrix has many growing and 
dividing neuronal and glial precursor cells. Prior GMH studies have documented 
increased proliferative cytokines and pathways, such as TGF-β and mTOR, after injury, 
and we speculate proliferative signaling triggers more profound gliosis after neonatal 
brain hemorrhage (Lekic, Klebe et al. 2015). While brain cell death is definitely 
occurring, we speculate proliferative signaling in conjunction with increased leukocyte 
infiltration contributes towards these observed results in neonatal brains. Although 
activated microglia/macrophages contribute to brain injury in adults, some evidence 
suggests microglia/macrophages have important defense mechanisms against injury in 
neonates, which could be explained by the vital role microglia play in neonatal brain 
development (Faustino, Wang et al. 2011; Harry and Kraft 2012). Furthermore, activated 
microglia/macrophages have two differentiated states, a pro-inflammatory classically 
activated state (M1), and an immune dampening and tissue regenerative alternatively 
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activated state (M2) (Klebe, McBride et al. 2015).  CD36 stimulation can contribute 
towards microglia/macrophage activation as well as M2 polarization (Kouadir, Yang et 
al. 2012; Rios, Koga et al. 2013; Chavez-Sanchez, Garza-Reyes et al. 2014).  PPARγ 
stimulation also polarizes microglia/macrophages towards the M2 state (Yoon, Jeon et al. 
2008; Pisanu, Lecca et al. 2014; Penas, Mirkin et al. 2015).  To corroborate these findings 
in GMH, immunohistochemical co-localization of activated microglia and mannose 
receptor (CD206), an M2 marker, demonstrated increased co-expression in 15d-PGJ2 
treated GMH animals compared to other groups, providing more evidence PPARγ 
induces M2 polarization (Figure 2.5.A). Similarly, CD206 Western blots demonstrated 
increased CD206 expression levels in treated GMH animals compared to sham, GMH 
animals with CD36 siRNA alone, and GMH animals with CD36 siRNA and 15d-PGJ2 
treatment. Interestingly, vehicle treated GMH animals showed a small tendency towards 
having increased CD206 expression levels, which also did not achieve a statistically 
significant difference compared to 15d-PGJ2 treated GMH animals. After hemorrhage, 
M2 microglia/macrophages are expected to increase over time as the peri-hematoma 
milieu transitions into an immune dampened tissue repair phase in which M2 
microglia/macrophages play a pivotal role (Klebe, McBride et al. 2015). CD36 
knockdown eliminated the tendency observed in the vehicle group, achieving a 
significantly reduced expression compared to 15d-PGJ2 treatment. CD36 knockdown also 
reversed 15d-PGJ2 induced upregulation of CD206 expression (Figure 2.5.C). CD36, 
thus, is important for M2 polarization, particularly after PPARγ stimulation. To further 
confirm microglial/macrophage CD36 plays a pivotal role in PPARγ-induced blood clot 
clearance, siRNA was used to knockdown CD36 expression. CD36 knockdown reversed 
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15d-PGJ2 treatment effects on enhanced hematoma resolution at 72 hours, which was not 
reversed by scrambled siRNA (Figure 2.4.D).  
In our long-term evaluations, vehicle treated GMH animals had significant 
cortical, white matter, and basal ganglia loss as well as post-hemorrhagic ventricular 
dilation, but 15d-PGJ2 treatment ameliorated these brain morphological maladies, which 
were reversed by PPARγ antagonist, GW9662, co-administration (Figure 2.3.A-D). 
Surprisingly, GW9662 co-administration did not completely reverse 15d-PGJ2’s effects 
on reducing basal ganglia loss, although a tendency was observed. Our ICP 
measurements agreed with the brain morphological assessment, where ICP levels were 
significantly lower in treated groups when compared to vehicle and PPARγ antagonist 
group (Figure 2.2.B). Additionally, vehicle treated GMH animals performed poorly in the 
Morris Water Maze, Foot Fault, and Rotarod tests, but 15d-PGJ2 treatment significantly 
improved spatial memory and motor function, which were reversed by GW9662 co-
administration (Figure 2.1.A-D). The foot fault test evaluates locomotor function, the 
rotarod test evaluates sensorimotor coordination and balance, and Morris Water Maze 
evaluates spatial learning and memory (Schaar, Brenneman et al. 2010). Although 15d-
PGJ2 reduced the number of foot faults, it did not significantly improve performance in 
the rotarod test. GMH and consequent post-hemorrhagic ventricular dilation may cause 
cerebellar injury that affects motor coordination (Volpe 2009; Brouwer, de Vries et al. 
2015; Fumagalli, Bassi et al. 2015). More thorough investigations are needed to elucidate 
the pathophysiology between GMH and cerebellar injury. Although motor coordination is 
an important factor in both the rotarod and foot fault tests, the element of balancing on an 
accelerating cylinder platform leads us to speculate cerebellar injury may more 
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profoundly affect performances in the rotarod evaluations. 15d-PGJ2 treatment may not 
be effective enough to ameliorate potential cerebellar injury from GMH and consequent 
post-hemorrhagic hydrocephalus, and, if this is the case, modulating the immune 
response after GMH may not be sufficient to promote complete functional recovery.  
Additionally, the rotarod test may not be sensitive enough for detecting improved 
sensorimotor outcomes in treatment groups, which is why we performed multiple 
neurofunctional evaluations. Nonetheless, these results provide sufficient evidence that 
enhanced hematoma resolution corresponds with improved long-term brain 
morphological and neurocognitive outcomes after GMH.  Most importantly, more rapid 
blood clot clearance resulted in significantly decreased post-hemorrhagic ventricular 
dilation, providing evidence that blood products play an important role in post-
hemorrhagic hydrocephalus development.  
The CD36 scavenger receptor is important in microglia/macrophage-mediated 
phagocytosis of cellular debris and blood products. Our results suggest PPARγ 
stimulation by 15d-PGJ2 increases microglia/macrophage phagocytic function by 
upregulating CD36 scavenger receptor expression in our experimental GMH model, 
leading to enhanced hematoma resolution. We are first to report the positive long-term 
effects on brain morphological and neurofunctional outcomes from more efficient 
hematoma resolution after GMH. Blood products disrupt cerebrospinal circulation and 
absorption in the cerebroventricular system, often resulting in post-hemorrhagic 
hydrocephalus.  Herein, we provide evidence that more rapid blood clot clearance 
reduces long-term post-hemorrhagic ventricular dilation after GMH. Removing the 
hematoma without damaging surrounding tissues is ideal and clinically relevant. PPARγ 
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stimulation could be a promising therapeutic approach for GMH patients, especially since 
PPARγ stimulation by Pioglitazone is already being evaluated in clinical trials for adult 
cerebral hemorrhage. 
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Abstract 
This study investigated if acute and delayed Deferoxamine treatment attenuates 
long-term sequelae after germinal matrix hemorrhage (GMH). Bacterial collagenase (0.3 
U) was infused intraparenchymally into the right hemispheric ganglionic eminence in P7 
rat pups to induce GMH.  GMH animals received either Deferoxamine or vehicle twice a 
day for 7 consecutive days.  Deferoxamine administration was initiated at either 1 hour or 
72 hours post-GMH.  Long-term neurocognitive deficits and motor coordination were 
assessed using Morris water maze, rotarod, and foot fault tests between day 21-28 post-
GMH.  At 28 days post-GMH, brain morphology was assessed and extracellular matrix 
protein (fibronectin and vitronectin) expression was determined. Acute and delayed 
Deferoxamine treatment improved long-term motor and cognitive function at 21-28 days 
post-GMH.  Attenuated neurofunction was paralleled with improved overall brain 
morphology at 28 days post-GMH, reducing white matter loss, basal ganglia loss, post-
hemorrhagic ventricular dilation, and cortical loss.  GMH resulted in significantly 
increased expression of fibronectin and vitronectin, which was reversed by acute and 
delayed Deferoxamine treatment. Acute and delayed Deferoxamine administration 
ameliorated long-term sequelae after GMH. 
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Introduction 
Germinal matrix hemorrhage (GMH) occurs when immature blood vessels 
rupture within the subventricular tissue in premature infants (Ballabh 2010).  GMH 
occurs in approximately 12000 live births per every year in the US and often results in 
developmental delays, mental retardation, cerebral palsy, and post-hemorrhagic 
hydrocephalus, posing significant socioeconomic burdens (Ballabh 2010; Kochanek, 
Kirmeyer et al. 2012).  Because current clinical management is limited, research is 
needed to investigate innovative therapeutic modalities. 
In adult rodent intracerebral hemorrhage and subarachnoid hemorrhage models, 
red blood cells present in the intraparenchymal tissue are lysed and hemoglobin 
metabolized to release iron, resulting in a highly oxidative environment and consequent 
iron toxicity that damages brain tissue (Lee, Keep et al. 2010; Xiong, Wang et al. 2013).  
Chelation of iron using Deferoxamine improved neurofunctional outcomes after 
intracerebral hemorrhage and subarachnoid hemorrhage, yet its efficacy has not been 
evaluated after neonatal GMH (Lee, Keep et al. 2011; Hatakeyama, Okauchi et al. 2013).  
Blood products and proliferation of extracellular matrix proteins are theorized to disrupt 
CSF flow dynamics following hemorrhage, leading to consequent post-hemorrhagic 
hydrocephalus development (Crews, Wyss-Coray et al. 2004). 
We hypothesized acute and delayed Deferoxamine treatment will ameliorate extracellular 
matrix protein proliferation, post-hemorrhagic ventricular dilation, and long-term 
neurofunctional outcomes after GMH. 
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Materials and Methods 
Animal Surgery and Experimental Groups 
All protocols and procedures were approved by the Institutional Animal Care and 
Use Committee at Loma Linda University. Timed-pregnant rats were purchased from 
Harlan Laboratories (Indianapolis, IN). Stereotaxic infusion of 0.3 U bacterial 
collagenase into the right ganglionic eminence was performed to induce GMH in P7 rat 
pups, as described (Lekic, Manaenko et al. 2012).  While some consider P7 rat pups to be 
equivalent in brain development of a term human infant, recent evidence suggests P7 is 
closer in brain development to 30-32 week gestation age human infants, which is 
approximately the point we want to model GMH (Lekic, Manaenko et al. 2012).  Briefly, 
rat pups were anesthetized with isoflurane (3 % in a 30/70 oxygen/medical air mixture) 
and placed prone with their head secured onto a rodent stereotaxic frame. After sterilizing 
the rodent’s scalp, a small midline incision was made to expose bregma. Next, a cranial 
burr hole was made 1.8 mm rostral and 1.5 mm right lateral from bregma, using a 
standard dental drill (1 mm). A 26-gauge needle was inserted through the cranial burr 
hole and stereotactically lowered 2.8 mm into the brain parenchyma. Following that, 
bacterial collagenase VII-S (0.3 U, Sigma; St. Louis, MO) was infused into the right 
hemispheric ganglionic eminence, at a rate of 0.25 µl/minute. Back-leakage of 
collagenase was prevented by keeping the needle in place for 10 minutes after completed 
infusion. Following that, the needle was withdrawn at a rate of 1 mm/minute, the burr 
hole was sealed with bone wax, and the scalp sutured. Sham animals were subjected to 
needle insertion only. Rat pups were returned to their dams after full recovery from the 
anesthesia.  Forty animals were divided into four groups:  Sham, Vehicle (PBS 
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intraperitoneally BID starting 1 hour post-GMH for 7 days), acute Deferoxamine (100 
mg/kg intraperitoneally BID starting 1 hour post-GMH for 7 days), and delayed 
Deferoxamine (100 mg/kg intraperitoneally BID starting 72 hours post-GMH for 7 days).  
Each animal group was alternated when undergoing surgeries. Blinded investigators 
performed the neurobehavioral, histological, and Western blot analyses. 
 
Behavioral Testing 
Neurocognitive deficits and motor coordination were evaluated by Morris water 
maze, rotarod, and foot fault tests between 21-28 days post-GMH (n=10/group).  The 
mentioned neurofunctional tests have been previously utilized for the evaluation of long-
term deficits in rodents subjected to unilateral hemorrhagic brain injury (Lekic, 
Manaenko et al. 2012; Leitzke, Rolland et al. 2013; Rolland, Lekic et al. 2013). All tests 
were conducted in a blinded fashion. Learning and memory abilities in rats were assessed 
via the Morris water maze by measuring (1) the swim distance for each animal before 
detecting a slightly submerged platform in a pool of water (diameter: 110 cm) and (2) the 
time each animal spent searching the target quadrant, after the platform has been removed 
from the pool (probe trial). An overhead infrared camera linked to a computerized 
tracking system (Noldus Ethovision, Tacoma, WA) recorded the swim path and time of 
each animal. The water maze experiments were conducted on day 21 to 25 post-GMH 
induction, one block per day followed by the probe trial. Animals that failed to swim or 
only swam in stationary circles were excluded from further analysis in our study.  Motor 
and coordination function were evaluated on post-operative days 26 to 28. The rotarod 
apparatus (Columbus Instruments, Columbus, OH), consisting of horizontally rotating 
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cylinders (7 cm in diameter, 9.5 cm in width) rotate either at constant velocity or 
accelerate 2 RPM every 5 seconds starting at a speed of 5 or 10 RPM. Continuous 
walking was required to avoid falling; the latency to fall was recorded for each animal by 
a photobeam circuit. Foot-fault testing was conducted by placing each animal on a 
horizontally elevated wire-grid (20 cm x 100 cm) and missteps through the grid were 
recorded over 2 minutes.  
 
Histopathological Analysis 
Ventricular volume, cortical thickness, white matter loss, and basal ganglia loss were 
calculated in Nissl stained histological brain sections 28 days post-GMH using NIH 
Image J software (n=5/group).  Brain tissue preparation, staining, and volumetric 
evaluations were conducted as previously described (Lekic, Manaenko et al. 2012; 
Leitzke, Rolland et al. 2013). Briefly, animals under deep isoflurane anesthesia were 
euthanized by transcardiac perfusion with PBS and 4% paraformaldehyde. Following 
that, brains were collected, formalin fixed (in 4% paraformaldehyde for 3 days), 
dehydrated (in 30 % sucrose for 3 days), and frozen coronal brain slices (10 µl) were 
obtained, using a cryostat (CM3050S; Leica Microsystems). Nissl stained histological 
brain sections were evaluated via computer assisted (Image J) hand delineation of 
cerebral and cerebroventricular structures, based on criteria from stereologic studies 
using optical dissector principles (Oorschot 1996; Ekinci, Acer et al. 2008). Volumes 
were calculated as the average delineated area from 10 μm sections taken at 
approximately 2.5 mm, 1.2 mm, 0.7 mm rostral and 2.9 mm caudal of bregma multiplied 
by the depth of the cerebroventricular system. The ventricular volume (mm3) was 
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calculated as average ventricular area multiplied by the depth of the cerebroventricular 
system. The cortical thickness was calculated and expressed as ratio of the contralateral 
brain cortex. Basal ganglia volumes and white matter loss were expressed as % of the 
sham group.  Basal ganglia and white matter volumes were calculated and expressed as 
% of the sham group by dividing their volumes to the overall average sham volume. 
 
Western Blotting 
Fibronectin and vitronectin expressions were quantified by Western blot at 28 
days post-GMH (n=5/group).  Briefly, whole brain samples were processed according to 
previously published protocols (Ma, Huang et al. 2011), and equal amounts of protein (50 
µg) were separated by SDS-PAGE before being transferred onto nitrocellulose 
membranes.  The latter were then blocked and incubated with the following primary 
antibodies: anti-fibronectin, anti-vitronectin (1:1000; Abcam) and anti-β-actin (1:4000; 
Santa Cruz Biotechnology, Santa Cruz, CA). After incubation with the primary and the 
appropriate secondary antibodies (1:4000; Santa Cruz Biotechnology, Santa Cruz, CA), 
immunoblots were visualized with the ECL Plus chemiluminescence reagent kit 
(Amersham Bioscience, Arlington Heights, IL) and bands were quantified using Image J 
(NIH). Results, expressed as mean±SEM, were normalized to the average values of the 
sham group.   
 
Statistical Analysis 
Sample size estimations were made by power analysis using a type I error rate of 
0.05 and a power of 0.8 on a two-sided test. Data are expressed as meanSEM. Western 
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blot and histological data were analyzed by one-way ANOVA followed by the Tukey 
post-hoc test, and behavior data were analyzed by one-way ANOVA on ranks and the 
Student-Newman-Keuls method.  A P value <0.05 was considered statistically 
significant. 
 
Results 
Deferoxamine Improved Brain Morphology after GMH 
At 28 days post-GMH, brain morphology was assessed in Nissl stained brain 
sections (n=5 group).  Ventricular volume was found significantly increased in  the 
vehicle group compared to sham, but acute and delayed Deferoxamine treatment 
significantly reduced GMH-induced ventricular dilation (P<0.05; Figure 3.1.A).  Cortical 
thickness was evaluated as a right hemisphere/left hemisphere ratio to the mean of sham 
and was significantly decreased in the vehicle group compared to sham-operated animals, 
but acute and delayed Deferoxamine treatment ameliorated cortical loss (P<0.05, Figure 
3.1.B).  Basal ganglia volume was evaluated as a percentage to mean sham basal ganglia 
volume (Figure 3.1.C).  Acute and delayed Deferoxamine treated groups had significantly 
less basal ganglia loss compared to the vehicle group (P<0.05; Figure 3.1.C).  White 
matter loss was evaluated as a percent loss using sham-operated animals as a baseline 
(Figure 3.1.D).  Acute and delayed Deferoxamine treated groups had significantly less 
white matter loss compared to the vehicle group (P<0.05; Figure 3.1.D). 
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Figure 3.1: Long-term brain morphological outcomes after acute and delayed 
Deferoxamine treatment at 4 weeks post-GMH. Quantification of (A) ventricular 
volume, (B) cortical thickness, (C) basal ganglia loss, and (D) white matter loss at 28 
days after germinal matrix hemorrhage.  Values are expressed as meanSEM.  *P<0.05 
compared to sham, and #P<0.05 compared to vehicle.  N=5 per group. 
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Deferoxamine Reduced Extracellular Matrix Protein Expression after GMH 
Western blot analyses were conducted at 28 days post-GMH induction (n=5 per 
group).  Fibronectin expression was found increased in the vehicle group compared to 
sham-operated animals, and acute and delayed Deferoxamine treatment significantly 
reduced fibronectin expression after GMH (P<0.05; Figure 3.2.A).  Vitronectin 
expression was also significantly increased in the vehicle group compared to sham-
operated animals, and acute and delayed Deferoxamine treatment tended to reduce 
vitronectin expression after GMH (P>0.05 vs sham; Figure 3.2.B). 
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Figure 3.2: Extracellular matrix protein expression levels after acute and delayed 
Deferoxamine treatment at 4 weeks post-GMH.  Western blot analysis of (A) 
Fibronectin and (B) Vitronectin at 28 days after germinal matrix hemorrhage.  
Representative microphotographs of Nissl stained brain sections (C) at 28 days after 
germinal matrix hemorrhage.  Values are expressed as meanSEM.  *P<0.05 compared 
to sham, and #P<0.05 compared to vehicle.  N=5 per group. 
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Deferoxamine Improved Long-term Neurofunctional Outcomes after GMH 
Vehicle treated GMH animals demonstrated significant spatial memory loss 
compared to sham-operated animals in the Morris water maze by swimming greater 
distances finding the platform (P<0.05; Figure 3.3.A) and spending less time in the target 
quadrant during the probe trials (P<0.05; Figure 3.3.B).  Acute and delayed treatment 
animals showed significant cognitive functional recovery by having reduced swimming 
distances (P<0.05; Figure 3.3.A) and tended to spend more time in the target quadrant 
during the probe trials (P>0.05 vs sham; Figure 3.3.B).  Furthermore, vehicle animals had 
significantly more foot faults than sham, but acute and delayed Deferoxamine treated 
GMH animals had significantly reduced foot faults compared to vehicle (P<0.05; Figure 
3.3.C).  Vehicle animals had significantly worse rotarod performances compared to sham, 
but acute and delayed Deferoxamine treated animals had significantly better rotarod 
performances than vehicle rats (P<0.05; Figure 3.3.D). 
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Figure 3.3: Long-term neurocognitive and sensorimotore recovery after acute and 
delayed Deferoxamine treatment at 3-4 weeks post-GMH. Neurofunctional 
assessment of (A) & (B) Morris water maze, (C) rotarod, and (D) foot fault test at 21-28 
days after germinal matrix hemorrhage.  Values are expressed as meanSEM.  *P<0.05 
compared to sham, and #P<0.05 compared to vehicle.  N=10 per group. 
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Discussion 
Iron toxicity is known to play a crucial pathophysiological role in brain injury 
following hemorrhage, with some evidence indicating iron overload may contribute to 
hydrocephalus development (Lee, Keep et al. 2010; Chen, Gao et al. 2011; Xiong, Wang 
et al. 2013).  Blood products and extracellular matrix protein proliferation are thought to 
significantly contribute to post-hemorrhagic hydrocephalus development by disrupting 
normal cerebrospinal fluid flow in the ventricles (Crews, Wyss-Coray et al. 2004).  
Deferoxamine treatment attenuated brain injury in adult brain hemorrhage models (Lee, 
Keep et al. 2011; Hatakeyama, Okauchi et al. 2013), yet it has not been evaluated in 
neonates nor has it been shown to significantly attenuate neonatal post-hemorrhagic 
hydrocephalus development and long-term neurofunctional deficits.  This study evaluated 
the efficacy of 1 hour (acute) and 72 hour (delayed) Deferoxamine treatment as a 
potential therapeutic modality for GMH-induced brain injury, the delayed time point 
serving as a more clinically relevant treatment regimen.  Extracellular matrix protein 
proliferation is indicative of gliosis and is hypothesized to deposit within the ventricles, 
disrupting cerebrospinal fluid flow and contributing to post-hemorrhagic hydrocephalus 
development.  Fibronectin and vitronectin were significantly increased in GMH animals 
compared to sham-operated animals, yet acute and delayed Deferoxamine treated animals 
had significantly reduced fibronectin and vitronectin expressions compared to vehicle, 
indicating GMH leads to increased extracellular matrix protein proliferation, which was 
attenuated by iron chelation.  
Additionally, vehicle treated GMH animals demonstrated significantly enlarged 
ventricular volume, decreased cortical thickness, increased basal ganglia loss, and 
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increased white matter loss, while acute and delayed Deferoxamine treated animals 
showed significantly improved brain morphological outcomes across all measures.  
Consequently, acute and delayed Deferoxamine treated GMH animals had significantly 
improved spatial memory and motor coordination compared to vehicle animals.  Our 
results corroborate with similar brain hemorrhage animal models depicting Deferoxamine 
treatment ameliorates post-hemorrhage brain injury.  Furthermore, acute and delayed 
post-GMH iron chelation significantly reduced neonatal post-hemorrhagic ventricular 
dilation. 
Our results suggest that iron toxicity at acute and delayed time points following 
GMH is associated with post-hemorrhagic ventricular dilation, but the pathophysiological 
mechanisms remain to be elucidated.  The choroid plexus is an epithelial layer in the 
ventricles specialized for cerebrospinal fluid production and is susceptible to injury 
following hemorrhage (Simard, Tosun et al. 2011).  It also contains high expression 
levels of iron metabolic proteins relative to other brain tissues (Rouault, Zhang et al. 
2009).  Iron-overload in the cerebroventricular system following GMH may adversely 
affect normal functioning of the choroid plexus, leading to pathologically increased 
cerebrospinal fluid production.  Another possible explanation is GMH-induced 
cerebroventricular iron overload destroys subarachnoid granulations, as is observed in 
subarachnoid hemorrhage, reducing overall cerebrospinal fluid reabsorption (Okubo, 
Strahle et al. 2013).  Further investigations are needed to determine mechanisms linking 
GMH-induced iron toxicity with long-term post-hemorrhagic ventricular dilation. 
Our study is the first to show Deferoxamine attenuates long-term neurocognitive 
and sensorimotor deficits, improves overall brain morphology, and reduces post-
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hemorrhagic ventricular dilation following GMH when treatment is initiated as late as 72 
hours post-ictus in neonates, providing evidence for a potentially clinically translatable 
therapeutic modality. 
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Abstract 
This study examines the role of thrombin’s protease-activated receptors (PAR)-1, 
PAR-4 in mediating cyclooxygenase-2 and mammalian target of rapamycin following 
germinal matrix hemorrhage. Germinal matrix hemorrhage was induced by 
intraparenchymal infusion of bacterial collagenase into the right ganglionic eminence of 
P7 rat pups. Animals were treated with either PAR-1, PAR-4, cyclooxygenase-2, or 
mammalian target of rapamycin inhibitors by 1 hour and up to ≤5 days. We found 
increased thrombin activity 6 to24 hours after germinal matrix hemorrhage,, and PAR-1, 
PAR-4 inhibition normalized cyclooxygenase-2 and mammalian target of rapamycin by 
72 hours. Early treatment with NS398 or rapamycin substantially improved long-term 
outcomes in juvenile animals. Suppressing early PAR signal transduction, and postnatal 
NS398 or rapamycin treatment, may help reduce germinal matrix hemorrhage severity in 
susceptible preterm infants. 
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Introduction 
Germinal matrix hemorrhage (GMH) is the leading cause of mortality and 
morbidity from prematurity because this brain region is selectively vulnerable to 
spontaneous bleeding within the first 72 hours of preterm life (Ballabh 2010). 
Cerebroventricular expansion contributes to long-term injury through mechanical 
compression of surrounding brain tissues (Aquilina, Chakkarapani et al. 2011). 
Neurological outcomes include hydrocephalus, mental retardation, and cerebral palsy 
(Ballabh 2010; Heron, Sutton et al. 2010). Current neonatal intensive care treatments are 
ineffective at preventing GMH, and neurosurgical shunts are prone to devastating 
complications (Whitelaw 2001). 
Importantly, the blood constituent thrombin has been identified as a causative 
factor in hydrocephalus formation (Gao, Liu et al. 2014). Thrombin activates a subfamily 
of G protein-coupled receptors, named proteinase-activated receptors (PAR; specifically 
PAR-1 and PAR-4) (Kataoka, Hamilton et al. 2003), leading to phosphorylation and 
activation of mammalian target of rapamycin (mTOR) (Jiang, Zhu et al. 2008) and 
increased cyclooxygenase (COX)-2 expression (Lo, Chen et al. 2009).  
Therefore, we hypothesized that modulation of the thrombin- (PAR)-1,-4 – 
(COX)-2/ mTOR pathway could be a promising strategy to improve outcomes after 
GMH.  
 
Materials and Methods 
Animal Surgeries 
All studies, protocols, and procedures were approved by the Loma Linda 
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University IACUC. One hundred and fifty-seven P7 rat pups (comparable with human 
30-32 gestational weeks (Lekic, Manaenko et al. 2012); 14–19 g; Harlan Laboratories, 
Indianapolis, IN) were randomly subjected to either GMH or sham operations. The 
number of pups needed for the experiments and study mechanisms was accounted for in 
each test group. The sample size estimates for all groups assumed type 1 error rate = 0.05 
and power = 0.8 on a two-sided test. Sample size estimates were then made using data 
from our previous experiments (per previous assumptions, mean values, standard 
deviation, and up to a 20% change in means). A stereotactically guided, 0.3 U bacterial 
collagenase infusion model was used to mimic preterm right-sided ganglionic eminence 
bleeds (Lekic, Manaenko et al. 2012; Leitzke, Rolland et al. 2013; Manaenko, Lekic et al. 
2014) (except for the cohort using either heat-deactivated collagenase, 30µl of donor 
blood, or corresponding amount of thrombin [5U], directly injected into the ventricles to 
study hydrocephalus). Time pregnant rats were purchased from Harlan Laboratories 
(Indianapolis, IN) and pups of both genders were subjected to spontaneous germinal 
matrix hemorrhage (GMH) using collagenase infusion (Lekic, Manaenko et al. 2012).   
Briefly, general anesthesia was achieved by isoflurane (3% in 30/70% Oxygen/Medical 
Air). The anesthetized rat pup was positioned prone, with its head secured onto a neonatal 
stereotactic frame (Kopf Instruments, Tujunga, CA). Next, the scalp was sterilized (using 
betadine solution), and a small midline incision was made to expose the bregma. Then, a 
1 mm cranial burr hole was made using a standard dental drill (coordinates from bregma: 
1.8 mm anterior, 1.5 mm lateral, 2.8 mm in depth) through which a 26-gauge needle was 
stereotaxically lowered into the rodent’s brain. At this position, clostridial collagenase 
VII-S (0.3 U, Sigma; St. Louis, MO) was infused at a rate of 0.25μl/min into the right 
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striatum. The needle was left in place for 10 minutes following infusion completion to 
prevent backflow of collagenase. Thereafter, the needle was slowly withdrawn at a rate of 
1mm/min; the burr hole was sealed with bone wax; and the scalp was sutured closed.  All 
animals were allowed to recover under observation on a 37°C warm heating blanket 
before being returned to their dams. Shams received needle insertion only without 
collagenase infusion. 
 
Tissue Processing and Analysis 
Rats were euthanized at 72 hours (for Western blot) at various time points 
between 6 hrs and 21 days (for thrombin assay), and after 28 days (for neuropathological 
analysis) post-GMH, and analyzed by blinded experts (Lekic, Manaenko et al. 2012; 
Leitzke, Rolland et al. 2013; Manaenko, Lekic et al. 2014). Standard protocols (Lekic, 
Manaenko et al. 2012; Leitzke, Rolland et al. 2013; Manaenko, Lekic et al. 2014) were 
used for Western blot analysis at 72 hours post-GMH. Briefly, deeply anesthetized pups 
were transcardially perfused using 50ml PBS, and the whole brain tissue samples were 
collected. Both hemispheres (i.e. bilateral forebrain) were placed into a single test tube 
for further analysis. Following tissue preparation and protein extractions of the bilateral 
hemispheres, western blotting was performed using the following primary antibodies: 
anti-COX-2 (1:200; Cayman Chemical, Ann Arbor, MI), or anti-phospho-mTOR 
(1:1000; Cell Signaling Technology, Danvers, MA). The appropriate secondary 
antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).  
Immunoblots were visualized using ECL Plus chemiluminescence kit (Amersham 
Bioscience, Arlington Heights, IL) and further semi-quantitatively analyzed using Image 
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J (4.0, Media Cybernetics, Silver Springs, MD). Results are expressed as a relative 
density ratio, adjusted to sham.  
Standard protocols (Lekic, Manaenko et al. 2012; Leitzke, Rolland et al. 2013; 
Manaenko, Lekic et al. 2014) were used for Thrombin assay.  Briefly, animals were 
transcardially perfused with phosphate-buffered saline at 6 hours, 1 day, 5 days, 7 days, 
10 days, and 21 days after GMH.  Brain samples were then homogenized and thrombin 
activity was measured using the thrombin-specific chromogenic substrate, S2238 
(Anaspec, Fremont, CA) as previously described (Gong, Xi et al. 2008).  The final 
concentration of the s2238 solution was 20mM in phosphate-buffered saline.  Thrombin 
standards were made using rat thrombin (Sigma Aldrich, St. Louis, MO) at 
concentrations of 0, 1.5625, 3.125, 6.25, 12.5, 25, and 50 mU/ml.  Reaction mixtures 
consisted of 10 µl of brain sample supernatant and 1.5ul of the s2238 chromogenic 
substrate mixture, which were then added to 90 µl of phosphate-buffered saline.  
Reaction mixtures were allowed to incubate for 1hr at room temperature, after which the 
sample absorbance were spectrophotometrically measured at 405 nm. 
Standard protocols (Lekic, Manaenko et al. 2012; Leitzke, Rolland et al. 2013; 
Manaenko, Lekic et al. 2014) were used for histopathological analysis at 28 days post-
GMH. Briefly, deeply anesthetized pups were transcardially perfused using 50 ml ice-
cold PBS and 10% paraformaldehyde. Whole brain tissue samples were post-fixed in 
10% paraformaldehyde solution (at 4°C for 3 days), then dehydrated in 30% sucrose for 
the same amount of time. 10 μm frozen coronal brain sections were cut every 600 μm 
using the cryostat (CM3050S, Leica Microsystems), then mounted, and cresyl violet 
stained on poly-L-lysine-coated slides. Morphometric analysis was conducted using 
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computer-assisted (ImageJ 4.0, Media Cybernetics, Silver Spring, MD) hand delineation 
of the ventricle system (lateral, third, cerebral aqueduct, and fourth), hemisphere (cortex, 
subcortex), corpus callosum (white matter), caudate, thalamus, and hippocampus. 
Borderlines of these structures are based on criteria derived from stereologic studies 
using optical dissector principles (Oorschot 1996; Ekinci, Acer et al. 2008; Lekic, 
Manaenko et al. 2012; Leitzke, Rolland et al. 2013; Manaenko, Lekic et al. 2014). 
Volumes were calculated: (Average  [(Area of coronal section) × Interval × Number of 
sections]).  
 
Animal Treatments and Experimental Groups 
For the 72-hour (short-term; n=49) western blot study: GMH animals received i.p. 
co-injections of PAR-1 (SCH79797) and PAR-4 (P4pal-10) antagonists (1, 3, 7, 10, or 15 
mg/kg given 1, 24, and 48 hrs post-GMH). For thrombin assay time-course study (n=49, 
n=7/per time point); GMH animals were euthanized at 0 hour, 6 hours, 1 day, 5 days, 7 
days, 10 days, and 21 days after GMH. For the 28-day (long-term; n=26) study, COX-2 
(NS398) or mTOR (rapamycin) treatment consisted of six intraperitoneal. injections (1, 6, 
24, 36, 48, and 60 hours after GMH). Inhibitors were prepared using distilled water 
containing five percent Dimethyl Sulfoxide (DMSO) solvent. Controls received the 
vehicle (5% DMSO). All drugs were purchased from Sigma-Aldrich (St. Louis, MO).10-11 
 
Assessment of Neurological Deficits 
Cognitive (T-maze, Water-maze) and sensorimotor (Rotarod, Foot Fault) testing 
from 21 to 28 days post-GMH was performed by experienced blinded investigators as 
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described (Leitzke, Rolland et al. 2013; Manaenko, Lekic et al. 2014). Briefly, the T-
Maze1-2 assessed short-term (working) memory ability. For each trial, the pup was 
placed into the stem (40cm×10cm) and allowed to explore until either the left or right 
arm was chosen. From the sequence of 10 trials, the rate of spontaneous alternation (0% 
= none and 100% = complete; alternations/trial) was calculated. The Morris Water-maze 
(Lekic, Manaenko et al. 2012; Leitzke, Rolland et al. 2013; Manaenko, Lekic et al. 2014) 
measured spatial learning and memory on three daily blocks. The apparatus consists of a 
metal pool (110cm diameter) filled with water to within 15cm of the upper edge and 
containing a small platform (11cm diameter) for the animal to climb onto.  The swim 
path length was digitally analyzed by Noldus Ethovision tracking software. Cued trials 
(maximum of 60 sec/trial) measured general associative learning, sensorimotor ability, 
and motivation to escape the water with the platform visible above the water surface. The 
platform’s location changed every other trial. Spatial trials (maximum of 60 sec/trial) 
measured spatial learning with the platform submerged, but discoverable. Probe trials 
measured spatial memory by recording the amount of time in the target quadrant after the 
escape platform was removed. For the rotarod (Lekic, Manaenko et al. 2012; Leitzke, 
Rolland et al. 2013), this test assessed motor and coordination ability. The apparatus 
(Columbus Instruments, Columbus, OH) consists of a horizontally rotating cylinder 
requiring continuous walking in order to avoid falling (7 cm diameter, 9.5 cm width) and 
programmed to either maintain a constant velocity, or to accelerate 2 rpm every 5 sec. 
The time to fall was recorded by photobeam circuit. For Foot Fault testing (Lekic, 
Manaenko et al. 2012; Manaenko, Lekic et al. 2014), this documented the number of 
completed limb missteps through the openings while the animal explored an elevated 
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wire (3mm) grid (20cmx100cm) over 120sec. All neurobehavior assessments were 
conducted in a blinded fashion by experienced investigators. 
 
Statistical Analysis 
P values of <0.05 were considered statistically significant. Neurobehavioral data 
were analyzed using one-way ANOVA on ranks with Student–Newman–Keuls post-hoc 
test. All other data were analyzed by one-way ANOVA with Tukey post-hoc test. Data 
are expressed as mean±SEM. 
 
Results 
GMH Activated Thrombin 
Thrombin activity increased at 6 and 24 hours following collagenase infusion 
compared to sham (P<0.05), and then normalized over 5 to 21 days (Figure 4.1.B). 
 
Molecular Mediators of Post-hemorrhagic Hydrocephalus 
Post-hemorrhagic hydrocephalus at 28 days was greatest in the group receiving 
direct intraparenchymal infusion of collagenase into the ganglionic eminence (P<0.05; 
Figure 4.1.C-D) compared with intracerebroventricular injections of collagenase, heat-
deactivated collagenase, donor blood, or thrombin. 
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Figure 4.1: Thrombin activity after germinal matrix hemorrhage and association 
between specific GMH model elements and post-hemorrhagic ventricular dilation 
development. (A) Proposed mechanism. (B) Time-course of thrombin activity 
(n=7/group; * P<0.05 compared with sham). (C) Representative 2mm coronal brain 
section pictographs (28 days after infusion). (D) Quantification of ventricular volume 
(n=6/group; * P<0.05 compared with vehicle). ICV indicates intracerebroventricular; 
RAPA, rapamycin. 
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Western Blots 
Early PAR-1 and PAR-4 signal inhibition reduced mTOR phosphorylation and 
COX-2 expression (P<0.05; Figure 4.2A-B) in a dose responsive fashion at 72 hours 
post-GMH induction. 
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Figure 4.2: Dose-response changes of COX-2 and p-mTOR expression after 
combinatorial PAR-1 and PAR-4 inhibition at 72 hours post-GMH as well as long-
term brain morphological outcomes after COX-2 or mTOR inhibition at 4 weeks 
post-GMH. (A- B) Western blot analyses of p-mTOR (left) and COX-2 expression 
(right) at 72 hours after GMH (n=7/group). (C) Representative Nissl stained brain 
micrograph sections (left), quantification of cortical thickness (right) and (D) ventricular 
volume at 28 days after GMH. * P<0.05 compared with sham; ϯ P<0.05 compared with 
vehicle.  
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Early Signal Inhibition Improved Long-term Outcomes 
Treatments using either COX-2 or mTOR inhibitors significantly ameliorated 
long-term cortical thickness, ventricular volume (P<0.05; Figures 4.2.C-D), and 
neurodeficits (Figure 4.3.A-D) compared to vehicle treated animals at 28 days post-
GMH. 
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Figure 4.3: Long-term neurocognitive and sensorimotor outcomes after COX-2 or 
mTOR inhibition at 3-4 weeks post-GMH. Neurological assessments at 21-28 days 
after GMH using A. Morris water maze, B. T-maze, C. Foot fault, and D. Rotarod test 
(n=5-7/group). * P<0.05 compared with sham; ϯ P<0.05 compared with vehicle. 
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Discussion 
This study investigated the effectiveness of modulating thrombin- PAR-1 and 
PAR-4 in reversing COX-2 and p-mTOR upregulation, as well as the effect of direct 
COX-2 and p-mTOR inhibition upon post-hemorrhagic hydrocephalus and neurological 
deficits. Previous studies hypothesized the mechanism of hydrocephalus involved 
increased production of infiltrating extracellular matrix proteins throughout the 
cerebroventricular system, leading to the disruption of CSF outflow (Crews, Wyss-Coray 
et al. 2004; Ballabh 2010; Aquilina, Chakkarapani et al. 2011; Strahle, Garton et al. 2012; 
Manaenko, Lekic et al. 2014). Our results suggest that thrombin-induced PAR-1, PAR-4 
stimulation upregulates detrimental signaling: exacerbating inflammatory (COX-2 
mediated) and proliferative responses (p-mTOR mediated) that are potentially upstream 
of extracellular matrix protein dysregulation (Jiang, Zhu et al. 2008; Lo, Chen et al. 2009; 
Ballabh 2010; Lekic, Manaenko et al. 2012; Gao, Du et al. 2014; Gao, Liu et al. 2014; 
Manaenko, Lekic et al. 2014).Multiple parallels (especially with thrombin) (Jiang, Zhu et 
al. 2008; Lo, Chen et al. 2009; Ballabh 2010; Aquilina, Chakkarapani et al. 2011; Lekic, 
Manaenko et al. 2012; Leitzke, Rolland et al. 2013; Manaenko, Lekic et al. 2014) exist 
between our study and the pathophysiology of adult intracerebral hemorrhage (Whitelaw 
2001; Crews, Wyss-Coray et al. 2004; Strahle, Garton et al. 2012; Gao, Du et al. 2014; 
Gao, Liu et al. 2014). Thus, in extension, our findings may have a much broader 
therapeutic implication in terms of further adult stroke mechanistic study (Keep, Zhou et 
al. 2014).   
To address the question of molecular mediators of GMH, our first aim 
demonstrated that intraparenchymal infusion of collagenase generated the majority of 
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hydrocephalus. This is likely the sum contribution of blood products (Gao, Du et al. 
2014) (red blood cell lysis and inflammation) and thrombin. In fact, thrombin 
demonstrated greatest activity in the acute phase, between 6 and 24 hours post-ictus, with 
tendency to remain elevated  ≤10 days and normalized by 21 days. 
We next hypothesized that thrombin binds to PAR-1, PAR-4 receptors, and 
consequently upregulates COX-2 and p-mTOR. Because thrombin is most active in the 
acute phase, we examined levels at 72 hours post-ictus and determined COX-2 and p-
mTOR were significantly greater in vehicle treated animals than in sham. Furthermore, 
inhibiting PAR-1, PAR-4 using SCH79797 (PAR-1 antagonist) and p4pal10 (PAR-4 
antagonist) significantly normalized COX-2 and p-mTOR levels at 72 hours.  
Then, we asked whether directly inhibiting COX-2 or p-mTOR after GMH could 
circumvent long-term post-hemorrhagic ventricular dilation, cortical cell loss, and 
improve sensorimotor and neurocognitive outcomes. Our findings demonstrated that 
vehicle treated animals had significantly worsened outcomes compared to shams, and 
treating with either NS398 (COX-2 inhibitor) or rapamycin (mTOR inhibitor) 
significantly improved brain neuropathology and neurological ability. Thus, by 
attenuating early inflammatory (COX-2), and proliferative (p-mTOR) signaling 
pathways, we improved long-term outcomes in the juvenile animals. 
In summary, this study is the first to show thrombin-PAR-1, thrombin-PAR-4 
signal inhibition normalizing early COX-2 and p-mTOR expression levels, and this, in 
turn, improving long-term neurological outcomes after GMH.  
 
 119 
References 
Aquilina K, Chakkarapani E, Love S, and Thoresen M (2011). "Neonatal Rat Model of 
Intraventricular Haemorrhage and Post-Haemorrhagic Ventricular Dilatation with 
Long-Term Survival into Adulthood." Neuropathol Appl Neurobiol 37(2): 156-
165. 
Ballabh P (2010). "Intraventricular Hemorrhage in Premature Infants: Mechanism of 
Disease." Pediatr Res 67(1): 1-8. 
Crews L, Wyss-Coray T, and Masliah E (2004). "Insights into the Pathogenesis of 
Hydrocephalus from Transgenic and Experimental Animal Models." Brain Pathol 
14(3): 312-316. 
Ekinci N, Acer N, Akkaya A, Sankur S, Kabadayi T, and Sahin B (2008). "Volumetric 
Evaluation of the Relations among the Cerebrum, Cerebellum and Brain Stem in 
Young Subjects: A Combination of Stereology and Magnetic Resonance 
Imaging." Surg Radiol Anat 30(6): 489-494. 
Gao C, Du H, Hua Y, Keep RF, Strahle J, and Xi G (2014). "Role of Red Blood Cell 
Lysis and Iron in Hydrocephalus after Intraventricular Hemorrhage." J Cereb 
Blood Flow Metab 34(6): 1070-1075. 
Gao F, Liu F, Chen Z, Hua Y, Keep RF, and Xi G (2014). "Hydrocephalus after 
Intraventricular Hemorrhage: The Role of Thrombin." J Cereb Blood Flow Metab 
34(3): 489-494. 
Gong Y, Xi G, Hu H, Gu Y, Huang F, Keep RF, and Hua Y (2008). "Increase in Brain 
Thrombin Activity after Experimental Intracerebral Hemorrhage." Acta Neurochir 
Suppl 105: 47-50. 
Heron M, Sutton PD, Xu J, Ventura SJ, Strobino DM, and Guyer B (2010). "Annual 
Summary of Vital Statistics: 2007." Pediatrics 125(1): 4-15. 
Jiang X, Zhu S, Panetti TS, and Bromberg ME (2008). "Formation of Tissue Factor-
Factor Viia-Factor Xa Complex Induces Activation of the Mtor Pathway Which 
Regulates Migration of Human Breast Cancer Cells." Thromb Haemost 100(1): 
127-133. 
Kataoka H, Hamilton JR, McKemy DD, Camerer E, Zheng YW, Cheng A, Griffin C, and 
Coughlin SR (2003). "Protease-Activated Receptors 1 and 4 Mediate Thrombin 
Signaling in Endothelial Cells." Blood 102(9): 3224-3231. 
Keep RF, Zhou N, Xiang J, Andjelkovic AV, Hua Y, and Xi G (2014). "Vascular 
Disruption and Blood-Brain Barrier Dysfunction in Intracerebral Hemorrhage." 
Fluids Barriers CNS 11: 18. 
 120 
Leitzke AS, Rolland WB, Krafft PR, Lekic T, Klebe D, Flores JJ, Van Allen NR, 
Applegate RL, 2nd, and Zhang JH (2013). "Isoflurane Post-Treatment 
Ameliorates Gmh-Induced Brain Injury in Neonatal Rats." Stroke 44(12): 3587-
3590. 
Lekic T, Manaenko A, Rolland W, Krafft PR, Peters R, Hartman RE, Altay O, Tang J, 
and Zhang JH (2012). "Rodent Neonatal Germinal Matrix Hemorrhage Mimics 
the Human Brain Injury, Neurological Consequences, and Post-Hemorrhagic 
Hydrocephalus." Exp Neurol 236(1): 69-78. 
Lo HM, Chen CL, Tsai YJ, Wu PH, and Wu WB (2009). "Thrombin Induces 
Cyclooxygenase-2 Expression and Prostaglandin E2 Release Via Par1 Activation 
and Erk1/2- and P38 Mapk-Dependent Pathway in Murine Macrophages." J Cell 
Biochem 108(5): 1143-1152. 
Manaenko A, Lekic T, Barnhart M, Hartman R, and Zhang JH (2014). "Inhibition of 
Transforming Growth Factor-Beta Attenuates Brain Injury and Neurological 
Deficits in a Rat Model of Germinal Matrix Hemorrhage." Stroke 45(3): 828-834. 
Oorschot DE (1996). "Total Number of Neurons in the Neostriatal, Pallidal, Subthalamic, 
and Substantia Nigral Nuclei of the Rat Basal Ganglia: A Stereological Study 
Using the Cavalieri and Optical Disector Methods." J Comp Neurol 366(4): 580-
599. 
Strahle J, Garton HJ, Maher CO, Muraszko KM, Keep RF, and Xi G (2012). 
"Mechanisms of Hydrocephalus after Neonatal and Adult Intraventricular 
Hemorrhage." Transl Stroke Res 3(Suppl 1): 25-38. 
Whitelaw A (2001). "Intraventricular Haemorrhage and Posthaemorrhagic 
Hydrocephalus: Pathogenesis, Prevention and Future Interventions." Semin 
Neonatol 6(2): 135-146. 
 
 
 121 
CHAPTER FIVE 
DABIGATRAN AMELIORATES POST-HAEMORRHAGIC HYDROCEPHALUS 
DEVELOPMENT AFTER GERMINAL MATRIX HAEMORRHAGE IN 
NEONATAL RAT PUPS 
 
Damon Klebe1, Jerry J Flores1, Devin W McBride1, Paul R Krafft1, William B Rolland1, 
Tim Lekic1, John H Zhang1, 2 
 
1Department of Physiology and Pharmacology, Loma Linda University School of 
Medicine, Loma Linda, California, USA 
2Department of Anesthesiology and Neurosurgery, Loma Linda University School of 
Medicine, Loma Linda, California, USA 
 
 
 
 
 
 
 
 
 
Chapter content currently submitted and under peer-review for publication 
 122 
Abstract 
We aim to determine if direct thrombin inhibition by Dabigatran will improve 
long-term brain morphological and neurofunctional outcomes and if potential therapeutic 
effects are dependent upon reduced PAR-1 stimulation and consequent mTOR activation. 
Germinal matrix hemorrhage was induced by stereotaxically injecting 0.3 U type VII-S 
collagenase into the germinal matrix of P7 rat pups. Animals were divided into 5 groups: 
Sham, Vehicle (5% DMSO), Dabigatran intraperitoneal, Dabigatran intraperitoneal + 
TFLLR-NH2 (PAR-1 agonist) intranasal, SCH79797 (PAR-1 antagonist) intraperitoneal, 
and Dabigatran intranasal. Neurofunctional outcomes were determined by Morris water 
maze, rotarod, and foot fault evaluations at 3 weeks. Brain morphological outcomes were 
determined by histological Nissl staining at 4 weeks. Expression levels of p-mTOR/p-
p70s6k at 3 days and vitronectin/fibronectin at 28 days were quantified. Intranasal and 
intraperitoneal Dabigatran promoted long-term neurofunctional recovery, improved brain 
morphological outcomes, and reduced intracranial pressure at 4 weeks after GMH. PAR-
1 stimulation tended to reverse Dabigatran's effects on post-hemorrhagic hydrocephalus 
development. Dabigatran also reduced expression of short-term p-mTOR and long-term 
extracellular matrix proteins, which tended to be reversed by PAR-1 agonist co-
administration. PAR-1 inhibition alone, however, did not achieve the same therapeutic 
effects as Dabigatran administration. Direct thrombin inhibition ameliorated long-term 
germinal matrix hemorrhage brain sequelae, which was associated with decreased short-
term mTOR activation. PAR-1 stimulation tended to reverse some therapeutic effects, but 
PAR-1 inhibition alone was not sufficient to improve outcomes.  
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Introduction 
Occurring in approximately 3.5 per 1000 live births, germinal matrix hemorrhage 
(GMH) remains a leading cause of mortality and lifelong morbidity in premature and/or 
very low birthweight infants (Heron, Sutton et al. 2010). The rupturing of immature 
blood vessels in the subependymal brain tissue is thought to result from deficient 
autoregulatory mechanisms that inadequately function in response to abnormal cerebral 
blood flow fluctuations spurred by cardiorespiratory and hemodynamic instability 
(Ballabh 2014). Long-term clinical complications from GMH include developmental 
delays, learning and psychiatric disorders, cerebral palsy, and post-hemorrhagic 
hydrocephalus, all of which pose significant economic burdens on both the patients and 
the US healthcare system (1993; Vohr, Wright et al. 2000; Murphy, Inder et al. 2002). 
Prenatal glucocorticoid administration remains the best treatment for preventing GMH in 
premature infants, yet few clinical approaches exist for GMH clinical management post-
ictus (Leviton, Kuban et al. 1993; Vinukonda, Dummula et al. 2010). Minimal 
advancements have also been made in post-hemorrhagic hydrocephalus clinical 
management, which is mostly limited to surgical insertion of shunts that drain excess 
cerebrospinal fluid from the ventricles into the peritoneum (Whitelaw 2001; Ballabh 
2014). Thus, a non-invasive, safe therapeutic approach that successfully mitigates post-
hemorrhagic hydrocephalus development after GMH would significantly improve the 
quality of life for this patient population. 
Immediately after hemorrhage, the coagulation cascade is triggered and thrombin, 
a serine protease, is activated (Babu, Bagley et al. 2012). In addition to inducing clot 
formation by converting fibrinogen into fibrin, thrombin also stimulates proteinase-
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activated receptors (PARs) (Kataoka, Hamilton et al. 2003; Steinhoff, Buddenkotte et al. 
2005; Luo, Wang et al. 2007), leading to phosphorylation and subsequent activation of 
mammalian target of rapamycin (mTOR) (Lekic, Klebe et al. 2015). Activated mTOR 
has been associated with extracellular matrix (ECM) protein proliferation in fibroblasts, 
which possibly disrupts CSF dynamics in the cerebroventricular system (Paul, Leef et al. 
2000; Crews, Wyss-Coray et al. 2004; Del Bigio 2004; Xue and Del Bigio 2005; Ballabh, 
Xu et al. 2007; Dummula, Vinukonda et al. 2010). In our prior studies, long-term post-
GMH ventricular dilation was associated with increased expression of vitronectin and 
fibronectin (Klebe, Krafft et al. 2014), combinatorial PAR-1 and PAR-4 inhibitors 
reduced p-mTOR expression at 72 hours after GMH, and rapamycin treatment 
ameliorated long-term neurocognitive deficits and improved brain morphology at 4 
weeks post-GMH (Lekic, Klebe et al. 2015). Yet, long-term evaluations for PAR-1 
and/or PAR-4 inhibitor administration as well as ECM protein expression levels were not 
investigated in these studies. Nonetheless, inhibiting the Thrombin/PAR/mTOR pathway 
seems be a promising strategy for ameliorating post-hemorrhagic hydrocephalus 
formation after GMH.  
Dabigatran, an oral anti-coagulant also known as Pradaxa, is a direct thrombin 
inhibitor clinically approved for preventing deep vein thrombosis, pulmonary embolism, 
and stroke from atrial fibrillation (Eisert, Hauel et al. 2010; van Ryn, Stangier et al. 
2010). While Dabigatran reduced overall major and minor bleeding events compared to 
Warfarin, gastrointestinal bleeds were significantly higher (Blommel and Blommel 
2011). An antidote, Idarucizumab, was developed to reverse Dabigatran’s anti-coagulant 
effects in the event of major, uncontrolled bleeds (Starke, Komotar et al. 2015). Although 
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inhibiting thrombin may ameliorate brain injury, Dabigatran’s anti-coagulant properties 
pose a risk of increased bleeding after cerebral hemorrhage. Dabigatran was evaluated in 
a rodent model of adult intracerebral hemorrhage and was determined to not increase 
hematoma volume while attenuating brain injury for the doses evaluated (Lauer, 
Cianchetti et al. 2011), but an additional study suggests high doses of Dabigatran do 
increase hematoma volume, which can be controlled by intravenous injection of 
prothrombin complex concentrate (Zhou, Schwarting et al. 2011). We perform a similar 
dosing study to evaluate Dabigatran’s safety for GMH and to determine the best dose for 
further investigation.  
Herein, we evaluate if direct thrombin inhibition by Dabigatran ameliorates long-
term neurocognitive deficits, improves brain morphological outcomes, and reduces ECM 
proliferation. We further investigate if potential therapeutic effects are dependent upon 
reduced PAR-1 stimulation and subsequent mTOR activation, since PAR-1 inhibition 
reduced brain injury severity in both adult cerebral ischemic and hemorrhage models. 
Given Dabigatran’s anti-coagulant effects, inhibiting one of thrombin’s receptors may be 
a safer approach if it still achieves the same degree of efficacy, and we aim to determine 
if PAR-1 inhibition alone will potentially achieve the same therapeutic benefits as direct 
thrombin inhibition. We further evaluate if PAR-1 stimulation will reverse Dabigatran’s 
therapeutic effects to better confirm this pathway’s role in GMH pathophysiology. 
Additionally, intranasal drug administration has been shown to be an effective, localized 
delivery route to the brain and we aimed to determine if this route would be efficacious 
for Dabigatran administration (McMartin, Hutchinson et al. 1987; Djupesland, Messina et 
al. 2014). We determine the effects of the thrombin/PAR-1 pathway on mTOR 
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phosphorylation in the short-term as well as ECM protein expression, brain morphology, 
neurocognitive and sensorimotor function, and intracranial pressure in the long-term. 
 
Materials and Methods 
GMH Surgical Procedures 
All procedures were approved by the Loma Linda University Institutional Animal 
Care and Use Committee in accordance with the National Institute of Health’s guidelines. 
For GMH induction, postnatal day 7 rat pups weighing between 12-15 grams (brain 
development comparable to 30-32 week human gestation) were anesthetized using 2-3% 
isoflurane delivered in a mixture of medical grade oxygen and air. The scalp was 
sterilized by topically applying isopropyl alcohol and betadine, and then the heads were 
fixed onto a stereotaxic frame. An incision was made to expose bregma and a 1 mm burr 
hole was drilled at 1.6 mm right lateral and 1.5 mm rostral relative to bregma. A 10 µL 
Hamilton syringe filled with 0.3 U/µL collagenase solution was fixed to an infusion 
pump (Harvard Apparatus, Holliston, MA) and the needle inserted to a depth of 2.8 mm 
below the dura with the bevel facing the midline. 0.3 U type VII-S collagenase from 
Clostridium hystolyticum (Sigma Aldrich, St. Louis, MO) was infused at a rate of 0.1 
U/min, and the needle was left in place for 5 minutes before being removed at a rate of 1 
mm/min to reduce backflow. The burr hole was sealed using bone wax and the incision 
sutured with 5-0 silk. Animals were allowed to recover on a 37ᵒC heating pad then 
returned to the dam after awakening from anesthesia.  Sham surgery involved needle 
insertion without collagenase infusion. The average surgery time was approximately 30 
minutes per animal. 
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Experimental Groups and Treatments 
For the Dabigatran plasma concentration studies, 72 P7 rat pups were randomly 
divided into three treatment groups: low dose 3 mg/kg, medium dose 10 mg/kg, or high 
dose 30 mg/kg administered intraperitoneally. Lyophilized Dabigatran (Boehringer 
Ingelheim, Ingelheim am Rhein, Germany) was dissolved into a 5% dimethyl sulfoxide 
(DMSO) solution (Sigma Aldrich, St. Louis, MO). Blood was collected by cardiac 
puncture prior to euthanization at 2, 4, 8, 12, 18, or 24 hours after Dabigatran 
administration for all three treatment groups (n=4/group/endpoint). For the hematoma 
expansion safety study, 48 P7 rat pups were randomly divided into 8 groups (n=6/group): 
Sham, Vehicle (5% DMSO), 3 mg/kg Dabigatran QD, 3 mg/kg Dabigatran BID, 10 
mg/kg Dabigatran QD, 10 mg/kg Dabigatran BID, 30 mg/kg Dabigatran QD, and 30 
mg/kg Dabigatran BID. Dabigatran was administered intraperitoneally for this study. For 
long-term evaluations, 72 P7 rat pups were randomly divided into 6 groups (n=10-
12/group, split evenly between histology and Western blot/intracranial pressure): Sham, 
Vehicle, 3 mg/kg Dabigatran intraperitoneally, 3 mg/kg Dabigatran intraperitoneally + 1 
mg/kg TFLLR-NH2 (PAR-1 agonist) intranasally (Tocris, Minneapolis, MN), 10 mg/kg 
SCH79797 (PAR-1 antagonist) intraperitoneally (Tocris, Minneapolis, MN), and 3 mg/kg 
Dabigatran intranasally. All pups were randomized among treatment groups and all 
treatments commenced 2 hours post-ictus and then twice a day for 3 days. For time 
course Western blots, 48 P7 rat pups were randomly divided into 8 groups (n=6/group) 
and euthanized at the indicated time point after GMH: Naïve, 3, 6, 12 hours, 1 3, 5, and 7 
days post-ictus. For short-term evaluations, 48 P7 rat pups were randomly divided into 8 
groups (n=6/group): Sham, Vehicle BID for 3 days, 3 mg/kg Dabigatran 
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intraperitoneally; 3 mg/kg Dabigatran intraperitoneally + 1 mg/kg TFLLR-NH2 
intranasally; 10 mg/kg SCH79797 intraperitoneally; 3 mg/kg Dabigatran intranasally; 3 
mg/kg Dabigatran intranasally + 1 mg/kg TFLLR-NH2 intranasally. The TFLLR-NH2 
intranasal dose was derived from a prior in vivo rodent study (Aerts, Hamelin et al. 2013), 
and the SCH79797 intraperitoneal dose was derived from our prior GMH study (Lekic, 
Klebe et al. 2015). 
 
Intracranial Pressure Measurement 
Intracranial pressure was measured as previously described (Lackner, Vahmjanin 
et al. 2013). At 28 days post-ictus, animals were anesthetized and mounted onto a 
stereotaxic frame with their heads inclined 30ᵒ downward.  The atlanto-occipital 
membrane was exposed by a midline skin excision and the cisterna magna punctured 
with a 26G needle connected to a pressure transducer (Digi-Med LPA 400, Micro-Med, 
Louisville, KY).  
 
Neurobehavioral Assessments 
A battery of tests was performed, by blinded investigators, to evaluate 
sensorimotor and cognitive deficits between 21-28 days post-ictus, as previously 
performed (Klebe, Krafft et al. 2014; Flores, Klebe et al. 2016). Foot Fault Test: Rats 
were placed on a wire grid (20x40 cm) 2 feet above the ground and allowed to walk for 2 
minutes. The left limb faults are reported as a percentage of the total steps taken by the 
left limbs ((left faults/left steps) x 100). Rotarod: Rats were placed on a rotating cylinder 
(San Diego Instruments, Columbus, OH), 7 cm diameter, 9.6 cm lanes) accelerating at 2 
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RPM per 5 seconds (starting speeds of either 5 or 10 RPM), and a photobeam circuit 
detected the latency to fall off the cylinder. Morris Water Maze: Briefly, rats were trained 
using a visible platform (10 cm diameter, Cued test) on day 1. Days 2-5, latency to find a 
submerged platform was measured (Memory Blocks 1-4, 5 trials each block, 1 minute 
each trial). After completing the memory test, the platform was removed and the rats 
were tested to determine the amount of time spent within the platform quadrant (Probe 
Trial, 1 minute trial). An overhead camera with a computerized tracking system (Noldus 
Ethovision, Tacoma, WA) recorded the swim path and measured swim distance, speed, 
and time spent in target quadrant.  
 
Perfusions and Tissue Extraction 
Deeply anesthetized (5% isoflurane) animals were euthanized by trans-cardiac 
perfusion with ice-cold phosphate buffered saline (PBS) for hemoglobin assay and 
Western blot samples or with ice-cold PBS followed by 10% formalin for histology 
samples. Forebrains were either snap-frozen in liquid nitrogen and stored in -80ᵒC freezer 
for Western blot and hemoglobin assay or post-fixed in 10% formaldehyde for at least 3 
days then dehydrated with 30% sucrose for at least 3 days (4ᵒC) for histology. Histology 
forebrains were embedded in Optimal Cutting Temperature compound and stored at -
20ᵒC. 
 
Hemoclot Assay 
Blood was drawn by cardiac puncture and collected in a 0.106 mol/L trisodium 
citrate solution (1 part anti-coagulant to 9 parts blood).  Blood was centrifuged at 2600g 
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for 10 minutes at 20ᵒC. Platelet poor plasma was collected and snap-frozen in liquid 
nitrogen then stored at -80ᵒC until analysis. Dabigatran plasma concentration was 
determined by Hemoclot Assay (Aniara, West Chester, OH) as previously 
described.(Stangier and Feuring 2012) Briefly, a calibration curve was created using 
control plasma with 0, 1.25, 2.5, 3.75, and 5 µg/mL Dabigatran. The Hemoclot Assay 
was performed following the manufacturer guidelines Absorbance was measured on a 
microplate spectrophotometer (iMark, Bio-Rad, Hercules, CA) at 405 nm against a blank.   
 
Hemoglobin Assay 
Frozen forebrains were homogenized in 3 mL PBS for at least 60 seconds then 
sonicated for at least 60 seconds. The homogenate was centrifuged at 13000 RPM, 20ᵒC 
for 30 minutes. 200 µL supernatant was combined with 800 µL Drabkin’s reagent 
(Sigma-Aldrich, St. Louis, MO). After 15 minutes, absorbance at 450 nm was measured 
using a spectrophotometer (Genesis 10 UV; Thermo Fisher Scientific, Waltham, MA). 
Hemorrhage volume was calculated against a standard curve (created using naïve 
forebrains and known quantities of blood).  
 
Western Blot 
Forebrains were homogenized in RIPA lysis buffer (Santa Cruz Biotechnology, 
Dallas, TX) for at least 60 seconds. The homogenate was centrifuged at 15000 RPM, 4ᵒC 
for 20 minutes and supernatant collected, aliquoted, then stored at -80ᵒC. Protein 
concentrations were determined by DC protein assay (Bio-Rad, Hercules, CA). 50 µg 
protein per sample were loaded into wells of 10% gels, ran for 30 minutes at 50 V, then 
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90 minutes at 125 V. Proteins were transferred onto a nitrocellulose membrane at 0.3 A 
for 120 minutes (Bio-Rad, Hercules, CA). Primary antibodies were applied to the 
membranes and incubated overnight at 4ᵒC: p-mTOR (1:1000; Cell Signaling 
Technology, Danvers, MA); p-p70s6k (1:1000; Cell Signaling Technology, Danvers, 
MA); mTOR (1:1000; Cell Signaling Technology, Danvers, MA); p70s6k (1:1000; Cell 
Signaling Technology, Danvers, MA); vitronectin (1:1000; Abcam, Cambridge, MA); 
and actin (1:1000 Santa Cruz Biotechnology, Dallas, TX). Membranes were washed then 
incubated in secondary antibodies (1:2000; Santa Cruz Biotechnology, Dallas, TX) for 2 
hours at 4ᵒC. Proteins were exposed onto radiography film after applying enhanced 
chemiluminescent solution (GE Healthcare and Life Science, Piscataway, NJ) onto the 
membranes. ImageJ software (Media Cybernetics, Silver Spring, MD) was used to 
analyses relative density. 
 
Histology 
A cryostat (Leica Microsystems LM3050S, Wetzlar, Germany) was used to cut 10 
µm thick coronal sections every 600 µm into the brain. Brain slices were Nissl stained 
and morphometrically analyzed using ImageJ (Media Cybernetics, Silver Spring, MD) 
assisted delineation of brain structures, as previously performed in our lab (Lekic, 
Manaenko et al. 2012). Ventricle volume was calculated as average ventricular area 
multiplied by the depth of the cerebroventricular system. White matter loss was 
calculated as the average white matter area multiplied by depth of the cerebroventricular 
system and expressed as % of the sham group by dividing volumes to the overall average 
volume of the Sham group. 
 132 
Statistical Analysis 
Data are expressed as mean  standard deviation. One-way ANOVA using the 
Newman-Keuls post-hoc test was used to analyses all data. A p<0.05 was considered 
statistically significant in all analyses except neurobehavior; a p<0.10 was considered 
statistically significant for neurobehavioral analyses. 
 
Results 
Dabigatran Half-life and Hematoma Volume after GMH 
A dosing study was performed to assess the safety and efficacy of Dabigatran. 
Plasma concentrations reached maximum levels 2 hours after injection and have an 
approximate half-life of 8-12 hours (Figure 5.1.A). 30 mg/kg Dabigatran administered 
intraperitoneally QD or BID significantly increased hematoma volume 24 hours after 
GMH. 10 mg/kg Dabigatran administered intraperitoneally QD or BID had no effect on 
hematoma volume 24 hours after GMH. 3 mg/kg Dabigatran QD administered 
intraperitoneally had no effect on hematoma volume while Dabigatran BID tended to 
decrease hematoma volume (Figure 5.1.B). Excessive bleeding and mortality associated 
with excessive bleeding, where uncoagulated blood was usually found at the 
abdomen/intestine, intraperitoneal injection site, and/or surgical suture on the head, was 
also observed in all groups, particularly the higher dose groups (between 0-33% 
mortality, data not shown). 
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Figure 5.1: Dabigatran dose response for hematoma volume 24 hours post-GMH 
and plasma concentration time course. Time course of Dabigatran plasma 
concentrations after intraperitoneal injection of either 3 mg/kg, 10 mg/kg, or 30 mg/kg 
Dabigatran (A). Hematoma volumes 24 hours post-GMH (B). *P<0.05 vs Sham; #P<0.05 
vs Vehicle. 
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Thrombin Inhibition Improved Long-term Neurofunctional Recovery, which 
Was Not Reversed by PAR-1 Stimulation; PAR-1 Inhibition Alone Was Not 
Sufficient to Promote Recovery 
Using the best-tolerated dose, 3 mg/kg Dabigatran administered intraperitoneally 
BID, we evaluated its efficacy on promoting long-term neurofunctional recovery. After 
observing the bleeding side effects, particularly bleeding near the injection sites, as well 
as mortality data from systemic Dabigatran administration, we decided to investigate if a 
localized intranasal administration would promote long-term recovery. Dabigatran 
intranasal administration may increase brain concentration compared to intraperitoneal 
administration and avoids repeated abdominal injections, which may cause the observed 
bleeding, although the high bioavailability of small drugs after intranasal delivery may 
make blood plasma concentrations similar to intraperitoneal delivery and have the same 
bleeding risk (McMartin, Hutchinson et al. 1987). The vehicle group performed 
significantly worse than sham in the foot fault (Figure 5.2.A), rotarod (Figure 5.2.B), and 
Morris water maze tests (Figure 5.2.C-D). Dabigatran administered intraperitoneally 
significantly improved performances on the foot fault and rotarod tests, but did not 
improve performance in the Morris water maze test compared to vehicle. PAR-1 agonist, 
TFLLR-NH2, did not reverse neurobehavioral outcomes from intraperitoneal Dabigatran. 
PAR-1 antagonist, SCH79797, administration did not improve performances on the foot 
fault or Morris water maze tests, and only tended to improve performance on the rotarod 
test compared to vehicle. Intranasal Dabigatran did not improve performance on the foot 
fault test, tended to improve performance on the rotarod test, and significantly improved 
performance on the Morris water maze test compared to vehicle. 
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Figure 5.2: Long-term neurobehavioral outcomes after thrombin or PAR-1 
inhibition at 3-4 weeks post-GMH. assessment using the foot fault (A), rotarod (B), and 
Morris water maze tests for swim distance (C) and percentage of time spent in platform 
quadrant (D). *P<0.10 vs Sham; #P<0.10 vs Vehicle; $P<0.10 vs Dabigatran i.p.; 
&P<0.10 vs Dabigatran i.n.; @P<0.10 vs SCH79797. 
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Thrombin Inhibition Improved Long-term Brain Morphological Outcomes, 
which Tended to be Reversed by PAR-1 Stimulation; PAR-1 Inhibition Alone 
Was Not Sufficient to Promote Recovery 
To determine treatment effects on long-term post-hemorrhagic hydrocephalus 
outcomes, intracranial pressure was measured and brain morphological outcomes 
determined by histological analysis at 4 weeks post-GMH (Figure 5.3). Dabigatran 
administered either intraperitoneally or intranasally had significantly diminished post-
hemorrhagic ventricular dilation (Figure 5.3.B) and white matter loss (Figure 5.3.C) 
compared to vehicle. PAR-1 agonist co-administration significantly reversed 
intraperitoneal Dabigatran’s effect on reduced post-hemorrhagic ventricular dilation and 
tended to reverse intraperitoneal Dabigatran’s effect on ameliorating white matter loss.  
PAR-1 antagonist administration did not significantly diminish post-hemorrhagic 
ventricular dilation or white matter loss compared to vehicle. Additionally, the vehicle 
group had significantly increased intracranial pressure compared to sham, which was 
prevented by Dabigatran (intraperitoneal and intranasal) but not PAR-1 antagonism 
(Figure 3.D). PAR-1 agonist co-administration significantly reversed intraperitoneal 
Dabiagatran’s effects on diminishing intracranial pressure.  
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Figure 5.3: Long-term brain morphological outcomes after thrombin or PAR-1 
inhibition at 4 weeks post-GMH. Long term brain morphological. Representative 
photomicrographs (A), ventricular volumes (ratio to sham mean) (B), and white matter 
loss (percentage to sham mean) (C). Intracranial pressure at 4 weeks post-GMH (D). 
*P<.05 vs Sham; #P<.05 vs Vehicle; $P<.05 vs Dabigatran i.p.; &P<.05 vs Dabigatran 
i.n.. 
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Short-term p-mTOR and Downstream p-p70s6k Expression Levels Are 
Significantly Increased after GMH 
Activated mTOR has been implicated as a potential downstream effector of 
thrombin-induced PAR stimulation, leading to consequent ECM protein proliferation. We 
evaluated the expression time course of p-mTOR (Figure 5.4.A) and its downstream 
effector, p-p70s6k (Figure 5.4.B), after GMH. Activated mTOR (p-mTOR) expression 
levels were significantly increased 3 hours, and remained elevated up to 7 days post-
ictus. Activated p70s6k (p-p70s6k) expression levels were significantly increased 3 
hours, and remained increased at 3 days post-ictus, before returning to levels 
indistinguishable from that of sham at 5 days post-ictus. 
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Figure 5.4: Time course of mTOR/p70s6k activation after GMH. Time course of p-
mTOR (A) and p-p70s6k (B) protein expression in the brain after GMH. *P<.05 vs 
Sham. 
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Thrombin Inhibition Reduced p-mTOR and p-p70s5k Expression Levels at 3 
Days Post-ictus, which Were Reversed by PAR-1 Stimulation; PAR-1 Inhibition 
Alone Did Not Significantly Reduce p-mTOR and p-p70s6k Expression 
Three days post-GMH, the effect of treatment on p-mTOR expression was 
evaluated (Figure 5.5). Dabigatran (intraperitoneal and intranasal) significantly decreased 
p-mTOR and p-p70s6k expression levels compared to vehicle, which were reversed by 
PAR-1 agonist co-administration. Intraperitoneal PAR-1 antagonist administration did 
not significantly reduce p-mTOR or p-p70s6k expression levels compared to vehicle 
(Figure 5.5.A-B). 
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Figure 5.5: Expression of activated mTOR/p70s6k after thrombin inhibition and 
PAR-1 stimulation at 72 hours after GMH.  Expression of p-mTOR and p-p70s6k 
protein expression in the brain at 3 days post-GMH in rats treated with Dabigatran 
administered intraperitoneally (A-B) or intranasally (C-D). *P<.05 vs Sham; #P<.05 vs 
Vehicle; $P<.05 vs Dabigatran i.p.; &P<.05 vs Dabigatran i.n.. 
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Thrombin Inhibition Significantly Reduced Long-term ECM Protein 
Proliferation after GMH, which Was Not Reversed by PAR-1 Stimulation; 
PAR-1 Inhibition Alone Tended to Reduce ECM Protein Proliferation 
ECM protein proliferation has been associated with post-hemorrhagic 
hydrocephalus after GMH, thus we evaluated treatment effects on vitronectin (Figure 
5.6.A) and fibronectin (Figure 5.6.B) expression levels 4 weeks post-ictus. The vehicle 
group had significantly increased expression of both vitronectin and fibronectin 
compared to sham, which was prevented by Dabigatran (intraperitoneal and intranasal) 
and tended to decrease by PAR-1 antagonism. PAR-1 agonist co-administration did not 
significantly reverse intraperitoneal Dabigatran effects on reducing vitronectin expression 
and only tended to reverse intraperitoneal Dabigatran effects on reducing fibronectin 
expression. 
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Figure 5.6: Long-term expression of extracellular matrix proteins after thrombin 
and PAR-1 inhibition at 4 weeks post-GMH. Expression of vitronectin (A) and 
fibronectin (B) proteins in the brain at 4 weeks post-GMH. *P<.05 vs Sham; #P<.05 vs 
Vehicle. 
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Discussion 
Post-hemorrhagic hydrocephalus is a common neurological sequelae afflicting 
severe grade GMH patients, and a non-invasive therapeutic approach would significantly 
improve the quality of life for this patient population. Elucidating clinically translatable 
pathophysiological mechanisms contributing towards post-hemorrhagic hydrocephalus 
development will hopefully yield novel therapeutic modalities to accomplish this aim. 
Thrombin has been identified as a potentially critical player since intraventricular 
thrombin injection results in brain tissue damage and ventricular dilation in adult rats, 
which was reversed by intraventricular PAR-1 antagonist injection (Gao, Liu et al. 2014). 
Thrombin activity is significantly upregulated 24 hours after GMH and tends to remain 
elevated up to 10 days post-ictus (Lekic, Klebe et al. 2015). Additionally, stimulation of 
thrombin’s receptors, protease-activated receptors-1, -3, and -4, upregulates downstream 
proliferative pathways associated with brain injury, including PI3K/Akt, mTOR, and 
MAPK (Kataoka, Hamilton et al. 2003; Steinhoff, Buddenkotte et al. 2005; Luo, Wang et 
al. 2007). Our prior studies determined active p-mTOR is significantly upregulated in 
GMH rats at 72 hours post-ictus, and co-administration of PAR-1 and PAR-4 inhibitors 
reduced p-mTOR expression levels. Additionally, mTOR inhibition by rapamycin 
treatment improved long-term neurofunctional and brain morphological outcomes after 
GMH (Lekic, Klebe et al. 2015). Thus, this pathway warrants further investigation.  
 Dabigatran is a novel direct thrombin inhibitor clinically approved for treating 
deep vein thrombosis and preventing stroke from atrial fibrillation (Eisert, Hauel et al. 
2010; van Ryn, Stangier et al. 2010). Similar to Argatroban (Chen 2001), Dabigatran is a 
competitive inhibitor that reversibly binds to thrombin’s active site. We aimed to evaluate 
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this clinically available drug in our neonatal rat GMH model. We first performed a 
dosing study to 1) identify the half-life of Dabigatran, and 2) determine the best treatment 
regimen to prevent hematoma expansion and other adverse effects. Plasma Dabigatran 
concentrations after intraperitoneal administration was measured at 2, 4, 8, 12, 18, and 24 
hours after injection using three doses: 3 mg/kg, 10 mg/kg, and 30 mg/kg. Plasma 
concentrations for all three doses had peaked by 2 hours and the half-life was 8-12 hours 
in neonatal rats (Figure 5.1.A). 
While thrombin inhibition has yielded positive results in intracerebral hemorrhage 
models, evidence suggests that high doses of thrombin inhibitors result in increased 
hematoma volumes due to their anti-coagulant effects (Lauer, Cianchetti et al. 2011; 
Zhou, Schwarting et al. 2011). Given Dabigatran’s 8-12 hour half-life, Dabigatran was 
given QD and BID. Dabigatran (30 mg/kg) QD and BID resulted in significantly greater 
hematoma volumes compared to that of the vehicle. Dabigatran (10 mg/kg) QD and BID 
and Dabigatran (3 mg/kg) QD had hematoma volumes comparable to that of the vehicle, 
whereas Dabigatran (3 mg/kg) BID tended to decrease hematoma volume (Figure 5.1.B). 
We speculate Dabigatran’s anti-coagulant properties at 3 mg/kg are potent enough to 
attenuate the accumulation of blood in the brain and cerebroventricular system while 
preventing excess bleeding and consequent hematoma expansion. These findings are 
analogous to studies investigating fibrinolytic agents to break down cerebroventricular 
blood clots after intraventricular hemorrhage (Staykov, Huttner et al. 2009). 
During the dosing study, some mortality was observed in the medium and high 
dose groups, but many of the animals in those groups suffered from adverse bleeding 
side-effects, particularly in the abdomen. We were concerned systemic administration of 
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Dabigatran may be risky, so we decided to investigate if intranasal administration, which 
is more localized to the brain, could be therapeutically beneficial, thus, an intranasal 
administration group was added to the long-term study, and only 3 mg/kg Dabigatran 
BID administered either intraperitoneally or intranasally was used, since it was best 
tolerated. Recognizing that direct thrombin inhibitors have an inherent bleeding risk, we 
investigated if 1) inhibiting PAR-1, a downstream thrombin receptor, will achieve the 
same therapeutic results, and 2) stimulating PAR-1 will reverse Dabigatran’s therapeutic 
effects. 
Dabigatran treatment ameliorated long-term neurofunctional deficits. 
Interestingly, intraperitoneal Dabigatran only improved locomotor and sensorimotor 
outcomes, evidenced by better foot-fault and rotarod performances, while intranasal 
Dabigatran administration only improved neurocognitive function, evidenced by better 
Morris water maze performances (Figure 5.2). PAR-1 stimulation did not reverse 
intraperitoneal Dabigatran’s therapeutic effects on foot-fault and rotarod performance, 
and PAR-1 inhibition did not significantly attenuate any neurofunctional deficits, 
although it tended to improve performance on the rotarod test. While both administration 
routes had identical effects in every aspect of this study with neurobehavioral outcomes 
being the only exception, these results may partially be explained by the inherent error 
and variability within the tests, but the potential differential effects from the given 
administration routes cannot be ignored. Regardless, both administration routes showed 
significant neurofunctional recovery after GMH. 
Both Dabigatran administration routes improved long-term brain morphological 
outcomes by reducing post-hemorrhagic ventricular dilation and white matter loss 
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compared to vehicle, and both routes reduced long-term intracranial pressure compared to 
vehicle (Figure 5.3). PAR-1 stimulation showed a strong tendency to reverse 
intraperitoneal Dabigatran’s therapeutic effects on brain morphological and intracranial 
pressure outcomes since this group did not achieve a statistically significant difference 
from the vehicle group. PAR-1 inhibition alone failed to ameliorate post-hemorrhagic 
ventricular dilation, white matter loss, and elevated intracranial pressure.  These results 
suggest thrombin activity is associated with long-term post-hemorrhagic hydrocephalus 
development, but post-hemorrhagic hydrocephalus development is not exclusively 
dependent upon thrombin-induced PAR-1 stimulation, although it may play a minor role 
in conjunction with other pathways. Indeed, activated thrombin also stimulates PAR-3 
and PAR-4 as well, and their potential roles in GMH pathophysiology have not been 
elucidated. PAR-1 inhibition alone also failed to ameliorate short-term subventricular 
zone damage in a neonatal mouse GMH model (Mao and Del Bigio 2015), which is 
consistent with our results showing PAR-1 inhibition failed to ameliorate long-term white 
matter loss. Future investigations should rule out PAR-1 inhibition alone and focus on 
PAR-3, PAR-4, or a combinatorial treatment approach. 
Active thrombin is hypothesized to contribute towards fibrosis and consequent 
ECM protein proliferation, which disrupt cerebrospinal fluid dynamics in the 
cerebroventricular system, potentially causing post-hemorrhagic hydrocephalus. PAR 
stimulation leads to activation of multiple proliferative signaling pathways, including 
PI3K/Akt, MAPK, and mTOR (Kataoka, Hamilton et al. 2003; Steinhoff, Buddenkotte et 
al. 2005; Luo, Wang et al. 2007). Previously, mTOR inhibition improved long-term brain 
morphological and neurofunctional outcomes after GMH, and combinatorial PAR-1,-4 
 148 
inhibition reduced mTOR activation at 72 hours post-GMH. Yet, neither mTOR 
inhibition, PAR-1,-4 inhibition, nor ECM protein proliferation have been evaluated for 
long-term outcomes after GMH (Lekic, Klebe et al. 2015). Herein, p-mTOR expression 
was increased immediately following GMH and remained elevated to 7 days, and a 
similar trend was observed for p-p70s6k (Figure 5.4). Dabigatran attenuated the elevated 
expressions of p-mTOR and p-p70s6k, which was reversed by PAR-1 stimulation. Yet 
PAR-1 inhibition alone did not significantly decrease p-mTOR or p-p70s6k (Figure 5.5). 
Our results suggest thrombin inhibition decreases mTOR activation, yet is seems that 
stimulation of any of thrombin’s downstream PARs is sufficient to increase mTOR 
activation. When thrombin is inhibited, it is not able to stimulate PARs inducing mTOR 
activation, yet stimulation of one PAR, PAR-1 here, was capable of activating mTOR. 
This is supported by the current work that inhibition of only PAR-1 was unable to 
prevent mTOR activation. Additionally, this is supported the work of Lekic et al. that 
combinational PAR-1,-4 inhibition reduced p-mTOR expression 72 hours after GMH, 
indicating that combinatorial PAR inhibition may be necessary to completely target this 
pathway. 
Activated mTOR is hypothesized to contribute towards long-term ECM protein 
proliferation, which was observed in this work. Dabigatran (intraperitoneally and 
intranasally) significantly decreased vitronectin and fibronectin, and PAR-1 agonist co-
administration did not reverse Dabigatran’s effects on vitronectin expression but tended 
to reverse fibronectin expression. PAR-1 inhibition alone tended to reduce vitronectin 
and fibronectin (Figure 5.6). Long-term ECM protein proliferation weakly correlates with 
short-term p-mTOR expression levels, suggesting PAR-1/mTOR plays a small role, but 
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other signaling pathways must be involved as well. Most importantly, ECM protein 
proliferation does not strongly correlate with brain morphological and intracranial 
pressure outcomes, but p-mTOR expression levels do correlate, suggesting future 
investigations into post-GMH hydrocephalus development should focus less on ECM 
protein proliferation and more on alternative p-mTOR-related pathways, particularly 
active mTOR’s relationship with immunomodulatory and cell survival pathways. 
Our study has some limitations that need to be considered. First, neither the time 
course of Dabigatran plasma concentrations after intranasal injection, nor the time course 
of Dabigatran brain levels after intraperitoneal or intranasal administration. Second, the 
effects of intranasal Dabigatran on hematoma volume were also not examined, nor was a 
dosing study on intranasal Dabigatran performed. Third, thrombin has a plethora of 
downstream targets in addition to PAR/mTOR-induced ECM proliferation, including 
immunomodulatory and cell survival pathways (Krenzlin, Lorenz et al. 2016).The scope 
of this study was on PAR-1/mTOR to isolate a potentially effective pathway downstream 
of thrombin which may play an important role in post-hemorrhagic hydrocephalus 
development. PAR-1 agonist and antagonist effects should also be interpreted cautiously, 
since PAR-1 exhibits biased agonism and responds to various doses of drugs and stimuli 
differently (Mosnier, Sinha et al. 2012). Fourth, some evidence suggests plasma 
fibronectin and vitronectin leak into the brain tissue following hemorrhagic 
transformation after ischemia in adult mice, indicating another source of ECM proteins in 
addition to those produced from fibrosis (del Zoppo, Frankowski et al. 2012). Increased 
long-term ECM protein expression after GMH, however, may depend more on chronic 
fibrosis than acute vascular extravasation. Fifth, the therapeutic window for post-GMH 
 150 
treatments is poorly defined due to lack of clinically approved or tested therapies, and the 
initial two hour post-ictus treatment time point examined may be too narrow for clinical 
translation.  Finally, although our model produces consistent hemorrhages with 
consequent gliosis, neurological deficits, white matter loss, brain atrophy, and post-
hemorrhagic hydrocephalus consistent with human neonatal brain hemorrhage, vascular 
integrity is disrupted by direct protease infusion (Lekic, Manaenko et al. 2012), which 
does not perfectly model GMH pathophysiology caused by hemodynamic, microvascular, 
and cardiorespiratory instability emulated in other animal models (Chua, Chahboune et 
al. 2009; Yang, Baumann et al. 2013). These limitations will be the focus of future 
studies. 
 
Conclusions 
 Direct thrombin inhibition by Dabigatran decreased acute mTOR activation, 
reduced long-term ECM protein proliferation, ameliorated post-hemorrhagic 
hydrocephalus development, and improved long-term neurofunctional outcomes. 
Inhibition of PAR-1, a thrombin downstream receptor, was not sufficient to achieve the 
same observed therapeutic effectiveness as direct thrombin inhibition by Dabigatran. Yet 
PAR-1 stimulation tended to reverse Dabigatran’s therapeutic effects on long-term post-
hemorrhagic hydrocephalus development and short-term mTOR activation, suggesting a 
role for PAR-1 in GMH sequelae. Future investigations should employ combinatorial 
PAR-1, -3, and/or -4 inhibition treatment modalities and further investigate additional 
pathways related to thrombin and active mTOR, including inflammatory and cell survival 
pathways. 
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CHAPTER SIX 
DISCUSSION AND CONCLUSION 
 
Summary/Highlights of Findings 
 Our findings demonstrate blood, iron, and thrombin/PAR-1/mTOR activation 
contribute to GMH-induced brain injury and long-term PHH development. These 
findings are supported by the following observations: (1) PPARγ-induced upregulation of 
CD36 enhances short-term hematoma resolution and attenuates long-term neurological 
deficits and brain morphological outcomes; (2) acute and delayed iron chelation by 
Deferoxamine improves long-term brain morphological and neurobehavioral outcomes as 
well as reduced ECM protein proliferation; (3) combinatorial PAR-1 and PAR-4 
inhibition reduced short-term COX-2 and mTOR activation, and COX-2 and mTOR 
inhibition improved long-term brain morphological and neurocognitive outcomes; (4) 
direct thrombin inhibition by Dabigatran reduces short-term mTOR activation and 
ameliorates long-term PHH development and neurocognitive deficits, which was not 
reversed by PAR-1 stimulation, nor could PAR-1 inhibition alone achieve the same 
therapeutic benefits as direct thrombin inhibition. 
 
The State of the Field Prior to this Study 
 The pathophysiological mechanisms leading to PHH development after GMH 
remain to be clearly elucidated. Thrombin, intracerebroventricular blood clots, and iron 
have been identified as potentially causative factors of hydrocephalus formation. 
Thrombin initiates inflammatory responses, gliosis, and ECM protein proliferation that 
potentially obstruct the cerebroventricular system (Whitelaw 2001; Xue, 
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Balasubramaniam et al. 2003; Cherian, Whitelaw et al. 2004; Volpe 2009; Aquilina, 
Chakkarapani et al. 2011). Thrombin activates PARs, which subsequently activate 
downstream mTOR. Activation of mTOR is associated with ECM protein proliferation 
and impaired CSF dynamics (Paul, Leef et al. 2000; Kataoka, Hamilton et al. 2003; 
Crews, Wyss-Coray et al. 2004; Del Bigio 2004; Steinhoff, Buddenkotte et al. 2005; Xue 
and Del Bigio 2005; Ballabh, Xu et al. 2007; Dummula, Vinukonda et al. 2010). PPARγ 
stimulation enhances CD36 scavenger receptor-mediated microglial phagocytosis of red 
blood cells, resulting in increased clot resolution and improved outcomes after adult 
cerebral hemorrhage (Zhao, Zhang et al. 2006; Zhao, Sun et al. 2007). Iron chelation also 
improved adult cerebral hemorrhage outcomes (Hatakeyama, Okauchi et al. 2013). 
Pharmacological modulation of the thrombin/PAR/mTOR pathway, PPARγ, and iron, 
which all have clinically translatable pharmacological agents that target them available, 
for neonatal GMH have not been studied. A safe and non-invasive treatment for reducing 
PHH would significantly improve the quality of life for GMH patients. 
 
How Our Findings Advance the Field 
 The findings from this investigation further elucidate some of the underlying 
pathophysiological mechanisms contributing to PHH development after GMH. In 
particular, we investigate the role of thrombin/PAR-1/mTOR, PPARγ/CD36, and iron. 
Our study suggests some therapeutic benefit can be achieved by a clinically available 
direct thrombin inhibitor, Dabigatran. Since thrombin inhibition has the risk of increased 
bleeding, investigating downstream thrombin pathways may provide more safe 
therapeutic alternatives. Thrombin inhibition ameliorated long-term PHH, neurological 
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deficits, and ECM protein proliferation as well as decreased short-term mTOR activity 
after GMH. Interestingly, PAR-1 inhibition alone did not achieve the same therapeutic 
benefits as thrombin inhibition, nor did PAR-1 stimulation reverse all therapeutic effects 
from thrombin inhibition, although brain morphological outcomes and mTOR activity 
were reversed. PAR-1 inhibition also tended to decrease ECM protein proliferation while 
PAR-1 stimulation only tended to reverse ECM protein proliferation. Interestingly, 
combinatorial PAR-1 and PAR-4 inhibition reduced short-term mTOR activity, 
suggesting inhibiting one PAR is not sufficient to diminish activity of downstream 
effectors. Future studies should investigate long-term combinatorial inhibition of PARs 
after GMH. Our findings suggest ECM protein proliferation is weakly associated with 
long-term PHH development. Furthermore, two Dabigatran administration routes were 
investigated, intraperitoneal and intranasal, and both achieved the same therapeutic 
benefits. 
 Our findings also suggest enhancing hematoma resolution by stimulating PPARγ, 
which can be targeted by clinically available pharmacological agents, such as 
thiazolidinediones, enhances short-term hematoma resolution and improves long-term 
brain morphological and neurocognitive outcomes after GMH. PPARγ antagonization 
reversed treatment effects, and CD36 knockdown also reversed PPARγ agonist effects on 
short-term hematoma resolution. Enhanced hematoma resolution was associated with 
increased presence of alternatively activated M2 microglia/macrophages, suggesting 
PPARγ stimulation modulates microglia/macrophage differentiation. In addition to 
enhancing clot resolution, removing iron released from lysed erythrocytes by 
administering a clinically available iron chelator, Deferoxamine, also ameliorated long-
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term PHH, improved neurocognitive function, and reduced ECM proliferation. 
Therapeutic benefits were achieved when Deferoxamine was administered within hours 
after GMH as well as three days after GMH, suggesting iron chelation has a large 
therapeutic window. Our findings provide pertinent information regarding clinically 
viable therapeutic targets to attenuate long-term PHH development after GMH. 
 
Summary/Conclusion 
 Direct thrombin inhibition, enhanced hematoma resolution by PPARγ stimulation, 
and iron chelation all resulted in improved long-term brain morphological (i.e. reduced 
PHH) and neurocognitive outcomes after experimental GMH in rat pups. Direct thrombin 
inhibition and combinatorial PAR-1 and PAR-4 inhibition resulted in decreased short-
term p-mTOR expression. PAR-1 inhibition alone did not decrease p-mTOR activity, 
although PAR-1 stimulation with direct thrombin inhibition reversed treatment effects by 
increasing p-mTOR activity. Rapamycin treatment to inhibit mTOR improved brain 
morphological and neurocognitive outcomes. Direct thrombin inhibition reduced long-
term intracranial pressure, improved brain morphological outcomes, ameliorated 
neurological deficits, and reduced ECM protein proliferation, but PAR-1 inhibition alone 
did not achieve the same therapeutic benefits although ECM protein proliferation tended 
to be reduced. Additionally, PAR-1 stimulation with direct thrombin inhibition only 
tended to reverse treatment effects on brain morphological outcomes, intracranial 
pressure, and ECM protein proliferation. Short-term mTOR activity is strongly associated 
with PHH development after GMH, and ECM protein proliferation is weakly associated 
with PHH. Additionally, PPARγ stimulation enhanced short-term hematoma resolution, 
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which was reversed by PPARγ antagonism and CD36 knockdown. PPARγ stimulation 
improved long-term neurocognitive and brain morphological outcomes, which was 
reversed by PPARγ antagonism. Iron chelation starting immediately after GMH and 72 
hours after GMH improved long-term brain morphology, reduced neurocognitive deficits, 
and diminished ECM protein proliferation. Thus, the thrombin/PAR/mTOR pathway, the 
PPARγ/CD36 pathway, and iron play significant roles in long-term PHH development 
after GMH. 
 
Prospective 
 Although our findings show blood clots, iron, and the thrombin/PAR/mTOR 
pathway play important roles in PHH development after GMH, it cannot concluded if 
PHH developed because of an obstruction in the cerebroventricular system and/or 
subarachnoid spaces. Indeed, current hydrodynamic theory of CSF dynamics and 
hydrocephalus development suggests the source for CSF production is choroidal and 
ependymal capillaries and the source for CSF reabsorption is subarachnoid and 
parenchymal capillaries as well as perivascular channels following glymphatic-mediated 
CSF-interstitial fluid exchange. Hydrocephalus results from a disruption in hydrostatic 
and oncotic pressures in the brain microvasculature as well as possible abnormal 
distribution of vascular pulsations due to changes in brain compliance (Egnor, Zheng et 
al. 2002; Greitz 2004; Oreskovic and Klarica 2011; Iliff, Wang et al. 2012). Further 
investigations into PHH development after GMH should focus less on possible 
cerebroventricular obstructions and more on alterations in barrier mechanisms of the 
brain microvasculature as well as the glymphatic system.  
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Abstract 
Cerebral hemorrhages account for 15-20% of stroke sub-types and have very poor 
prognoses.  The mortality rate for cerebral hemorrhage patients is between 40-50%, of 
which at least half of the deaths occur within the first two days, and 75% of survivors are 
incapable of living independently after one year.  Current emergency interventions 
involve lowering blood pressure and reducing intracranial pressure by controlled 
ventilations or, in the worst case scenarios, surgical intervention.  Some hemostatic and 
coagulatherapeutic interventions are being investigated, although a few that were 
promising in experimental studies have failed in clinical trials.  No significant 
immunomodulatory intervention, however, exists for clinical management of cerebral 
hemorrhage.  The inflammatory response following cerebral hemorrhage is particularly 
harmful in the acute stage because blood-brain barrier disruption is amplified and 
surrounding tissue is destroyed by secreted proteases and reactive oxygen species from 
infiltrated leukocytes.  In this review, we discuss both the destructive and regenerative 
roles the immune response play following cerebral hemorrhage and focus on microglia, 
macrophages, and T-lymphocytes as the primary agents directing the response.  
Microglia, macrophages, and T-lymphocytes each have sub-types that significantly 
influence the over-arching immune response towards either a pro-inflammatory, 
destructive, or an anti-inflammatory, regenerative, state. Both pre-clinical and clinical 
studies of cerebral hemorrhages that selectively target these immune cells are reviewed 
and we suggest immunomodulatory therapies that reduce inflammation, while 
augmenting neural repair, will improve overall cerebral hemorrhage outcomes. 
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Cerebral Hemorrhage Pathophysiology 
Incidence, Outcomes, and Clinical Management 
Cerebral hemorrhage, the rupturing of blood vessels within the brain tissue, 
accounts for 10-15% of strokes (Qureshi, Mendelow et al. 2009; Mracsko and Veltkamp 
2014).  Occurring in approximately 25 per 100,000 people per year, cerebral hemorrhage 
is the leading cause of morbidity and mortality in stroke patients, having a mortality rate 
between 30-50% with nearly 75% of survivors incapable of living independently after 
one year (van Asch, Luitse et al. 2010).  Hospital admissions for cerebral hemorrhage 
cases have increased by 18% over the past decade, and admissions are expected to 
continue rising due to an increasing elderly population (Qureshi, Mendelow et al. 2009).   
Current clinically approved emergency interventions involve lowering blood 
pressure (Anderson, Huang et al. 2008; Morgenstern, Hemphill et al. 2010; Sakamoto, 
Koga et al. 2013) or surgical craniotomy (Morgenstern, Hemphill et al. 2010).  
Hematoma evacuation is also being investigated as a potential surgical intervention, but it 
has yet to yield positive results (Morgenstern, Frankowski et al. 1998; Mendelow, 
Gregson et al. 2005; Miller, Vespa et al. 2008; Wang, Jiang et al. 2009; Mendelow, 
Gregson et al. 2013). Hemostatic therapies have also been investigated in clinical trials, 
such as recombinant factor VII, but despite showing promise in experimental studies, 
none have been clinically approved (Mayer, Brun et al. 2006; Mayer, Brun et al. 2008; 
Diringer, Skolnick et al. 2010).  Unfortunately, cerebral hemorrhage is the least treatable 
stroke subtype, with minimal advancements being made in clinical management, despite 
its increasing prevalence (Kreitzer and Adeoye 2013).   
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Primary Brain Injury 
Most investigative therapeutic approaches for cerebral hemorrhage focus on 
ameliorating primary brain injury, which is caused by the mechanical pressure on brain 
tissue due to the hematoma mass effect, and the potential hematoma expansion (Xi, Keep 
et al. 2006; Keep, Hua et al. 2012; Mracsko and Veltkamp 2014).  Mechanical pressure 
applied to glia and neurons cause calcium influx and secretion of excitotoxic 
neurotransmitters, resulting in consequent cytotoxic edema and necrosis (Keep, Xi et al. 
2005; Xi, Keep et al. 2006). Indeed, hematoma volume and subsequent hematoma 
expansion, which occurs in approximately 30% of clinical cerebral hemorrhage cases, are 
currently the best prognostic indicators (Davis, Broderick et al. 2006; Dowlatshahi, 
Demchuk et al. 2011; Brouwers and Greenberg 2013).  Brain edema, caused by both 
primary and secondary brain injury mechanisms, is increasingly accepted as a valuable 
prognostic indicator (Thiex and Tsirka 2007; Staykov, Wagner et al. 2011).  
 
Secondary Brain Injury 
Mechanisms for secondary brain injury after cerebral hemorrhage have garnered 
increased research interests over the past decade.  Secondary brain injury results from 
blood components entering the brain tissue as well as injured brain cells that trigger 
multiple deleterious mechanisms and subsequently augment oxidative stress, 
inflammatory pathways, blood-brain barrier disruption, and vasogenic edema (Aronowski 
and Zhao 2011; Belur, Chang et al. 2013).  Coagulation cascade activation increases 
thrombin formation, which stimulates the complement pathway as well as protease-
activated receptors (PARs) (Hua, Keep et al. 2007; Babu, Bagley et al. 2012).  PAR 
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stimulation after hemorrhage, particularly PAR-1 activation in neurons, leads to increased 
NMDA receptor potentiation and consequent activation of excitotoxicity, apoptosis, and 
pro-inflammatory pathways (Babu, Bagley et al. 2012).  PAR-1 has also been implicated 
in playing an important role in thrombin-induced cerebral hemorrhaging (Cheng, Xi et al. 
2014). Complement activation after cerebral hemorrhage leads to membranous pore 
formation, called membrane attack complexes, in neurons and red blood cells, causing 
cytotoxicity and cell lysis (Hua, Xi et al. 2000; Ducruet, Zacharia et al. 2009).   
Red blood cell lysis releases hemoglobin, which is metabolized by heme 
oxygenase 1 to release iron and heme, into the surrounding tissue (Wu, Xi et al. 2006).  
Heme and iron are critical constituents in redox reactions that produce injurious free 
radicals and increase oxidative stress, causing significant tissue injury, DNA damage, 
blood-brain barrier disruption, and inflammation (Wu, Xi et al. 2006; Xi, Keep et al. 
2006; Babu, Bagley et al. 2012; Xiong, Wang et al. 2014).  Administering Deferoxamine, 
an iron chelator, resulted in improved neurofunctional outcomes following experimental 
cerebral hemorrhage and reduced hydrocephalus development in other brain injury 
models (Nakamura, Keep et al. 2004; Klebe, Krafft et al. 2014; Zhao, Chen et al. 2014). 
Indeed, post-hemorrhagic hydrocephalus is a common consequence of intracerebral 
hemorrhage as well, and iron has been implicated as a causative factor (Chen, Zhang et 
al. 2014; Gao, Du et al. 2014; Meng, Li et al. 2014). 
Inflammation is a key component of secondary brain injury following cerebral 
hemorrhage (Wang 2010; Mracsko and Veltkamp 2014; Zhou, Wang et al. 2014; Chen, 
Yang et al. 2015).  An inflammatory response ensues immediately after blood enters the 
brain tissue via activation of resident immune cells and subsequent infiltration of 
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peripheral leukocytes, leading to secretion of pro-inflammatory mediators, extracellular 
proteases, and reactive oxygen species that further damage brain tissue and disrupt the 
blood-brain barrier (Aronowski and Hall 2005; Wang and Dore 2007).  Immune cells, 
particularly pro-inflammatory macrophages, also play an important role in cerebral 
aneurysm formation, a primary cause for cerebral hemorrhage (Hosaka and Hoh 2014; 
Starke, Raper et al. 2014).  Some evidence, however, suggests inflammation may play an 
important role in repair and recovery following central nervous system injury (Correale 
and Villa 2004; Hohlfeld, Kerschensteiner et al. 2006; McCombe and Read 2008; Wee 
Yong 2010).  The potential neuroprotective branch in inflammation may be 
therapeutically exploited following cerebral hemorrhage to promote hematoma resolution 
as well as tissue repair and regeneration.  
 
Review Scope 
In this review, we will discuss microglia, macrophage, and T-helper lymphocyte 
immunology following cerebral hemorrhagic insult, the roles which the subtypes for each 
play in neurodegeneration or neuroprotection, as well as possible therapeutic approaches 
to potentially shift the inflammatory response towards a neuroregenerative phenotype.  
We will also discuss evidence from current cerebral hemorrhage research and address 
gaps in the literature that warrant further investigation.  Explicating the immune response 
in its entirety following cerebrovascular insult will discern therapeutic 
immunomodulatory approaches that dampen the neurodegenerative inflammatory 
response in favor for a neuroregenerative one, promoting functional recovery and 
improving overall outcomes.  Cerebral hemorrhage pathophysiology is very complex and 
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multi-modal approaches are being increasingly encouraged, and exploiting 
immunomodulatory mechanisms may prove beneficial when investigating such 
approaches since inflammation is an important component of secondary brain injury 
(Pandey and Xi 2014). 
 
Macrophage, Microglia, and T-helper Lymphocyte Characterization 
Macrophage and Microglia Subtypes 
Macrophages are a type of white blood cell of myeloid lineage found in almost all 
tissue types and play a quintessential role in innate (non-specific) immunity by searching 
for and engulfing potential pathogens (Murray and Wynn 2011).  Microglia are the 
resident macrophages of the central nervous system, and, unfortunately, they are 
extremely difficult to distinguish from infiltrated macrophages following central nervous 
system injury (Saijo and Glass 2011). Traditionally, macrophages and microglia 
phagocytose microbes, cellular debris, apoptotic cells, cancer cells, and foreign 
substances.  Stimulation of microglia/macrophage toll-like receptors, nod-like receptors, 
scavenger receptors, and/or cytokine receptors from inflammatory cytokines, pathogens, 
and blood products will potentiate the inflammatory response through further secretion of 
pro-inflammatory cytokines, such as TNF-α and IL-1β, resulting in leukocyte 
recruitment.  Recent immunology research, however, discerned macrophages can also 
dampen the immune response, promoting tissue repair and regeneration.  Microglia and 
macrophages have been classified into two predominant subtypes modeled similar to the 
Th1/Th2 paradigm: classically activated or M1 and alternatively activated or M2 (Murray 
and Wynn 2011; Saijo and Glass 2011).  Further elucidating the role each subtype plays 
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in cerebral hemorrhage pathophysiology may yield potential therapeutic avenues that 
coax the immune response to create a neural regenerative milieu in the peri-hematoma 
region.   
 Classically activated M1 macrophages and microglia are primarily responsible for 
the innate immune defense mechanisms, producing a pro-inflammatory response (Murray 
and Wynn 2011; Saijo and Glass 2011).  The M1 phenotype can be induced by 
lipopolysaccharides, interferon-γ, TNF-α, or stimulation of nod-like receptors (NLR) or 
toll-like receptors (TLR), primarily TLR-4 (Martinez, Helming et al. 2009; Chen and 
Nunez 2010).  Very few definitive cell surface markers for the M1 subtype have been 
identified, although CD80 and CD86 are widely used. M1 macrophages and microglia 
also secrete TNF-α, IL-1β, IL-6, IL-12, and IL-23 pro-inflammatory cytokines (Martinez 
and Gordon 2014; Wang, Liang et al. 2014). Alternatively, activated M2 macrophages 
and microglia are primarily responsible for mediating wound healing and produce an 
anti-inflammatory response (Murray and Wynn 2011; Saijo and Glass 2011). The M2 
phenotype can be induced by IL-4, IL-10, TGF-β, and IL-13 stimulation (Martinez, 
Helming et al. 2009; Martinez and Gordon 2014; Wang, Liang et al. 2014).  Common 
cell surface markers attributed to the M2 subtype include CD163 and CD206, and M2 
macrophages and microglia secrete IL-10 and TGF-β anti-inflammatory cytokines 
(Martinez, Helming et al. 2009; Martinez and Gordon 2014; Wang, Liang et al. 2014).   
Evidence suggests macrophages and microglia do not exist as terminally differentiated 
M1 or M2 states, but rather have the ability to switch phenotypes depending upon their 
microenvironment (Stout and Suttles 2004; Stout, Jiang et al. 2005; Eggen, Raj et al. 
2013; Giunti, Parodi et al. 2014).  Table A.1 contains the macrophage/microglia 
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subtypes, cytokines inducing their activation, common markers, secreted cytokines, as 
well as known mechanisms of action.   
The M1/M2 paradigm, however, has limitations.  Indeed, M2 microglia are being 
further classified into 3 subsets based on how differentiation is stimulated:  M2a is 
stimulated by IL-4 and IL-10; M2b is stimulated by toll-like receptor activation; and M2c 
is stimulated by IL-10, glucocorticoids, and TGF-β (Cherry, Olschowka et al. 2014).  
M2a and M2c have the typical markers and responses attributed to alternatively activated 
M2, while M2b lacks certain markers and has a response similar to M1 (Cherry, 
Olschowka et al. 2014).  Additionally, An increasing number of macrophage/microglia 
subsets in addition to M1/M2 are being classified in other diseases and disorders, such as 
atherosclerosis, multiple sclerosis, and lupus, including M4, Mox, Mhem, and M(Hb) 
(Orme and Mohan 2012; Bogie, Stinissen et al. 2014; Chinetti-Gbaguidi, Colin et al. 
2015). Furthermore, distinct macrophage/microglia responses have been characterized in 
vitro following stimulation by cytokines and extracellular pathogenic debris as well as in 
vivo following infection, yet the exact roles distinct microglia/macrophage subtypes play 
in most neurological diseases, disorders, and injuries have yet to be well elucidated.  M1 
and M2 may represent two extremes on a large spectrum of macrophage/microglia 
subsets where each subset plays a very critical immunomodulatory role in cerebral 
hemorrhage pathophysiology, and more research is needed to fill these gaps in our 
knowledge and help advance immunotherapeutic approaches. 
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Table A.1:  Macrophage/Microglia and T-helper Lymphocyte Subtypes 
Cell 
Types 
Activating 
Cytokines 
Markers 
Secreted 
Cytokines 
Mechanisms of action References 
M1 
IFN-γ, TNF-
α, LPS 
CD86, 
CD80, MHC 
II↑, IL-1R I, 
TLR2, 
TLR4, iNOS 
TNF-α, IL-
12, and IL-23 
Inhibits cell proliferation and 
causes tissue damage 
(Martinez, Helming et al. 
2009; Chen and Nunez 
2010; Cherry, Olschowka 
et al. 2014; Martinez and 
Gordon 2014; Wang, Liang 
et al. 2014) 
M2 IL-4, IL-13 
CD163, 
MHC II, 
SR, CD206↑, 
(MR↑), 
TGM2↑, 
DecoyR, IL-
1R II,  
Ym1, Fizz1, 
Arg-1 
IL-10, TGF-
β, and IL-
1RA 
Promotes cell proliferation 
and tissue repair 
(Martinez, Helming et al. 
2009; Murray and Wynn 
2011; Saijo and Glass 
2011; Cherry, Olschowka 
et al. 2014; Martinez and 
Gordon 2014; Wang, Liang 
et al. 2014) 
Th1 IL-12, IL-18 
CD4, 
CXCR3, 
CCR5 
IFN-γ, IL-2, 
and TNF-α 
Activate macrophages and 
are responsible for cell-
mediated immunity and 
phagocyte-dependent 
protective responses 
(Romagnani 1999; Zhu and 
Paul 2008; Luckheeram, 
Zhou et al. 2012) 
Th2 IL-4 
CRTH2, 
CCR3, 
CCR4 
IL-4, IL-5, 
IL-10, and 
IL-13 
Are responsible for strong 
antibody production, 
eosinophil activation, and 
inhibition of several 
macrophage functions, thus 
providing phagocyte-
independent protective 
responses 
(Romagnani 1999; Zhu and 
Paul 2008; Luckheeram, 
Zhou et al. 2012) 
Th17 
IL-2, IL-6, 
TGF-β, IL-
1β, IL-23 
CD4, CCR4, 
CCR6 
IL-17A/F, IL-
21, IL-22, 
CCR6 and 
ROR/t 
Creates inflammation and 
tissue injury in autoimmune 
diseases 
(Stockinger and Veldhoen 
2007; Dong 2008; Hirota, 
Martin et al. 2010; Peck 
and Mellins 2010; Dong 
2011; Zambrano-Zaragoza, 
Romo-Martinez et al. 2014) 
Treg IL-2, TGF-β 
CD4, CD25, 
and Foxp3 
TGF-β, IL-
10, and IL-35 
Are essential for maintaining 
peripheral tolerance, 
preventing autoimmune 
diseases and limiting chronic 
inflammatory diseases 
(Chen, Jin et al. 2003; 
Vignali, Collison et al. 
2008; Mantel and Schmidt-
Weber 2011; Yoshimura 
and Muto 2011) 
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T-helper Lymphocyte Subtypes 
T-helper cells are CD4+ white blood cells of lymphoid origin that develop within 
the thymus which are critical in regulating cell-mediated and adaptive immunity 
(Luckheeram, Zhou et al. 2012).  The two predominant paradigms for T-helper cell 
subtypes,  analogous to the M1/M2 macrophage and microglia paradigm in that the two 
phenotypes oppose each other, are Th1/Th2 and Th17/Treg (Kleinewietfeld and Hafler 
2013; Bretscher 2014).  Macrophages and microglia are capable of switching phenotypes 
according to their microenvironment, and some evidence supports T-helper cells 
switching phenotypes too, particularly between Th17 and Treg, although more conclusive 
evidence is needed (Stout and Suttles 2004; Stout, Jiang et al. 2005; Xu, Kitani et al. 
2007; Kleinewietfeld and Hafler 2013). 
Th1 cells direct the immune system towards fighting intracellular pathogens by 
inducing a cell-mediated response.  Th1 cell differentiation is kindled by IL-12 and 
interferon-γ stimulation, the latter of which Th1 cells secrete to further drive Th1 
differentiation.  Th2 cells direct the immune system towards fighting extracellular 
pathogens by inducing a humoral response.  Th2 cell differentiation is sparked by IL-4 
and IL-2 stimulation, and Th2 cells secrete IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13 (Zhu 
and Paul 2008; Zhu and Paul 2010; Luckheeram, Zhou et al. 2012).  Th1 cells are 
characterized by CCR5, CXCR3, and T-bet markers, while Th2 cells are identified by 
CCR3, CCR4, CRTH2, and GATA3 markers.  Th1 and Th2 both drive their own 
differentiation while suppressing differentiation into the other through their cytokine 
expressions (Zhu and Paul 2008; Zhu and Paul 2010; Luckheeram, Zhou et al. 2012).   
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The other T-helper phenotype paradigm relies on the promotion or suppression of 
inflammation. Th17 cells which potentiate inflammation and have been implicated as 
potential sources for many autoimmune diseases differentiate through IL-6, IL-21, IL-23, 
and TGF-β stimulation.  T17 cells, which express CCR6 and RORγt markers, secrete IL-
17, IL-21, and IL-22 (Stockinger and Veldhoen 2007; Dong 2008; Hirota, Martin et al. 
2010; Peck and Mellins 2010; Dong 2011).  Treg cells which dampen inflammation and 
mediate immune tolerance to self-antigens, differentiate through IL-2 and TGF-β 
stimulation (Chen, Jin et al. 2003; Mantel and Schmidt-Weber 2011; Yoshimura and 
Muto 2011). Treg cells, characterized by CD25 and FOXP3 markers, secrete IL-10 and 
TGF-β.  Evidence suggests plasticity between Th17 and Treg cell differentiation, which 
is highly dependent upon their surrounding milieu (Zhou, Chong et al. 2009; 
Kleinewietfeld and Hafler 2013).  Interestingly, differentiation of both Th17 and Treg 
cells can be driven by TGF-β (Li, Wan et al. 2007).  TGF-β at low concentrations and in 
conjunction with IL-6 or IL-21 will drive Th17 differentiation, but TGF-β at high 
concentrations and in conjunction with IL-10 will drive Treg differentiation (Chen, Jin et 
al. 2003; Mantel and Schmidt-Weber 2011; Yoshimura and Muto 2011).  Table A.1 
contains the T-helper lymphocyte subtypes, cytokines inducing their activation, common 
markers, secreted cytokines, as well as known mechanisms of action. 
 
Macrophage/Microglia and T-helper Lymphocyte Communication 
 T-helper lymphocytes, macrophages, and microglia are capable of influencing 
each other’s differentiation as well as phenotype switching (Murray and Wynn 2011; 
Saijo and Glass 2011; Luckheeram, Zhou et al. 2012).  M1 macrophages secrete TNF-α, 
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IL-6, IL-12, and IL23 (Murray and Wynn 2011; Saijo and Glass 2011), which recruits 
and induces differentiation of both Th1 and Th17 cells.  In turn, Th1 cells secrete 
interferon-γ while Th17 cells secrete IL-17, which further augments M1 macrophage 
polarization and potentiates the inflammatory response (Fiorentino, Zlotnik et al. 1991; 
Denning, Wang et al. 2007; Martinez, Sica et al. 2008; Savage, de Boer et al. 2008; 
Biswas and Mantovani 2010).  M1 macrophage and Th1 / Th17 cross-talk acts as a 
positive feed-back loop that further drives their own differentiation and create a highly 
inflamed microenvironment.  Analogously, M2 macrophages secrete IL-4, IL-10, and 
TGF-β (Martinez, Sica et al. 2008; Murray and Wynn 2011; Saijo and Glass 2011), 
which recruits and induces differentiation of both Th2 and Treg cells.  In turn, Th2 cells 
secrete IL-4 and IL-10 while Tregs secrete IL-10 and TGF-β, which further drives M2 
polarization, dampening inflammation and promoting tissue repair (Denning, Wang et al. 
2007; Martinez, Sica et al. 2008; Savage, de Boer et al. 2008; Biswas and Mantovani 
2010).  Disproportion between macrophage/microglia and T-helper cells, in which either 
the M1/Th1/Th17 or M2/Th2/Treg branches are overexpressed, intensify many disorders, 
including allergies, asthma, cancer, autoimmune diseases, atherosclerosis, and fibrosis.  
Consequently, many therapeutic approaches have been developed to exploit the cross-talk 
between macrophages/microglia and T-helper cells, restoring homeostasis between pro-
inflammatory and regenerative signaling in those aforementioned disorders (Murray and 
Wynn 2011; Saijo and Glass 2011; Luckheeram, Zhou et al. 2012). 
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Inflammation after Cerebral Hemorrhage 
Role of Macrophages and Microglia 
Explicating the inflammatory component of cerebral hemorrhage pathophysiology 
and discerning the immune cells involved, particularly the distinct macrophage/microglia 
and T-helper cell subsets, could lead to novel therapeutic approaches in which the peri-
hematoma milieu is switched from a pro-inflammatory microenvironment to a 
neuroregenerative one. Macrophages, microglia, and T-helper cell subsets are ideal 
targets because of the cross-talk and capability of potentiating either the damaging branch 
of inflammation via M1/Th1/Th17 or the repair/regenerative branch via M2/Th2/Treg 
(Murray and Wynn 2011; Saijo and Glass 2011; Luckheeram, Zhou et al. 2012).  The 
M1/Th1/Th17 branch creates an oxidative, caustic microenvironment to destroy 
pathogens, but cerebral hemorrhage is a brain injury of endogenous origin, thus 
attenuating this branch in favor of the M2/Th2/Treg branch may be beneficial (Chen and 
Nunez 2010).  Macrophages and microglia are of particular interest since they are the 
first to be activated following hemorrhage and are quintessential drivers of the immune 
response (Mracsko and Veltkamp 2014; Zhou, Wang et al. 2014). Furthermore, microglia 
and macrophages have great plasticity and aptly switch phenotypes between M1 and M2 
in response to the pathophysiology of their microenvironment.   
Activated microglia become present within 1-4 hours after cerebral hemorrhage in 
rodents, peak between 3-7 days, and finally return to basal levels between 3-4 weeks 
(Wang and Dore 2007; Zhou, Wang et al. 2014).  Following microglia activation, 
peripheral macrophages also infiltrate the injured tissue, although they are extremely 
difficult to distinguish from microglia.  Microglia/macrophages also recruit neutrophils 
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within hours of activation, which potentiate blood-brain barrier disruption and tissue 
damage by secreting extracellular proteases (Wang and Dore 2007; Zhao, Sun et al. 
2014).  While the activated microglia time course has been established in these 
experimental rodent cerebral hemorrhage models, the time course of M1 and M2 
phenotype expression has yet to be well-defined. Determining the ratio of M1/M2 
microglia and macrophages could be indicative of the pathophysiological milieu, as a 
high M1/M2 ratio implies a more oxidative, caustic inflammatory environment while a 
low M1/M2 ratio implies a more repair, regenerative environment.  M2 microglia and 
macrophages have increased scavenger receptor expression levels as well as augmented 
phagocytic activity compared to their M1 counterparts, therefore the M2 phenotype may 
be important for hematoma resolution after cerebral hemorrhage (Cherry, Olschowka et 
al. 2014).  Indeed, hematoma volume peaks 72 hours after experimental cerebral 
hemorrhage, remains relatively elevated from 3-7 days, and is finally resolved between 2-
4 weeks (Zhao, Grotta et al. 2009). Coincidentally, this correlates with the time course of 
activated microglia number, thus elucidating the time course of the M1/M2 ratio 
following cerebral hemorrhage may yield more information on the neuroprotective role 
microglia and macrophage subtypes play, as it is expected the M1/M2 ratio will rise and 
fall with hematoma volume, implying M2 microglia and macrophages are important for 
hematoma resolution. 
A thoroughly investigated therapy involves enhancing hematoma resolution by 
peroxisome proliferator receptor gamma (PPARγ) stimulation.  PPARγ stimulation 
enhances hematoma resolution, reduces oxidative stress, ameliorates damaging 
inflammation, decreases brain edema, and improves functional outcomes starting at 24 
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hours after cerebral hemorrhage in experimental rodent models (Zhao, Sun et al. 2007; 
Zhao, Grotta et al. 2009).  Furthermore, Pioglitazone, a PPARγ agonist, is being 
investigated in a clinical trial for enhancing hematoma resolution after cerebral 
hemorrhage.   PPARγ stimulation upregulates the red blood cell scavenger receptor 
CD36, consequently enhancing red blood cell phagocytosis in vitro and in vivo (Zhao, 
Sun et al. 2007).  Furthermore, the change in the M1/M2 ratio induced by PPARγ 
stimulation has not been investigated.  However, other studies indicate that PPARγ 
stimulation polarizes microglia and macrophages towards the M2 phenotype (Pisanu, 
Lecca et al. 2014).  Thus the neuroprotective effect from PPARγ treatment may include 
polarizing microglia and macrophages towards the M2 phenotype, reducing the M1/M2 
ratio, and creating a regenerative peri-hematoma milieu that promotes tissue repair and 
hematoma resolution. 
After cerebral vessel rupture, damage-associated molecular patterns, molecules 
capable of initiating and perpetuating a non-infectious inflammatory response following 
injury, stimulate the TLRs and NLRs of microglia, inducing microglia activation (Fang, 
Wang et al. 2013). TLR-4 stimulation by damage-associated molecular patterns, in 
addition to hemoglobin degradation products, induces M1 differentiation in macrophages 
and microglia. In a rodent model of cerebral hemorrhage, TLR-4 knockout mice had 
decreased microglia activation and macrophage infiltration at 72 hours post ictus (Fang, 
Wang et al. 2013).  Additional studies established that TLR-4 blockade also ameliorates 
neurological deficits and brain edema after experimental cerebral hemorrhage (Fang, 
Wang et al. 2013).  While TLR-4 stimulation following cerebral hemorrhage activates 
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microglia and induces an M1-like phenotype, the effect on the M2 phenotype is 
unknown.  
 Rather than reduce the M1/M2 phenotype ratio, some studies have aimed at 
inhibiting microglia activation altogether.  Experimental cerebral hemorrhage studies in 
rodents found that microglia inhibitor factor ameliorates brain injury and improves 
functional outcomes, which was correlated with overall reduced microglia activation 
(Wang and Dore 2007; Zhou, Wang et al. 2014).  One such microglia activation inhibitor 
is minocycline.  Nervous system injury studies discerned minocycline treatment inhibits 
M1 microglia and macrophage polarization without affecting M2 polarization.  While 
preclinical studies have reported that minocycline attenuates brain injury and improves 
functional outcomes, one study challenges minocycline’s overall therapeutic potential 
(Wang and Dore 2007; Zhou, Wang et al. 2014).  Indeed, the authors of a study which 
determined that minocycline is neuroprotective also argued that long-term microglia 
inhibition may not be beneficial because of the role microglia play in tissue repair, 
suggesting that M2 microglia and macrophages may play a long-term neuroprotective 
role.  This concept may provide an explanation for the results acquired in the negative 
minocycline cerebral hemorrhage study.  Despite seemingly contradictory studies, 
minocycline is currently being evaluated in clinical trials for cerebral hemorrhage. 
 Evidence provided by other brain injury preclinical models suggests manipulating 
M1/M2 polarization by decreasing the M1 phenotype and/or by increasing the M2 
phenotype has beneficial outcomes.  Although microglia and macrophages are known to 
play a very important role in potentiating secondary brain injury after cerebral 
hemorrhage, since several studies also suggest they are important for functional recovery, 
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little is known about the roles individual microglia subtypes play.  Discerning the exact 
microglia and macrophage subtypes involved in cerebral hemorrhage pathophysiology, as 
well as their time course of action following injury, may yield novel, effective therapeutic 
approaches, since decreasing the M1/M2 ratio by either reducing the M1 pro-
inflammatory phenotype and/or increasing the M2 regenerative phenotype may improve 
overall outcomes. 
 
Role of T-Helper Lymphocytes 
 Although cerebral hemorrhage is a brain injury of endogenous origin, and 
mounting an antigen specific adaptive immune response may take nearly one week to 
occur, increasing evidence suggests that CD4+ T-helper lymphocytes play an important 
role in secondary brain injury.  Clinical evidence shows the presence of T-helper 
lymphocytes within the peri-hematoma region of patients with cerebral hemorrhage 
(Guo, Li et al. 2006).  Pre-clinical rodent cerebral hemorrhage models indicate T-helper 
lymphocyte infiltration is delayed, commencing between 2-4 days post-ictus, yet some 
studies have reported T-helper lymphocyte infiltration occurs within one day post-ictus, 
peaking at 5 days post-ictus, before subsiding (Mracsko, Javidi et al. 2014).  Intuitively, 
this suggests T-helper cells, which heavily influence the surrounding milieu of injured 
tissue, direct the delayed immune response of cerebral hemorrhage, at least in part, by 
encouraging either a highly inflammatory, oxidative microenvironment or a regenerative 
and repair microenvironment, although preclinical evidence for the exact role of T-helper 
subtypes is lacking. 
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 Fingolimod, a sphingosine-1 phosphate inhibitor, downregulates sphingosine-1 
phosphate receptors in T-helper lymphocytes to reduce their egress from lymphoid tissue 
and subsequent infiltration into injured tissue.  In a rodent model of cerebral hemorrhage, 
fingolimod reduced brain edema and improved neurofunctional outcomes 24 and 72 
hours post-ictus, which was associated with reduced T-helper lymphocyte egress in the 
blood, decreased T-helper lymphocyte infiltration into the brain, and decreased IL-17 
secretion (a pro-inflammatory cytokine typically secreted by Th17 cells (Rolland, 
Manaenko et al. 2011; Rolland, Lekic et al. 2013).  Fingolimod, however, is known to 
upregulate peripheral regulatory T cells with some evidence suggesting it decreases 
circulating Th17 cells in clinical and preclinical multiple sclerosis studies.  Thus, 
Fingolimod’s neuroprotective effects in cerebral hemorrhage may partially be explained 
by shifting the predominant T-helper cell response from the inflammatory Th17 subtype 
to the regenerative Treg phenotype, although this has yet to be confirmed.  Fingolimod is 
currently being investigated in clinical trials for cerebral hemorrhage (Fu, Hao et al. 
2014). 
 Another experimental rodent model of cerebral hemorrhage study investigated 
adoptive transfer of Treg cells, and observed that Treg cells reduced microglia activation 
and improved functional outcomes, however the effects on microglia and macrophage 
polarization were not evaluated (Yang, Yu et al. 2014).  Furthermore, neural stem cell 
transplantation, previously shown to protect the brain from inflammatory damage, 
resulted in increased peripheral and infiltrated Treg cells, and was associated with 
increased anti-inflammatory cytokines (IL-4, IL-10, and TGF-β)  and decreased pro-
inflammatory cytokines (IL-6, interferon-) (Gao, Lu et al. 2014).  Furthermore, 
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mammalian target of rapamycin (mTOR) inhibition following cerebral hemorrhage in rats 
resulted in improved neurofunctional outcomes 24 hours post-ictus which coincided with 
increased Treg cells, IL-10, and TGF-β, as well as reduced interferon- in the blood and 
brain (Lu, Gao et al. 2014).  Unfortunately, investigative studies on the Th1/Th2 
paradigm following cerebral hemorrhage are lacking.  Yet evidence suggests that 
inhibiting Th1 proliferation improves outcomes while inhibiting Th2 aggravates brain 
injury during cerebral ischemia (Theodorou, Marousi et al. 2008; Gu, Xiong et al. 2012). 
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Table A.2:  Current and Past Clinical Trials Evaluating Immunomodulatory Therapies for Cerebral 
Hemorrhage 
Hemorrhage 
type 
Agent Trial Phase Status References 
Supratentorial 
Intracerebral 
Hemorrhage 
Prophylactic forced 
normothermia 
Systemic 
Normothermia in 
Intracerebral 
Hemorrhage (ICH) 
(SNICH) 
0 
Not Yet 
Recruiting 
(Rincon, 
Friedman et al. 
2014) 
Intracerebral 
Hemorrhage 
Labetalol/Hydralazine/Enalapril 
The Intracerebral 
Hemorrhage Acutely 
Decreasing Arterial 
Pressure Trial II (ICH-
ADAPT II) 
2 Recruiting 
(Butcher, 
Jeerakathil et 
al. 2013) 
Intracerebral 
Hemorrhage 
Pioglitazone 
Safety of Pioglitazone 
for Hematoma 
Resolution In 
Intracerebral 
Hemorrhage 
(SHRINC) 
2 Ongoing 
(Gonzales, 
Shah et al. 
2013) 
Intracerebral 
Hemorrhage 
Minocycline 
A Pilot Study of 
Minocycline in 
Intracerebral 
Hemorrhage Patients 
(MACH) 
2 Recruiting 
(Kohler, 
Prentice et al. 
2013) 
Intracerebral 
Hemorrhage 
Rosuvastatin 
Effect of Rosuvastatin 
in Intracerebral 
Hemorrhage 
2 Complete 
(Tapia-Perez, 
Sanchez-
Aguilar et al. 
2009) 
Intracerebral 
hemorrhage 
Nicardipine 
IV Double and Triple 
Concentrated 
Nicardipine for Stroke 
and ICH 
4 Unknown 
(Koga, Arihiro 
et al. 2014) 
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Conclusion 
 In this review, we discussed the distinct macrophage and microglia, and T-helper 
lymphocyte subtypes, their known roles in cerebral hemorrhage pathophysiology, and 
current gaps in the literature.  Table A.2 contains a brief overview of current and past 
clinical trials investigating immunomodulatory therapies, which are sparse and often 
directly target another pathophysiological mechanism with immunomodulation as a 
secondary effect.  Although many pharmacological approaches showed promise 
experimentally, none have thus far successfully translated to the clinic (Ayer, Hwang et 
al. 2012). Although the discussion of the M1 and M2 microglia/macrophage subtypes and 
the Th1/Th2 and Th17/Treg subtypes is not novel, their unknown roles in cerebral 
hemorrhage pathophysiology warrants further investigation as possible therapeutic 
targets.  Our goal is to advance the discussion of inflammation and secondary brain injury 
to involve the distinct immune cell subtypes and their probable neurodegenerative or 
neuroprotective roles and encourage further investigation.  Indeed, modulating the 
immune response by shifting the peri-injury milieu from a highly oxidative, caustic 
environment, typically mediated by the M1/Th1/Th17 subtypes, to a regenerative and 
repair environment, mediated by the M2/Th2/Treg subtypes, is being increasingly 
encouraged in the cerebral ischemia field (Seifert and Pennypacker 2014).   Applying the 
same concept in polarizing towards a regenerative and repair immune response following 
cerebral hemorrhage may yield positive, novel therapeutic approaches, and may be more 
desirable than inhibiting inflammation altogether.   Applying a multi-modal approach 
involving immunomodulatory therapies to ameliorate secondary brain injury in 
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conjunction with conventional therapies targeting primary brain injury may improve both 
short and long-term outcomes and warrants further investigation. 
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